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Background: Acute coronary syndrome among older patients is associated with 
increased morbidity and mortality. In developed countries, there is an increase in 
the number of older patients managed by invasive strategy. Frailty is emerging as 
an independent marker of adverse cardiovascular outcomes and its prevalence 
among older patients undergoing invasive treatment in the setting of Non ST 
Elevation Acute Coronary Syndrome (NSTEACS) is not known. The impact of 
frailty, co-morbidity and cardiovascular status on cardiovascular outcomes and 
quality of life in older patients with NSTEACS managed by invasive strategy is not 
known. 
Aims:  
1. To determine the prevalence of frailty and compare frailty status by Fried and 
Rockwood Frailty scales 
2. To assess adverse cardiovascular outcomes at one month according to frailty status 
in older NSTEACS patients managed by invasive strategy 
3. To assess cardiovascular disease burden in relation to frailty status  
4. To assess comorbidity burden according to frailty status and asses its relation to 
adverse CV outcomes at one month 
5. To evaluate cardiac symptom burden and the quality of life in older NSTEACS 
patients managed by invasive strategy 
6. Assess cognitive function in older NSTEACS patients and its association with frailty 
Methods: This prospective observational study was conducted in Freeman Hospital, 
Newcastle upon Tyne. The study participants underwent invasive management of 
NSTEACS as per the guidelines. Fried Frailty Classification (FFC) was used to group 
patients as frail (F), pre-frail (PF) and robust (R); and Rockwood Frailty Classification 
(RFC) grouped patients as frail (F) and non-frail (NF). Charlson co-morbidity index was 
calculated to quantify co-morbidity burden. To assess the cognitive status of patients 
during admission, the Montreal Cognitive Assessment was utilised. Arterial stiffness, 
peripheral arterial tonometry, carotid intima media thickness (CIMT) and left ventricular 
function were evaluated for cardiovascular status assessment. Quality of life was 
assessed using Short Form 36 and EuroQoL questionnaires. All these assessments 
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were done prior to invasive management. Procedural complications, in-hospital 
complications and cardiovascular outcomes at 30 days were recorded. 
Results: Frailty was three times more common by FFC (30.8%) tool compared to RFC 
(10.1%). There was no significant difference by frailty status in adverse CV outcomes, 
in-hospital (9.6% vs. 4.2% vs. 2.2%, p=0.157 for F vs. PF vs. R by FFC and 4.2% vs. 
5.6%, p=1.0 for F vs. NF by RFC) and at 30-days (11.0% vs. 5.9% vs. 4.3%, p=0.302 
and 8.3% vs. 7.0%, p=0.685 respectively). Measures of arterial stiffness, endothelial 
dysfunction and CIMT did not vary between the patient groups. LV systolic function 
was similar in frail patients, but increased E/e’ was noted in frail patients suggestive of 
diastolic dysfunction. Frail patients had worsening dyspnoea severity by both frailty 
classifications but angina was worse in frail patients by RFC alone. Higher comorbidity 
burden was noted in frail patients by both FFC (43.8% vs. 24.6% vs. 13.0%, p=0.001 
respectively) and RFC (54.2% vs 25.4%, p=0.007) but did not have an association with 
rate of adverse CV outcomes. Subclinical cognitive impairment was more common in 
frail patients by Fried (67.2 % vs. 39.6% vs. 42.2%, p=0.002) and Rockwood (86.4% 
vs. 31.8%, P<0.001) classification. Physical components of QoL measures by EQ5D 
and SF-36 were lower in frail patients by both frailty classification but mental 
component by SF-36 was lower in frail patients by RFC only. 
Conclusion: Frailty was common among older patients with NSTAECS managed by 
invasive treatment strategy and the prevalence of frailty varied according to the 
assessment tool used. Frailty was not associated with short-term adverse CV 
outcomes, but long-term outcomes need to be studied. Higher comorbidity burden, 
subclinical cognitive impairment and poor QoL measures were more prevalent in frail 
patients. Vascular status measures like arterial stiffness, endothelial dysfunction and 
CIMT were not associated with frailty. Dedicated frailty assessment tool for older 
patients with coronary artery disease need to be developed. Frail patients may stand 
to benefit more from contemporary management strategy in the short term and frailty 
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1.1 Importance of understanding Health of Ageing Population 
Life expectancy now is the longest due to control and eradication of communicable 
diseases in the last century. This has resulted in ageing population with oldest old (>85 
years) making up 12% of proportion of over 65years old in the developed countries. 85 
years and over population is projected to increase by 351 percent by 2050 (Figure 
1.1). ('Global Health and Ageing,' 2011). It has to be mentioned that the functional 
status of older people is diverse and not directly related to the chronological age. 
Advancing age is associated with increased prevalence of non-communicable 
diseases like cardiovascular disease, dementia and cancer. This has huge impact on 
health care infrastructure and social care. More importantly there is evidence gap in 
caring for these older patients in hospitals. It is not known whether longer life 
expectancy translates into better health and wellbeing, independence and good quality 
of life. The main component of the policy framework of active ageing by world health 
organisation (WHO) is to prevent and reduce excess disabilities and chronic diseases, 
so poor health need not be the dominant and limiting factor of old age. ('WHO World 
Report on Ageing and Health,' 2015)  
 




Ischemic heart disease is a leading cause of mortality and morbidity especially in old 
age. Limited evidence is currently available in the management of these older patients. 
It is important to understand the interplay between older age, frailty, comorbidity and 
ischemic heart disease to better treat these patients with IHD. In trying to do so, 
understanding older patients in the context of non ST elevation acute coronary 
syndrome in relation to invasive treatment, comorbidities and frailty is the main aim of 
this thesis. Moreover subclinical cognitive impairment and quality of life measures will 
be assessed in detail. In addition, to know more about the cardiovascular disease 
burden in this group of patients; arterial stiffness, endothelial dysfunction and carotid 
intima media thickness are to be assessed. This will give broader understanding of the 




1.2 Literature Review 
In the introductory chapters the current literature has been reviewed mainly in the 
context of acute coronary syndrome in older patients in relation to frailty, comorbidity 
and quality of life. In addition the association of cardiovascular disease burden 
including arterial stiffness, endothelial dysfunction and carotid intima media thickness 
in relation to cardiovascular outcomes has been discussed from the currently available 
literature.  
The literature review was based on PubMed search terms including “acute coronary 
syndrome”, “elderly”, “frailty”, “comorbidity”, “percutaneous coronary intervention” and 
“coronary artery bypass surgery”. Further search was done for “arterial stiffness”, 
“endothelial dysfunction”, “carotid intima media thickness”, “quality of life” and 
“cognitive impairment”. Reviews, randomised control trials, subgroup analysis and 
retrospective studies were included that were relevant to the discussion. Cross 
references from the citation lists were examined and included for relevant material. It 
has to be noted this literature review is not systematic but includes selected relevant 
evidence for each of the topic discussed and efforts made to avoid selection bias. The 
review has been structured to discuss the selected literature in relation to older patients 
and coronary artery disease. Evidence for cardiovascular burden in relation to older 




1.3 Acute Coronary Syndrome 
Acute coronary syndrome (ACS) comprises of symptoms of sudden onset cardiac 
sounding chest pain associated with or without ECG changes. ACS broadly includes 
three group of patients. Symptoms of ongoing chest pain with persistent ST elevation 
on ECG are grouped as STEMI presentation and the other group of presentation is 
Non ST Elevation Acute Coronary Syndrome (NSTEACS). NSTEACS is further 
classified as Non ST elevation MI (NSTEMI) with troponin raise or Unstable Angina 
(UA) in which there is no troponin rise. STEMI needs emergency reperfusion by either 
angioplasty or fibrinolysis (ideally within 6 hours of symptom onset) and NSTEACS 
group of patients need to be considered for urgent invasive treatment (ideally within 72 
hours) based on risk stratification.(Roffi et al., 2015) 
Diagnosis of NSTEACS is based on history and clinical assessment, 12 lead 
electrocardiogram and biomarker assay with troponin. The initial treatment comprises 
of pharmacotherapy (systemic anticoagulation, oral antiplatelets, beta-blockers, 
angiotensin converting enzyme inhibitors and statins). Further invasive management 
with percutaneous coronary intervention (PCI) or coronary artery bypass surgery 
(CABG) according to findings on coronary angiogram and risk benefit analysis. 
1.3.1 Pathophysiology of Acute Coronary Syndrome 
Atherosclerosis results in plaque formation in large and medium sized arteries. The 
risk factors include advancing age, smoking, hypertension, diabetes and 
hyperlipidaemia. These risk factors initiate endothelial dysfunction which leads on to 
inflammation of the intima, resulting in intimal thickness and plaque formation. ACS 
results due to plaque rupture and erosion, precipitated by thrombogenicity of exposed 
sub endothelium.(Fuster et al., 1988)  
Platelet-rich ‘white’ thrombus forms in areas of high shear stress and fibrin rich ‘red’ 
thrombus is formed due to activated coagulation cascade. Red thrombus 
superimposed on white thrombus results in total occlusion of the vessel.(Mizuno et al., 
1992)  
In NSTEACS, pharmacotherapy with antiplatelets prevent further thrombus formation 
and PCI is performed to prevent occlusion and recurrent ischemia.  In STEMI, 
reperfusion by PCI or fibrinolysis leads to restoration of flow in an occluded coronary 
artery.(Roffi et al., 2015)  
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1.4 Non ST elevation acute coronary syndrome in older population 
In the following section IHD in older patients especially NSTEACS, from current 
available evidence will be discussed.  
1.4.1 Burden of NSTE ACS in older population 
In the general population, ischaemic heart disease (IHD) is the leading cause of death 
worldwide.(Murray and Lopez, 1997) Globally, mortality due to IHD increases steeply 
among those aged >70 years of age.(Finegold et al., 2013) In 2010, in the United 
Kingdom (UK), more than twice as many individuals >75 years of age (n=55,028) died 
from IHD compared to younger individuals <75 years (n=25,540).(Townsend et al., 
2012) According to the UK Myocardial Ischaemia National Audit Project (MINAP) 
Database annual public report 2012-13, there were 80,974 admissions with a final 
diagnosis of myocardial infarction (MI). Of these, 60% had non ST elevation myocardial 
infarction (NSTEMI). Of the patients with NSTEMI 59% were more than 70 years of 
age (26% were of age 70-79 years, 26% were 80-89 years and 7% were ≥90 
years).(Gavalova L, 2013) 
Mortality from IHD increases exponentially with age. In UK there is a 2.7-fold increase 
in IHD mortality for every decade of life for men and a 3.7-fold increase for 
women.(Finegold et al., 2013) This is similar to other developed countries like US, 
France and Japan (Figure 1.2). Though age-standardised IHD related death rates 
have fallen significantly by almost 50% in the developed countries, IHD still remains 
the leading cause of death due to higher mortality rate in the increasing proportion of 
older and ageing population. 
In the Global Registry of Acute Coronary Events (GRACE), increasing age was 
associated with increased incidence of NSTEMI. NSTEMI was diagnosed in <30% of 
patients aged <65 years compared with 41% in those aged ≥85 years. ST elevation 
myocardial infarction (STEMI) was more frequent in younger patients (36.5% in 45 to 
74 years vs. 30.7% in >75years). All in-hospital events after ACS were more frequent 
among elderly patients. Cardiogenic shock was nearly 6 times more common in the 
oldest compared with the youngest group (9.8% vs. 1.6%, respectively). Rates of major 
bleeding were twice more in patients aged ≥85 years compared to <65 years (p< 
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0.0001). Each 10-year increase in age resulted in 75% increase in in-hospital 
mortality.(Avezum et al., 2005) 
 
Figure 1.2: Age specific IHD mortality trend in UK, USA, France and Japan 
 
Reproduced from Finegold et al., Mortality from ischemic heart disease by country, region and age: 
Statistics from World Health Organisation and United Nations. International Journal of Cardiology 168 
(2013) 934-945  
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1.4.2 Management of NSTEACS in Older Patients 
Management of NSTEACS includes pharmacotherapy and revascularisation in 
suitable patients. In the following section role of invasive management strategy in older 
patients will be reviewed.  
1.4.2.1 Invasive or Conservative Management Strategy for NSTEACS 
In the Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or 
Conservative Strategy-Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) 
study (n=2220), patients aged >65 years (n=962) who were treated with an early 
invasive approach of catheterisation within 48 hours (n=491) and revascularisation if 
appropriate had a lower risk of death, subsequent MI or rehospitalisation for ACS at 6 
months than patients who underwent a conservative strategy (n=471) of 
revascularisation only with objective evidence of ischemia (14.9% vs. 17.8% 
respectively), however this was not statistically significant.(Cannon et al., 2001) 
From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients 
Suppress Adverse Outcomes With Early Implementation of the American College of 
Cardiology/American Heart Association Guidelines) Quality Improvement Initiative, the 
unadjusted incidence of in-hospital mortality for all patients (n=17926) was 2.0% of 
8037 patients who underwent early invasive management within 48 hours, compared 
with 6.2% of 9889 patients who did not undergo early invasive management (adjusted 
Hazard Ratio [HR]: 0.63, 95% Confidence Interval [CI] 0.52-0.77). In this study, 
younger and healthier patients (median age 63 years) generally receive the benefit of 
early invasive management, whereas older patients (median age 73 years), with more 
co-morbidities and a greater likelihood to benefit more from invasive treatment for 
NSTEMI, are more likely to be managed conservatively.(Bhatt et al., 2004a)  
In the Acute Coronary Syndromes Registry (ACOS) study, 1936 patients ≥75 years 
with NSTEMI were included and analysed by two groups. 1005 patients underwent 
coronary angiography and revascularisation if indicated and 931 patients received 
conservative treatment. The mean age was 78.7 years vs. 82.2 years (p<0.0001) and 
women comprised 48.3% vs. 58.6% (p<0.0001) of each group respectively. In-hospital 
mortality and the combined endpoint of death or non-fatal re-infarction were lower in 
the patients undergoing invasive management compared with the group managed by 
conservative strategy (6.0% vs. 12.5%, p<0.0001 and 9.6% vs. 17.3%, p<0.0001 
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respectively). There was a significant reduction in one-year mortality in the invasive 
treatment group compared to conservative treatment group (Odds Ratio [OR] 0.56, 
95% CI 0.38 to 0.81).(Bauer et al., 2007)  
In a recent study comparing the different management strategies utilised among 
patients >75 years of age (n=3279) between two different cities (Goteborg [Sweden] – 
n=968 and Minneapolis St Paul [USA] – n=2311), it was observed that in Goteborg a 
smaller proportion of patients received PCI (7.3% vs. 32.8%; p< 0.0001 among men, 
6.6% vs. 29.4%; p< 0.0001 among women). Subsequently, survival after 7.5 years 
follow up was observed to be lower in Goteborg (17.5% vs. 26.6%, [OR for survival at 
follow up: 0.66, 95% CI: 0.50-0.88] among men and 17.0% vs. 28.8% [OR: 0.49, 95% 
CI: 0.36–0.67] among women). Whilst the increased survival rate was thought to be 
attributable, at least in part, to the increased utilisation of PCI in Minneapolis cohort, it 
should be noted that several other factors could have contributed, such as differences 
in medical management and other geographical variables.(Smith et al., 2013) 
 
1.4.2.2 Timing of Revascularisation for NSTEACS 
Benefits from early invasive strategy for ACS in low risk patients are minimal. (Antman 
et al., 2000; Goto et al., 2010; Lansky et al., 2010) Current guidelines recommend early 
invasive strategy for high risk patients who would benefit more from early invasive 
treatment. (Anderson et al., 2007; Anderson et al., 2011a; Hamm et al., 2011) Benefits 
from invasive treatment compared to non-invasive treatment are observed more in >65 
year old patients compared to younger patients at 1 year and 5 years.(Wallentin et al., 
2000; Lagerqvist et al., 2006) But in real-world practice older patients are less likely to 
be offered invasive treatment compared to younger patients.(Bhatt et al., 2004b; Halon 
et al., 2004; Alexander et al., 2006) 
In the meta-analysis by Angeli et al,(Angeli et al., 2014) of 9 randomised control trials 
(RCTs) involving 9400 patients with NSTEACS, reduction in composite end-point (all-
cause death and recurrent MI) by early invasive strategy (≤24 hours) compared to 
conservative strategy was larger in RCTs enrolling patients with a mean age >65 years 
(249/1440 patients of invasive strategy vs 319/1461 patients of conservative strategy 
) than in RCTs with a mean age <62 years (168/573 patients vs 150/598 patients, OR 
0.65; 95% CI: 0.42–0.98; P=0.043). Similarly for rehospitalisation RCTs with a mean 
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age >65 years showed a 49% risk reduction (OR 0.51; 95% CI: 0.38-0.68) for this 
outcome when compared with trials with a mean age <62 years (P<0.0001). There was 
15% risk reduction of the composite end-point of all-cause death and recurrent MI by 
early invasive strategy and the benefit was achieved in >65 year old patients. The 
outcomes were unaffected by gender and benefits were similar in both male and 
female patients >65 years old. 
Of the 9 RCTs included in the above meta-analysis only one was specifically designed 
for patients ≥75 years while the others were sub-group analysis. In this Italian Elderly 
ACS study by Savonitto et al;(Savonitto et al., 2012) from January 2008 and May 2010, 
313 patients ≥75 years of age (mean 82 years) with NSTEACS were randomised within 
48 hours from diagnosis to an early aggressive (EA) strategy (n=154, coronary 
angiography and, when indicated, revascularization within 72 hours) or an initially 
conservative (IC) strategy (n=159; angiography and revascularization only for 
recurrent ischemia). During admission, 136/154 (88.3%) and 85/154 (55.1%, 76 PCI 
and 9 CABG) of the patients randomized to the EA strategy underwent coronary 
angiogram and revascularisation respectively. This proportion in the IC strategy was 
46/159 (28.9%) and 37/159 (23.2%, 36 PCI and 1 CABG). The primary endpoint 
(composite of all-cause mortality, non-fatal myocardial infarction (MI), stroke, repeat 
hospitalisation for cardiac causes and severe bleeding within 12 months) occurred in 
43 (27.9%) patients in the EA group and 55 (34.6%) patients in the IC group (HR 0.80; 
95% CI 0.53-1.19; log rank p=0.26). Patients with raised troponin levels at diagnosis 
had a significant 57% reduction in the primary endpoint rate (p for interaction <0.05). 
The power of the study was limited to arrive at a definite conclusion about the benefit 
of an EA approach among elderly patients with NSTEACS. The significant interaction 
of troponin level at baseline to the treatment benefit in EA group needs confirmation in 
a larger trial. 
Overall, these studies suggest that there may be better outcomes with an early invasive 
management strategy in the elderly population in carefully selected patients presenting 






1.4.2.3 Risks of PCI in older patients 
As older age predicts poor CV outcomes after ACS, age is an independent predictor 
of death after PCI. In a RCT to study anticoagulation during PCI comparing bivalirudin 
and heparin with glycoprotein IIb/IIIa inhibitor of 6010 patients undergoing PCI, 695 
patients were >75 years. Mortality was 5.2% at 1 year in >75 years compared to 1.6% 
in ≤ 75 years (HR 1.05, 1.03-1.07 P<0.001). (Lincoff et al., 2004) 
In a retrospective study from Scotland of 3513 patients >75 years old which was 11.1% 
of the total number of non-emergency PCI (n=35888) done from 2000 to 2007, the 
overall risk of MACE at 30 days was 4.5% in >75 years old compared to 2.7% in <75 
years old (OR 1.74, 95% CI 1.46 to 2.08, P<0.001).(Johnman et al., 2010) Though this 
was a retrospective study it included all >75 years old and avoided selection bias. 
Advanced age is an independent predictor of bleeding in acute coronary syndrome. 
(Moscucci et al., 2003) Patients with major bleeding (588 out of 10974 patients, 5.4% 
included haemorrhagic stroke, gastrointestinal bleeding and retroperitoneal bleeding) 
after PCI were older compared to minor or no bleeding (68yerars vs 65 years, 
P<0.001). Multivariate analysis identified age >80years as a strong predictor of major 
bleeding (OR 1.9, 95% CI 1.4-2.7, P<0.0001). (Kinnaird et al., 2003) This study 
included emergency procedures and almost all procedures were done from the femoral 
access site. 
Major bleeding after PCI was associated with increased incidence of mortality (6.4% 
vs 1.9%, OR 3.6, 95% CI 2.3 – 5.5, I2 89%) and MACE (22% vs 5.9%, OR 3.9, 95% CI 
3.2-4.8, I2 53%) at 1 year in a metanalysis of 42 studies.(Kwok et al., 2014)  
The increased rate of MACE after PCI in older patients are likely related to increased 
incidence of comorbidities, multivessel coronary artery disease, renal insufficiency and 




1.4.2.4 PCI versus CABG 
Older patients are more likely to have three vessel disease compared to younger 
patients.(Flather et al., 2012) In a retrospective study of 10141 ACS patients with multi-
vessel disease who were 85 years and older (mean age 87.2 years), patients were 
followed up for 3 years after either Coronary Artery Bypass Grafting (n=5803) or 
multivessel PCI (n=4338). Though lower survival was noted in the early months after 
CABG compared to PCI (80% vs 84%, OR 1.48, 95% CI 1.34-1.64, P<0.01), CABG 
provided significantly better survival (64% vs 60%, OR 0.60, 95% CI 0.53-0.69, 
P<0.05) and freedom from the composite outcome of death, repeat revascularization, 
stroke and acute myocardial infarction at 36 months (44% vs 37%, OR 0.83, 95% CI 
0.76-0.91, P<0.01).(Sheridan et al., 2010) Long term outcomes were poor in patients 
with heart failure, lung disease and peripheral vascular disease in the CABG group. 
Long term benefits of CABG need to be weighed against the perioperative morbidity 
and mortality in older patients. 
In a meta-analysis of 10 randomised control trials by Flather et al, (Flather et al., 2012) 
over a median follow-up of 5.9 years, the effect of CABG versus PCI with balloon 
angioplasty or bare metal stents (BMS), on mortality varied according to age. CABG 
(n=1279) led to an increased risk of mortality (11% vs 8%) among patients in the lowest 
tertile for age (n=2602, mean age 49.8), with adjusted CABG to PCI Hazard Ratio (HR) 
of 1.23 (95% CI 0.95-1.59). However, in the middle tertile (n=2602, mean age 61 
years), the HR was 0.89 (95% CI 0.73-1.10), favouring CABG (n=1307, 14% vs 15%). 
In the oldest tertile (n=2602, mean age 70.5), the HR decreases further with CABG 
(n=1301) to 0.79 (20% vs 24%, 95% CI 0.67-0.94). It was observed that, above 59 
years of age, the HR fell to <1, favouring CABG as a treatment strategy. A similar effect 
was observed with the composite outcome of death or further MI, with PCI favoured in 
the younger tertile compared to CABG in the more elderly groups. Though age was a 
predictor of outcomes for mortality and MI in the two groups, it was not significant in 
predicting repeat revascularisation (P=0.24) or the development of angina (P=0.94). 
Though benefit from CABG was noted in this meta-analysis, most of the patients 
underwent PCI with balloon angioplasty or BMS. There has been significant 
improvements with drug eluting stents (DES) and potent anti-platelets in the current 
era of PCI. 
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Similarly, in a collaborative analysis of data from 10 separate randomised trials 
comparing CABG (n=3889) to PCI (n=3923), patients’ age modified the effect of 
treatment on mortality, with CABG to PCI HRs of 1.25 (10% vs 8%, 95% CI 0.94-1.66) 
in patients younger than 55 years, 0.90 (14% vs 15%, 95% CI 0.75-1.09) in patients 
aged 55-64 years, and 0.82 (20% vs 24%, 95% CI 0.70-0.97) in patients 65 years and 
older (p=0.002 for interaction). It was concluded that CABG might be a better option in 
patients ≥65 years as mortality was lower in this group. However, very few of the 
patients in these trials were >75 years old, and the older patients were physically 
healthier than many of their contemporaries, due to selection bias.(Hlatky et al., 2009)  
In an observational study, compared to younger patients, physiological and 
psychological recovery patterns after CABG among older patients was similar in the 
first 6 weeks postoperatively.(Artinian et al., 1993) Slater and colleagues observed an 
increased risk of cognitive decline after CABG (n=202 out of which 58 had cognitive 
decline at 3 months) with advancing age (OR 1.76 per 10-year increase in age, 
p=0.055), and that cognitive decline was strongly associated with prolonged cerebral 
oxygen desaturation which can occur during the CABG procedure.(Slater et al., 2009) 
Healthy older patients probably benefit long term from CABG but randomised data in 
>75 years age group is lacking. 
 
1.4.3 Paucity of Evidence for Management of Older Patients 
Evidence from clinical trials to inform the management of ACS in older patients is 
limited. More than half of all trials for coronary disease in the past decade failed to 
enrol patients >75 years of age, with this subgroup accounting for just 9% of all patients 
enrolled in trials.(Lee et al., 2001) Analysis from the CRUSADE Quality Improvement 
Initiative demonstrated that among a community population with Non-ST Elevation 
Acute Coronary Syndrome (NSTE ACS), patients who were enrolled in a clinical trial 
(2.5% of the overall CRUSADE population) were younger (median 65 years vs. 68 
years), more often male (67.9% vs. 59.3%), had less renal insufficiency (8.5% vs. 
13.5%), and had less heart failure (13.2% vs. 19.0%) than those not enrolled in 
trials.(Kandzari et al., 2005) Evidence-based recommendations from trials do not 
account for the age related differences in physiology and disease that may alter these 
relationships. The age gap between trials and community populations begins at age 
75 years and widens with age.(Alexander et al., 2007b) Even the older patients 
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included in trials are different from the older patients in the community. Trial 
populations have lower rates of traditional cardiovascular risk factors, less co-morbidity 
and better renal function in each age subgroup than do community 
populations.(Kandzari et al., 2005) As older patients are at increased risk from cardiac 
events, the absolute benefit of treatment should increase if treatment risks can be 
balanced against benefits.(Alter et al., 2004) Risks and benefits derived from trials 
cannot always be extrapolated to older patients in daily clinical practice due to the 
differences between the patient groups.(Tinetti et al., 2004) Current evidence in the 
management of older ACS patients is limited due to less number of older patients in 
the randomised trials. 
 
1.4.4 Interpretation of available evidence in NSTEACS in Older Patients 
The definition of older and elderly when it comes to acute coronary syndrome is not 
clear. Though most of studies considered >65 years old as older/elderly in the current 
era of advancing age and life expectancy, >75 years need to be considered older. So 
the available evidence from these >65 years may not be the standard evidence for 
management of >75 year old patients. Advancing age is a risk factor for acute coronary 
syndrome and plays a role in the risk stratification of patients presenting with ACS. 
Evidence for management of older patients is limited from retrospective studies to sub 
group analysis. The proportion of older patients in RCT is small. From the limited 
evidence available patients with NSTEACS managed by early invasive strategy 
compared to conservative strategy, benefit older patients even when considering the 
risks associated with the procedure. This is because older patients perceived to be at 
higher risk are likely to benefit from intervention. With advancement in 
pharmacotherapy, radial access procedures and advanced PCI equipment, the role of 
intervention in >75 year old need to be studied in the current era. Older age also results 
in comorbidities and frailty, so assessing these >75 year old patients with NSTEACS 
in relation to frailty and comorbidity will play a key role in developing guidelines. Studies 
are needed to define risks and benefits of conservative versus invasive care in older 
patients with ACS, not just based on age but with comorbidity ad frailty especially the 
impact on quality of life.(Rich et al., 2016) Limited clinical randomised controlled trial 
data to guide acute care in older patients and uncertainty about risk-benefit 
assessment with advanced age is likely to explain the underuse of appropriate 
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medications and invasive treatment strategies.(Lee et al., 2001) Older patients who 
are at high risk of adverse outcomes following ACS are underrepresented in clinical 
trials despite the fact that older patients constitute a significant proportion of the patient 
population and are more likely to benefit from treatment strategies due to higher 
risk.(Hordijk-Trion et al., 2006; Alexander et al., 2007b) For gains in quality life-years 
following ACS to continue, survival from acute coronary syndrome will need to also 
extend to the very older population.(Gurwitz et al., 1994; Sahyoun et al., 2001) It is 
important to understand the risks and benefits of treatment in this group in order to 
improve outcomes. Frailty assessment might usefully be incorporated into the 
management of older patients with ACS. Future large scale randomised studies 
evaluating novel therapies in addition to contemporary care are required for the ageing 
patients presenting with ACS. In older patients with ACS, predictors of adverse 
cardiovascular outcomes and quality of life need to be evaluated in detail in ‘real world’ 
patients. Frailty, comorbidity and quality of life in the context of ACS will be reviewed 




1.5 Prevalence and impact of frailty on cardiovascular outcomes 
This section covers frailty, including the origins of the concept of frailty and its definition. 
Also the common frailty measures used and helpful in clinical practice and research 
are discussed. The impact of frailty on cardiovascular disease in community population 
and in patients with acute coronary syndrome is discussed. 
1.5.1 Frailty 
Frailty can be regarded as a complex syndrome in older age due to decreased reserve 
and resistance to stressors resulting in delayed and decreased resolution to baseline 
homeostasis following a stressor event (Figure 1.3). Frailty results from declining 
physiological systems in older age leading to adverse health outcomes including falls, 
hospitalisation and mortality.(Rockwood et al., 1996; Fried et al., 2001) Declining 
physiological reserve and resulting impaired resistance to stressors leads to frailty 
syndrome.(Bergman et al., 2007) 25% to 50% of patients with cardiovascular disease 
(CVD) can be identified as frail depending on the frailty scale used and the population 
group studied.(Afilalo, 2011).  
Figure 1.3: Response to stressor in frailty 
 
In response to a stressor non-frail patients (green line) return to baseline 
independence earlier compared to frail patients (red line) who become dependent 
and takes longer and do not return to baseline homeostasis. 






1.5.2 Concept of Frailty 
The two main models of frailty are phenotype model and cumulative deficit model. The 
phenotype model was developed from secondary analysis of the Cardiovascular 
Health Study (CHS) and identified five variables (unintentional weight loss, self-
reported exhaustion, low energy expenditure, slow gait speed and weak grip strength) 
establishing the frailty phenotype.(Fried et al., 2001a) Frailty criteria developed from 
this phenotype model is explained in the following sections. 
The cumulative deficit model was developed as a frailty index as part of the Canadian 
Study of Health and Ageing (CSHA).(Rockwood et al., 2005) This model included 92 
variables recorded as deficits in the form of symptoms, signs, abnormal laboratory 
values, disease states and disabilities. The frailty index in this model was calculated 
from the total number of deficits out of the 92 deficits present in an individual.  Without 
reducing the predictive ability the cumbersome list of 92 deficits have been reduced to 
a manageable number of 30 in subsequent work on this model. Distinction of older frail 
patients should be an essential assessment prior to an invasive procedure. This will 
help patients to weigh the risks and benefits to make informed choices and also will 
make sure that older patients are not denied interventions based on age alone.(Clegg 
et al., 2013) 
 
1.5.3 Frailty Measures 
Frailty can be assessed by a number of clinical instruments and scores.(Abellan van 
Kan et al., 2008; de Vries et al., 2011) The variables measured include physical 
inactivity, strength, exhaustion, co-morbid conditions and cognitive impairment as main 
components. A task force on frailty assessment in older people suggested that gait 
speed could represent the most suitable instrument to be implemented in both 
research and clinical evaluation of older people to assess frailty.(Abellan van Kan et 
al., 2008) The 5-minute gait speed test is a simple and effective way of objectively 
measuring frailty in patients with CVD and should be incorporated in risk assessment. 
Fried et al.(Fried et al., 2001b) used data from the Cardiovascular Health Study to 
develop a tool for assessment of frailty among adults aged ≥65 years. 5317 participants 
≥65 years were assessed annually. Examinations and surveillance was conducted 
assessing for the presence of incident disease, hospitalisation, falls, disability and 
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mortality. Frailty was defined as “a clinical syndrome in which three or more of the 
following criteria were present: unintentional weight loss (10 pounds in past year), self-
reported exhaustion, weakness (grip strength), slow walking speed and low physical 
activity”. According to the above criteria, 6.9% of the study population were frail. The 
prevalence increased with increasing age, and was greater in women than in men. 
Over a three year period, frailty was independently associated with increased incident 
falls, worsening mobility, disability in ADL, hospitalisation and mortality. The presence 
of one or two of the Fried frailty criteria indicating intermediate frail status showed 
intermediate risk of these outcomes as well as an elevated risk of becoming frail over 
a period of three to four years.  
Rockwood et al.(Rockwood et al., 2005) developed the 7 point Clinical Frailty Scale 
(category 1: Very fit - Robust, active, energetic, well-motivated and fit; these people 
commonly exercise regularly and are in the most fit group for their age to category 7: 
Severely frail - Completely dependent on others for the activities of daily living, or 
terminally ill) and utilised it to measure frailty in 2305 elderly patients participating in 
the Canadian Study of Health and Aging (CSHA). After adjustment for age, sex and 
education each 1-category increment of the clinical frailty scale significantly increased 
the risks of death (21.2%, 95% CI 12.5%-30.6%) and entry into an institution (23.9%, 
95% CI 8.8%-41.2%) within six years. 
1.5.4 Prevalence of Frailty in Community Population with CVD 
The prevalence of frailty in community population with CVD is summarised in Table 
1.1. The cause for decline in physiological reserve is multifactorial and involves 
multiple organ systems. Frailty has become increasingly relevant in the field of 
cardiovascular medicine as the patient population is ageing and also there is an 
increasing evidence in the association of CVD and frailty both at the mechanistic level 
and the epidemiologic level.(Afilalo et al., 2009) Activities of daily living (ADL), 
physiological reserves, nutritional status (albumin, weight loss) and functional status 
are all important markers of older patients at increased risk of morbidity and 
mortality.(Ferrucci et al., 2004) Altered cognition, hearing and vision may delay 
presentation and result in increased risks due to delays in commencing interventional 
treatment. Impaired communication affects decision making and these patients would 
find it difficult to adhere to treatment plan and consent for invasive procedures. As 
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frailty includes a number of components, better understanding of age-related health 
issues separate from disease-related risk is needed.(Fried et al., 2004) 
Frailty is not reflected by disabilities in ADL (for example, getting dressed unassisted) 
or instrumental ADL (such as going shopping unassisted) alone. Frailty occurs earlier 
than disability and can be elicited in a large number of well-functioning older adults. 
Disability can be viewed as the end-result of longstanding frailty and co-morbidity 
burden.(Afilalo, 2011) Though there is an overlap between frailty, disability and co-
morbid conditions, these represent distinct domains.(Fried et al., 2004) 
Table 1.1: Prevalent Frailty in Older Patients with CVD 
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1.5.5 Frailty and Cardiovascular Outcomes in Community Population 
Frail patients with CVD, especially those undergoing invasive procedures or suffering 
from coronary artery disease and heart failure, are more likely to suffer major 
cardiovascular events and death compared to their non-frail counterparts.(Afilalo, 
2011) Frailty is a powerful predictor of adverse cardiovascular outcomes and hence 
frailty measures should be routinely used in cardiovascular risk assessment. This is 
especially of importance in the management of ACS.  
Four studies have shown an association between frailty and CVD in community 
dwelling older adults: Zutphen Elderly Men’s Study (OR 4.1; 95% CI 1.8-9.3)(Chin et 
al., 1999), Cardiovascular Health Study (OR 2.79; 95% CI 2.12-3.67)(Newman et al., 
2001), Beaver Dam Eye Study (OR 1.43 per point; 95% CI 1.13-1.82)(Klein et al., 
2005), and the Women’s Health and Aging Studies (OR 2.72; 95% CI 1.72-
4.30).(Chaves et al., 2005) In the Cardiovascular Health Study, there was also an 
association between frailty and subclinical cardiovascular abnormalities such as left 
ventricular hypertrophy and carotid intima media thickness (CIMT).(Newman et al., 
2001)   
The French 3 City Study(Dumurgier et al., 2009) and the Health Aging and Body 
Composition Study(White et al., 2012) showed that community-dwelling older adults 
who were frail (as determined by gait speed) were at higher risk of cardiovascular 
events and mortality. In the French 3 City Study, slow gait speed was associated with 
a threefold increase in cardiovascular mortality over 5 years (OR 3.00; 95% CI 1.65–
5.57).(Dumurgier et al., 2009)   
Purser et al.(Purser et al., 2006) showed that, depending on the definition used, 27% 
to 50% of older patients admitted to hospital and subsequently found to have severe 
coronary artery disease on coronary angiogram were frail. Tjam et al. showed that 
frailty was more predictive of mortality than New York Heart Association (NYHA) class 
in frail older patients with heart failure.(Tjam et al., 2012) Mortality in frail older patients 
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1.5.6 Frailty and Cardiovascular Outcomes in IHD Patients 
1.5.6.1 Frailty in the Setting of ACS 
In a study of 307 hospitalised NSTEMI patients ≥75 years between October, 2009 to 
June,2010; 149 (48.5%) were considered frail by Rockwood(Rockwood et al., 2005) 7 
point frailty criteria (1 very fit – robust and active to 7 severely frail – bed ridden). Fewer 
frail patients underwent coronary angiography compared to non-frail patients (15% vs 
46%, p<0.001). Frailty was independently associated with risk of major adverse 
cardiovascular (death from any cause, myocardial re-infarction, revascularization due 
to ischemia, hospitalization for any cause, major bleeding, stroke/transient ischemic 
attack, and need for dialysis) outcomes (45% vs 27%, p=0.0009, OR 2.2; 95% CI 1.3-
3.7), in-hospital mortality (11% vs 2%, p=0.003, OR 4.6; 95% CI 1.3-16.8), and 1-
month mortality (15% vs 3%, p=0.002, OR 4.7; 95% CI, 1.7-13.0). From this study 
Ekerstad et al concluded that frailty was strongly and independently associated with 
in-hospital mortality, one-month mortality and prolonged hospital care.(Ekerstad et al., 
2011) Similarly in the 1 year follow up of this study there was increased mortality in 
frail patients compared with non-frail patients (unadjusted 49% vs 13%, p<0.001, HR 
4.3, 95% CI 2.4-7.8).(Ekerstad et al., 2013) 
In the above study a very high proportion of patients had type 2 myocardial infarction 
(n=106/307, 35%) secondary to anaemia, hypoxia and sepsis rather than a primary 
coronary ischemia. Though type 2 MI was not different between the frail and non-frail 
groups, significant differences were noted for CCF (38% vs 16%), severe renal 
impairment (eGFR <30, 38% vs 16%), dementia (28% vs 6%) and anaemia (56% vs 
32%). These differences explain why less than a third of patients underwent invasive 
angiography (30%) The patient group in this study are different from older patients 
undergoing invasive treatment in the UK. 
In a pilot study of 183 patients ≥ 65 years old admitted with ACS frailty was assessed 
using Edmonton Frailty Scale (EFS). EFS includes assessment of cognition, general 
health status, functional independence, social support, medications use (5 or more), 
nutrition, mood, continence and functional performance (timed get up and go test). 
30% of patients had EFS score of ≥7 suggestive of frailty. Higher frailty score was 
associated with increased length of hospital stay (7 days for EFS 0-3, 10 days for EFS 
4-6 and 13 days for EFS ≥7, p=0.03) and increased mortality at 1 year (1.6%, 7.7% 
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and 12.7% respectively, p=0.05).(Graham et al., 2013) Of the 183 recruited patients 
18.9% had STEMI, 77% underwent coronary angiogram and 26% underwent PCI. In 
this study almost 20% of patients had presented with STEMI in which the clinical status 
and outcomes are different compared to NSTEACS presentation. Though invasive 
angiogram was performed in a higher proportion of patients, PCI was performed only 
in about quarter of the patients. Because of this the study did not have enough power 





1.5.6.2 Frailty in Patients Undergoing PCI 
In a prospective cohort study of 628 patients > 65 years, by Singh et al, frailty (as 
defined by Fried frailty score) (Fried et al., 2001b) was added to conventional 
cardiovascular risk factors in the Mayo Clinic Risk Score. 18.6% were classified as 
frail, 47.4% as intermediate frail and 20.6% were non-frail. Frailty was associated with 
increased long-term (median follow up of 3 years) mortality or myocardial infarction 
(41% vs 17%, p<0.05, HR 2.45; 95% CI 1.33-4.53) among patients undergoing PCI. 
For mortality alone the difference was 28% vs 6% between frail and non-frail patients. 
The authors concluded that addition of frailty, co-morbidity and quality of life 
significantly improves the prognostic ability of Mayo Clinic Risk score.(Singh et al., 
2011)  
It has to be noted only 41% of eligible patients from the above study, were consented 
and also the presentations were both stable CAD and acute coronary syndrome. Frailty 
assessment was done after the PCI procedure and this can have an influence on the 
frailty status especially if femoral access has been used for the procedure. The 
proportion of patients who had femoral access has not been discussed. 
In a recent study by Murali-Krishnan et al,(Murali-Krishnan et al., 2015) frailty assessed 
by Rockwood criteria independently predicted 30-day and 1-year mortality in addition 
to length of hospital stay. In this study 745 patients (mean age 62 years) undergoing 
PCI for stable CAD and ACS were recruited into the study. 11% were classified as frail. 
Almost 40% of recruited patients had STEMI and required emergency PCI. At 30 days 
the mortality was 4.9% in frail and 1.1% in non-frail patients (HR 4.8, 95% CI 1.4 to 
16.3, p=0.01). At 1 year the mortality was 11.1% in frail and 1.9% in non-frail patients 
(HR 5.9, 95% CI 2.5 to 13.8, p<0.001). Frail patients stayed longer in hospital than 
non-frail patients (14 days vs 3.5 days, p<0.001). 
The data collection for the above study was done as a service improvement project. 
The patients were relatively younger and a high proportion of patients had presented 





Older patients constitute a significant group of ACS patients. With increasing life 
expectancy and advances in medicine the proportion of older patients presenting with 
ACS will increase. The older high-risk patients who are likely to benefit most from 
current pharmacotherapy and invasive procedures for ACS are managed 
conservatively due to the difficulty in risk-benefit assessment. This is a result of a lack 
of clear evidence due to under representation of this older group in clinical trials. It is 
important to recognise that chronological age does not always reflect biological age. 
Frailty, functional status and social aspects are not routinely assessed in older ACS 
patients. Future trials should enrol a greater proportion of older patients to reflect the 
real world population needing treatment and assess and report frailty status of trial 
participants. Standard reporting of age groups across trials and registries is needed to 
facilitate comparisons and pooling of data. A better understanding and phenotyping of 
older patients presenting with ACS is required. Prospective trials performed exclusively 
in the older patients will be of help in assessing the benefits and safety of 
pharmacotherapy and invasive procedures. 
1.5.7 Interpretation of available evidence on frailty and ACS 
Frailty is common among older patients both in community and hospitalised patients 
with CVD. Frailty predicts poor CV outcome in patients with stable CAD and ACS. But 
it has to be noted that different frailty assessment tools were used in the currently 
available evidence. There is no consensus on the best frailty measure to be used in 
CVD patients. Comparing different frailty tools in the same patient cohort with CVD 
could provide insight into better assessment of frailty status. The underlying 
presentation was different and varying, between elective procedures for stable angina 
to emergency procedure for STEMI. This is an important consideration as 
management and the risk of adverse CV outcomes varies according to the 
presentation. More importantly the benefit of contemporary invasive management in 
the specific subset of NSTEACS patients with frailty is not known. In addition to the 
benefits on improving mortality and adverse CV outcomes in frail older patients, the 
influence of comorbidity and the impact of quality of life in these patients need to be 
studied in detail. In the following section comorbidity in the context of ACS and frailty 




1.6 Impact of co-morbidity and cardiovascular outcomes 
1.6.1 Co-morbidity 
The decision to intervene in older ACS patients need to be balanced against the 
general health and co-morbidities of these patients.(Tinetti et al., 2004) Old age is not 
an isolated risk factor especially when age associated conditions such as anaemia, 
kidney disease, frailty, disability and cognitive dysfunction have an impact on the 
outcomes of ACS management. In addition, diminished organ reserves and abnormal 
functional and cognitive status influence the nature of disease presentation, response 
to treatment, and recovery.(Alexander et al., 2007b) Renal dysfunction is associated 
with an increased risk of bleeding in older populations.(Moscucci et al., 2003) Patients 
presenting with ACS have associated chronic comorbidities which can play a major 
role in short term and long term outcomes.(Alexander et al., 2007a; Alexander et al., 
2007b) Although there has been rapid improvements in the management of ACS 
based on randomised control trials patients with comorbidities are continuing to be 
excluded from these trials.(Sachdev et al., 2004) Old age related functional and 
cognitive changes have an impact on disease related risks, which needs to be 
assessed in the management of older ACS patients.  
 
1.6.2 Influence of Co-morbidity in Research 
Co-morbidity can influence disease presentation, diagnosis, treatment offered and 
prognosis. Hence failure to classify and analyse comorbidities can lead to 
misrepresentation of statistical results.(Feinstei.Ar, 1970) The important reasons for 
measuring co-morbidity in research are to improve the internal validity of studies by 
correcting for confounding factors, to identify effect modification, to use co-morbidity 
as a predictor of study outcome or natural history and a comprehensive co-morbidity 





1.6.3 Charlson Comorbidity Index 
There are various measures of co-morbidity. Of these the Charlson Co-morbidity Index 
(CCI) is the most extensively studied and is a valid and reliable method of co-morbidity 
measure that can be used in clinical research.(de Groot et al., 2003) Charlson Co-
morbidity Index was developed in 1987 as a prognostic index of co-morbid conditions, 
for patients with multiple medical conditions admitted to general medical wards. The 
co-morbid conditions on their own or in combination, might alter the risk of short-term 
mortality for patients enrolled in longitudinal studies.(E, 1987)  
There were 19 diseases used in this model and the co-morbidities were weighted by 
Charlson et al using a point system. One point each for past history of myocardial 
infarction (MI), heart failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic lung disease, connective tissue disease, peptic ulcer disease, mild 
liver disease and diabetes. 2 points were weighted for diabetes with target organ 
damage, hemiplegia, and moderate to severe renal disease, malignant neoplasm, 
leukaemia and lymphoma. Moderate to severe liver disease was weighted with 3 points 
and metastatic solid tumour and Acquired Immunodeficiency Syndrome (stage C) were 
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CCI was used to test the ability to predict risk of death from co-morbidities by using 1-
year mortality data of the primary study population. When CCI was developed, weights 
were assigned for each co-morbidity based on the relative risks (RR) for 1-year 
mortality: RR <1.5 were assigned a weight of 1; RR 1.5 to <2.5 a weight of 2; RR ≥2.5 
to <3.5 a weight of 3; and metastatic tumours and Acquired Immuno Deficiency 
Syndrome were assigned a weight of 6. To simplify the system, the conditions with a 
relative risk below 1.2 were dropped. The RR for each point was 1.39, but in a 
validation cohort for 10-year mortality the RR for each CCI point increased to 2.3 and 




1.6.3.1 Validation of Charlson Comorbidity Index in ACS Patients 
CCI was used to assess the co-morbidities in AMIS (Acute Myocardial Infarction in 
Switzerland) Plus prospective multicentre observational registry study in 29,620 
patients with acute coronary syndrome from 2002 to 2012.(Radovanovic et al., 2014) 
The outcome measures were in-hospital and 1-year mortality. 27% were women (mean 
age 72.1±12.6 years) and 73% were men (64.2±12.9 years). 54.5% had STEMI, 39.1% 
had NSTEMI and 6.4% had UA. Almost half (48.6%) of the patients had co-morbidities. 
Patients were grouped into CCI 0 – no comorbidities; CCI 1 – only one co-morbidity 
weighted as 1; CCI 2 – patients with 2 comorbidities weighted 1 or one co-morbidity 
weighted 2 and CCI ≥3 patients in which the sum of the weighted points of co-
morbidities 3 or above. Most frequent comorbidities were past history of MI (18.0%), 
diabetes mellitus (14.7%), moderate to severe renal disease (7.1%), cerebrovascular 
disease (6.0%) and chronic lung disease (6.0%). NSTEACS was more common in 
patients with higher CCI compared to lower CCI (CCI=0 39.8% vs. CCI ≥3 55.8%, 
p<0.001).  
 
1.6.3.2 CCI and In-hospital Mortality Following ACS 
Based on the impact of single co-morbidity the strongest predictors of in-hospital 
mortality adjusted for age and gender were heart failure (adjusted OR 1.88; 95% CI 
1.57-2.25, p<0.001), metastatic tumours (OR 2.25; 95% CI 1.60-3.19, p<0.001), renal 
diseases (OR 1.84; 95% CI 1.60-2.11, p<0.001) and diabetes (OR 1.35; 95% CI 1.19-
1.54, p<0.001). Based on weighted scoring of co-morbidities in-hospital mortality risk 
increased with increasing weightage as CCI 1 had an OR of 1.36 (95% CI 1.16-1.60, 
p=0.001), CCI 2 was 1.65 (95%CI 1.38-1.97, p<0.001) and CCI ≥3 had an OR of 2.20 
(95% CI 1.86-2.57,p<0.001). 
CCI together with age (Receiver operating characteristic [ROC] curve area=0.756; 
95% CI 0.743-0.768) was a better predictor of in-hospital mortality compared to CCI 
alone (area=0.670; 95% CI 0.656-0.685). CCI together with age and sex (area=0.761; 
95% CI 0.748-0.773) did not improve the predictive ability much. In patients >50 years 




1.6.3.3 CCI and Follow up mortality Following ACS 
In 7066 patients followed up (median 386 days [IQR 370 to 409 days]), each CCI point 
increase was associated with increased incidence of mortality (OR 1.44, 95% CI 1.36-
1.53). Each decade increase in age doubled the risk of follow up mortality (OR was 
2.08 95% CI 1.81-2.39). ROC area was 0.83, 95% CI 0.80-0.86. There was significant 
difference in the use of PPCI for STEMI (70% vs 47%, p<0.001) favouring CCI <3. This 
study confirmed in a real world registry of patients with ACS, co-morbidities were a 
common occurrence, which had an impact on diagnosis, management and outcomes. 
In ACS patients CCI is an appropriate predictor of in-hospital and mid-term mortality. 
The management strategy (invasive or conservative) employed for NSTEACS 
treatment is not known to relate comorbidity and mortality. Though CCI ≥ 3 was 







1.6.3.4 Simple Comorbidity Index in NSTEACS 
Sanchis et al,(Sanchis et al., 2011) developed the simple co-morbidity index (SCI) in a 
derivation cohort of 1017 patients with NSTEACS using five co-morbid conditions – 
mild (1 point) to severe (2 points) renal disease, dementia (2 points), peripheral arterial 
disease (2 points), previous heart failure (2 points) and previous MI (1 point). In addition 
to SCI, CCI and CAD specific index were calculated. The mean (standard deviation) 
age of patients was 68(13) years and 34% were women. 71% of patients underwent 
coronary angiogram while 44% underwent PCI. The patients were followed up for 
primary outcome of 1 year mortality. Mortality rate increased with increasing points on 
the SCI; from 3.6% in the lowest co-morbidity category (0 points) to 11% (HR 1.7; 95% 
CI 1.0-3.1; p=0.06) in the intermediate category (1 or 2 points) and 36% in the high co-
morbidity (≥3 points) category (HR 4.8; 95% CI 2.7-8.5; p=0.0001). Invasive 
management decreased with increased co-morbidity level (83% vs. 67% vs. 36%, 
p=0.0001). Even after adjustment for management strategy in the predictive tool, 
invasive management (HR 0.5; 95% CI 0.3-0.8; p=0.01) and SCI (per point: HR 1.5; 
95% CI 1.3-1.7; p=0.0001) were predictive of mortality. SCI developed from the above 
derivation cohort was externally validated on 652 patients with NSTEACS. C-statistic 
decreased from 0.848 to 0.831 on the validation cohort suggesting lower discriminative 
ability but the calibration slope was close to 1 and hence did not need shrinkage of the 
regression coefficients. SCI was independently associated with mortality (per point: HR 
1.3; 95% CI 1.1-1.6; p=0.001) and death or MI (per point: HR 1.3; 95% CI 1.1-1.5; 
p=0.0001). SCI with 5 easily available variables was equivalent to detailed indices such 
as CCI and CAD specific index but the impact of these indices needs to be studied on 
therapeutic (revascularisation) effects on prognosis. 
 
1.6.3.5 Predictive Ability of SCI in Patients Undergoing PCI for NSTEACS  
Palau et al, (Palau et al., 2012) sought to investigate the predictive ability of SCI on 
prognostic effect of in-hospital revascularisation in high-risk NSTEACS patients. 
Between 2002 and 2008, 1017 patients with NSTEACS were recruited. The treatment 
strategy was at the discretion of cardiologist in charge: early invasive revascularisation 
or conservative (selective invasive strategy). The indication for revascularisation was 
based on coronary angiogram performed within 96 (±48 hours). The mean age of the 
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patient population was 68(±13 years) and 34% were females. The primary endpoint 
was composite of death from any cause and non-fatal MI. With increasing SCI score 
of 0, 1, 2 and >2 coronary angiography was performed less frequently 83% vs. 68% 
vs. 56% vs. 36% (P<0.001) respectively. The trend was similar for performing 
revascularisation 54% vs. 41% vs. 28% vs. 18% (p<0.001). But the differences were 
less marked in patients undergoing coronary angiography proceeding to have 
revascularisation (64.9% vs. 60.6% vs. 52.9% vs. 48.9%, p=0.001). During a median 
follow up of 16 months, 20% of patients died, 17% suffered MI and 30% had composite 
endpoints (MI/death).  There was no significant difference between non-revascularised 
patients and revascularised patients with 0 point (1.017 vs. 1.021 per 10 person-year 
of follow-up, p=0.587) and 1 point (1.812 vs. 2.345 per 10 person-year of follow up, p= 
0.497) for rates of the composite end points of death and MI. In comparison, 
revascularisation significantly reduced the occurrence of the combined end point 
(0.711 vs. 3.415 per 10 person-year of follow-up, p=0.002 and 2.684 vs. 7.042 per 10 
person-year of follow-up, p= 0.028) in those patients with 2 and >2 points respectively. 
These differential prognostic effects on outcomes were obtained in multivariate 
analysis with significant risk reduction in revascularised patients with SCI ≥2 (HR 0.51; 
95% CI 0.29-0.89, p=0.018). There was no significant benefits from revascularisation 
in patients with SCI score 0 and 1. Revascularisation benefits were significantly higher 
in patients with increased co-morbidity burden. 
 
1.6.4 Impact of Co-morbidity on ≥65 year old patients undergoing PCI 
Singh et al,(Singh et al., 2011) assessed the prognostic value of frailty, co-morbidity 
and quality of life over and in addition to the mayo clinic risk score (MCRS) in predicting 
outcomes of death and death or MI over a median follow up period of almost three 
years in 628 patients ≥65 year old patients undergoing PCI. 12% of patients died and 
22% patients had composite endpoints (death/MI). Univariate analysis showed 
comorbidity assessed by CCI was associated with mortality (HR 1.10; 95% CI 1.05 -
1.16). Addition of co-morbidity to MCRS increased the predictive ability with increase 
in C-statistics from 0.628 to 0.671 and from 0.573 to 0.576 for death and death or MI 
respectively. Addition of frailty, co-morbidity and quality of life significantly increased 




1.6.5 Cardiovascular Comorbidity in Acute Myocardial Infarction 
Cardiovascular comorbidities including atrial fibrillation (AF), diabetes, heart failure, 
hypertension and stroke were examined in 9581 patients with acute myocardial 
infarction between 1990 and 2007.(McManus et al., 2012) The average age of the 
participants was 70 years and 43% were females. Patients with two or more 
cardiovascular co-morbidities were likely to have increased 30 day and 1 year mortality 
rate. From 1990 to 2007, the proportion of participants in whom no co-morbid illnesses 
were present almost halved (31% to 16%), but at the other end of the spectrum 
participants with four or more comorbidities more than doubled (3% to 7%; p<0.05). 
After adjustment for several potentially confounding factors (age, sex and in-hospital 
complications) of prognostic importance, patients with two or more comorbidities 
experienced significantly high 30-day (2 co-morbidities: HR 1.49; 95% CI 1.23-1.80; 3 
co-morbidities: HR 1.64; 95% CI 1.32–2.03 and co-morbidities ≥4: HR 1.68; 95% CI 
1.28–2.21) and 1-year mortality (2 co-morbidities: HR 1.62; 95% CI 1.41-1.87 ; 3 co-
morbidities: HR 1.94; 95% CI 1.66-2.26 and co-morbidities ≥4: HR 2.31; 95% CI 1.91-
2.78). The risk of 30-day and 1-year mortality was directly related to the number of co-
morbidities present. This study has clearly demonstrated the importance of CV co-
morbidities on outcomes in patients with MI. 
Advanced age is associated with increased comorbidities. It is very common to 
encounter older patients with multiple co-morbidities presenting with ACS. Co-
morbidity burden has a significant impact on CV outcomes, both short and long term. 
It has been shown that both detailed and simple co-morbidity assessments add to 
predictive ability of prognosis in patients with ACS. It has also been shown that patients 
with multiple co-morbidities who are unlikely to be offered early invasive strategy may 
benefit more from revascularisation. The impact of co-morbidity on CV outcomes in 
older patients needs to be studied in detail. Also patients with multiple co-morbidities 







1.6.6 Interpretation of available evidence on comorbidity and CVD 
Comorbidities are common in older patients with CVD and they influence presentation 
and management. But older patients with comorbidities are not represented in clinical 
trials. Also patients with comorbidities do not receive standard guideline based 
treatment which in turn has an impact on outcomes. Though patients with increased 
comorbidity are at higher risk of adverse CV outcomes, they stand to benefit from 
contemporary treatment. Revascularisation benefits were noted to be higher in patients 
with higher comorbidity burden after NSTEACS. Increased risk of adverse CV 
outcomes were noted in observational studies compared to randomised trials. This is 
due to under representation of patients with comorbidities in RCTs. Comorbidity in 
older patients managed by contemporary NSTEACS treatment need to be assessed 
in detail. 
In previous sections ACS in older patients and their relation to frailty and comorbidity 
were discussed. In the following sections CVD burden in older patients with non-




1.7 Non-invasive assessment of cardiovascular disease burden 
Non-invasive assessment of arterial stiffness, endothelial dysfunction, carotid intima 
media thickness and left ventricular function will be reviewed. These measures are 
markers of cardiovascular disease burden. Techniques used in their assessment and 
its association with CV outcomes will be discussed. 
1.7.1 Arterial Stiffness 
Atherosclerosis of the arterial system is the key pathological process that results in MI 
and ischemic stroke, causing considerable morbidity and mortality. Established risk 
factors for atherosclerosis include hypertension, diabetes, hyperlipidaemia, smoking 
and a family history of cardiovascular disease (CVD). Increasingly, aging is also 
considered an independent risk factor for atherosclerosis, and the pathological 
processes in aging vessels are similar to those seen in atherosclerosis.(O'Rourke and 
Hashimoto, 2007) The vessel wall is the common end organ on which all deleterious 
effects of these intermediate risk factors are targeted. Non-invasive assessment of the 
totality of damage caused to the vessel wall is therefore an attractive method for 
predicting vascular events and may be more accurate than measurement of any single 
risk factor alone. Arterial stiffness resulting from vascular remodelling (intimal and 
medial thickening) and loss of arterial elasticity is now increasingly recognized as a 
surrogate endpoint for the monitoring of CVD.(Laurent et al., 2006) Indeed, 
measurement of arterial elastic properties has been suggested as a tool for the 
assessment of sub-clinical target organ damage by the European Society of 
Hypertension and the European Society of Cardiology guidelines for the management 
of arterial hypertension.(Mancia et al., 2007) 
 
1.7.2 Pathophysiology of Arterial Stiffness 
The arterial system is made up of large elastic arteries that are rich in elastin and 
collagen, and smaller, more muscular peripheral arteries. The arterial wall consists of 
three layers: the tunica adventitia, tunica media and tunica intima. A monolayer of 
endothelial cells lines the tunica intima between the lumen and vessel wall.  
While arterial tone is regulated by the endothelium, arterial elasticity is largely 
determined by the content of elastin, collagen and smooth muscle in the vessel 
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wall.(Bank et al., 1996; Bank et al., 1999) Collagen and elastin are the two prominent 
scaffolding proteins which contribute to the stability, resilience and compliance of the 
vessel wall. The relative content of these molecules is regulated by a slow but dynamic 
process of production and degradation. Imbalance in this process, resulting from 
stimulation of inflammatory cascades, leads to overproduction of abnormal collagen 
and diminished quantities of normal elastin, with a consequential increase in vascular 
stiffness.(Fleenor, 2013) Excessive collagen production is also stimulated by 
hypertension and hypercholesterolemia.(Xu et al., 2000) In aging arteries, these 
molecular changes are manifested as a 2-3 fold increase in intima-media thickness 
with associated hypertrophy of the vascular smooth muscle layer.(Zieman et al., 2005) 
Significant coronary stenosis is associated with increased aortic stiffness which 
improves after percutaneous coronary intervention.(Kalay et al., 2012) 
Endothelial cell signalling and vascular smooth muscle cell tone also influence arterial 
stiffness. Vascular tone can be modified by cell stretch and changes in calcium 
signalling.(Ando and Yamamoto, 2013) In addition, vascular tone is influenced by 
autocrine and paracrine mediators such as angiotensin II,(Dzau, 1986) 
endothelins,(Yanagisawa et al., 1988) oxidative stress(Gurtner and Burke-Wolin, 
1991) and nitric oxide.(Forstermann and Munzel, 2006) Increased expression of the 
nitric oxide synthase inhibitor, asymmetrical dimethyl arginine, has also been linked to 
vascular stiffening.(Miyazaki et al., 1999) 
Arterial calcification has been associated with traditional atherosclerotic risk factors 
such as increasing age, hyperlipidaemia, diabetes mellitus and smoking.(Allison et al., 
2004), (Post et al., 2007) Aortic calcification, in particular, has been proven to be a 
predictor of aortic stiffness, and in addition, contributes to isolated systolic 
hypertension.(McEniery et al., 2009) 
Pressure wave is generated by the ejection of blood from the ventricle into the aorta. 
As this wave travels forward, it gets reflected back along branching points in the arterial 
tree more from the peripheral branches. The actual pressure waveform is a summation 
of the forward and reflected waves. In elastic arteries these reflected waves reach the 
ascending aorta in diastole. But with increasing arterial stiffness they reach the 
ascending aorta earlier in systole, augmenting systolic pressure and decreasing 




1.7.3 Importance of Arterial Elasticity 
As the largest elastic blood vessel, the aorta is the main determinant of arterial 
compliance and hence, stiffness. The distensibility of the aorta is responsible for 
buffering the variation in flow and pressure generated by intermittent cardiac 
contraction. Loss of elasticity and decreased absorption of this pressure wave by the 
aorta may increase cardiac after load and impair coronary blood flow.(Nichols and 
O’Rourke, 2005; Safar and O’Rourke, 2006) The elastic properties of the arterial tree 
vary with increasing distance from the heart due to differences in the molecular, cellular 
and histological structure of the vessel wall.(Fischer and Llaurado, 1966; Latham et al., 
1985; Bezie et al., 1998; Laurent et al., 2005) Fracture of elastic lamellae is seen in 
the aorta with aging, and this finding may account for the functional and structural 
changes.(Virmani et al., 1991)  
 
1.7.4 Effect of Arterial Stiffness on Coronary Perfusion 
In older subjects with hypertension, reflected waves travel rapidly back along the 
arterial tree towards the heart in early systole and are superimposed on the forward 
wave, increasing systolic pressure. In contrast, blood pressure falls sharply in diastole 
with reduced diastolic fluctuations.(Laurent et al., 2006) The combined effect of aortic 
stiffness is thus to increase systolic pressure and decrease diastolic pressure.(Lakatta 
and Levy, 2003; Nichols and O’Rourke, 2005; Safar and O’Rourke, 2006) The increase 
in systolic afterload results in LV hypertrophy (LVH) and increases LV oxygen 
requirements. Additionally, LVH increases the duration of systole while decreasing the 
length of diastole due to abnormalities in isovolumetric relaxation.(Nichols and 
O’Rourke, 2005; Safar and O’Rourke, 2006) The increased demands on coronary flow 
from the hypertrophied ventricle are not met due to decreased aortic pressure 
throughout diastole and reduced duration of diastole. Thus, coronary blood flow is 
impaired independent of coronary stenosis and myocardial ischemia results from both 
increased demand and decreased coronary perfusion.(Ferro et al., 1995) This leads to 
further impairment of ventricular relaxation and prolongation of the ejection period, all 
tending to further decrease myocardial perfusion.(Lakatta and Levy, 2003; Nichols and 
O’Rourke, 2005; Safar and O’Rourke, 2006) This vicious cycle may predispose to 
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angina in the presence of even minor coronary artery disease (CAD) and to the 
development of diastolic dysfunction, probably the commonest form of heart failure in 
the elderly.(Weber et al., 2006)  
 
1.7.5 Measures of Arterial Stiffness 
Arterial elasticity in vivo has been assessed by several invasive and non-invasive 
methodologies. The three most common non-invasive measures (pulse wave velocity 
[PWV], central pulse wave analysis [PWA] and measurements of changes in arterial 
diameter to distending pressure) are discussed below. 
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1.7.5.1 Pulse Wave Velocity  
Carotid-femoral PWV is generally accepted as the most simple, non-invasive, robust 
and reproducible method to determine arterial stiffness, and is currently considered the 
gold-standard measurement.(Laurent et al., 2006) PWV is usually measured by the 
foot-to-foot velocity method from various waveforms including pressure,(Asmar et al., 
1995) distension(van der Heijden-Spek et al., 2000) and Doppler.(Cruickshank et al., 
2002) Aortic PWV can also be measured non-invasively using magnetic resonance 
imaging (MRI).(Mohiaddin et al., 1993) Typically, the arterial PW is recorded at a 
proximal artery such as the common carotid, and at a distal site such as the femoral 
artery. The superficial location of these arteries means that their PW-forms are readily 
measured non-invasively, and between these two sites the PW has to travel through 
most of the aorta. The foot of the PW occurs at the end of diastole when the steep rise 
in pressure begins. The time delay between the wave foots at each location is 
simultaneously measured by continuous Doppler probe (Cruickshank et al., 2002) or 
by gating to the peak of the R-wave on the ECG.(Millasseau et al., 2000; van der 
Heijden-Spek et al., 2000)  
The measurement of PWV by the foot-to-foot method is illustrated in Figure 1.4. PWV 
is calculated as distance (meters)/transit time (seconds). The transit time is the time of 
travel of the foot of the wave over a known distance. Distance covered by the PW is 
defined as the surface distance between the two recording sites. Multiple branches of 
the aorta with focal atherosclerosis at branching points generate wave reflections and 
attenuation which can distort the transit time estimation and subsequently affect 
accurate measurement of PWV.(Stevanov et al., 2001) The measured distance is an 
estimate of the true distance travelled and may vary according to body habitus and the 
tortuosity of the abdominal aorta. Aortic tortuosity increases with age, (Wenn and 
Newman, 1990) potentially leading to an underestimation of PWV. Inaccurate 
measurement of the distance may therefore adversely affect the absolute value of the 
PWV.(Chiu et al., 1991) Figure 1.5 is an example of carotid-femoral PWV measured 
by the Vicorder device (Skidmore Medical Limited, Bristol, UK). It should be noted that 
the femoral pressure waveform may be difficult to record accurately in patients with 
metabolic syndrome, diabetes, obesity and peripheral vascular disease.(Van Bortel et 
al., 2002) Raised PWV occurs alongside a range of established cardiovascular risk 
factors,(Lehmann et al., 1998) including age,(Vaitkevicius et al., 1993) 
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hypercholesterolemia,(Lehmann et al., 1992) type I and II diabetes(Zhang et al., 2011; 




Figure 1.4: Measurement of carotid-femoral PWV with the foot to foot method   
 
The foot of the wave is at the end of diastole, when the steep rise of the wave front 
begins. The time between the foot of the carotid and femoral pulse waves is used to 
calculate the PWV.   PWV – pulse wave velocity. 
Adapted from Laurent et al. European Network for Non-invasive Investigation of Large 
A. Expert consensus document on arterial stiffness: Methodological issues and clinical 






Figure 1.5: PWV measurement: A case example   
 
Pulse wave velocity (PWV) measurement from a 75 year old man who had multi-vessel 
percutaneous coronary intervention for non ST elevation myocardial infarction using 
Vicorder device (Skidmore Medical Limited, Bristol, UK), which records simultaneous 
pulse volume at the carotid and femoral artery using pneumatic cuffs. Length travelled 
by the pulse wave is from the suprasternal notch to the mid cuff in the thigh. PWV is 
calculated from the distance travelled (L) divided by the transit time (TT). PWV 




1.7.5.2 Direct Measurement of Arterial Stiffness in Specific Arteries 
A direct measure of arterial stiffness may be made by assessing the change in 
diameter in relation to the distending pressure.(Oliver and Webb, 2003) This is possible 
in a number of superficial arteries, including the carotid, brachial, and radial arteries, 
and the aorta. Carotid stiffness may be of particular interest, since atherosclerosis is 
frequent in carotid arteries.(Laurent et al., 2006) Local arterial stiffness of superficial 
arteries is most commonly determined using ultrasound devices, although MRI has 
also been used. Ultrasound measurements, although simpler to perform, are limited in 
precision due to the need for video-image analysis. More recently, echo tracking 
devices have been developed to measure diameter at end-diastole and stroke change 
in diameter with very high precision. These devices use the radiofrequency signal to 
obtain a resolution 6-10 times higher than video-image systems.(Tardy et al., 1991)  
 
1.7.5.3 Central Pulse Wave Analysis  
The arterial pressure waveform is a composite of the forward pressure wave created 
by ventricular contraction and a reflected wave returning from the peripheries. Since 
the PWV is low in elastic vessels, under normal circumstances the reflected wave 
reaches the aortic root in diastole. However, as the PWV increases with increasing 
arterial stiffness, the reflected wave reaches the aortic root earlier, augmenting the 
forward wave and creating a second, higher peak systolic pressure in the forward wave 
(Figure 1.6). The difference between the first and second systolic peaks is defined as 
the augmentation pressure. The augmentation index (AI) is defined as the ratio of the 
augmentation pressure to pulse pressure (PP).(O’Rourke, 1982; London et al., 1992; 
Mackenzie et al., 2002) PP is calculated as the difference between the systolic blood 
pressure and diastolic blood pressure. The AI is thus the proportion of central PP that 
results from arterial wave reflection and is a commonly used measure of arterial 
stiffness. AI increases with mean arterial pressure (MAP),(Wilkinson et al., 2001) and 
is inversely related to heart rate(Wilkinson et al., 2000; Gatzka et al., 2001) and body 
height.(Smulyan et al., 1998)  
Ideally, the arterial pressure waveform should be analysed in the ascending aorta, 
since this represents the true load imposed on the left ventricle and large central 
arterial walls. Since this is rarely practical in a clinical context, the central aortic 
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pressure waveform can be estimated from the waveforms measured in the common 
carotid or radial arteries.(Chen et al., 1996; Chen et al., 1997; Pauca et al., 2001) 
Figure 1.7 is an example of PWA measured utilizing the Vicorder device. Because the 
waveform contour from the radial artery is different from that of the ascending aorta, a 
transfer function is required to approximate it with the central aortic 
waveform.(Karamanoglu et al., 1993; Chen et al., 1997) The transfer function is 
typically built into the computer software for PWA and is calibrated using peripheral 
blood pressure. However, the transfer function is typically derived from healthy 
subjects and may not be accurate in different patient populations.(Hope et al., 2004b) 
Furthermore, issues with methods to calibrate the tonometer to the non-invasively 
measured blood pressure and reflection waves, which are caused by compression of 
the peripheral artery by the tonometer, can make estimation of central waveforms 
unreliable using transfer functions.(Hope et al., 2004a)  
PWA should include central pulse pressure, central systolic pressure and AI.(Laurent 
et al., 2006) Compared to PWV, which is a direct measure of arterial stiffness, central 
PP and AI are indirect, surrogate markers of arterial stiffness. Central PWA and aortic 






Figure 1.6: Augmentation Index  
 
The height of the late systolic peak (P1) above the inflection (P2) defines the 











Figure 1.7: Pulse wave analysis:  A case example  
 
Pulse wave analysis from a 75 year old man who had multi-vessel PCI for NSTEMI 
using the Vicorder device (Skidmore Medical Limited, Bristol, UK) at the brachial and 
femoral artery measured by pneumatic cuffs. In this patient Augmentation Index (24%) 





1.7.6 Usefulness of Arterial Stiffness as a Predictor of Cardiovascular Events 
The utility of PWV as an additive and independent predictor of cardiovascular events 
has been tested prospectively in a number of different community and patient 
populations (Table 1.4). These are discussed below. 
 
1.7.6.1 Older Patients 
In a report involving patients from the Health Aging and Body Composition (Health 
ABC) study, aortic PWV was measured at baseline in 2488 generally healthy and 
community-dwelling older adult participants (mean age±SD, 73.7±2.9 years). Over 4.6 
years, 265 deaths occurred, 111 as a result of cardiovascular causes. Results were 
presented by quartiles because of a threshold effect between the first (lowest) and 
second aortic PWV quartiles. Higher aortic PWV was associated with both total 
mortality (relative risk [RR], 1.5, 1.6, and 1.7 for aortic PWV quartiles 2, 3, and 4 vs. 
quartile 1; p=0.019) and cardiovascular mortality (RR 2.1, 3.0, and 2.3 for quartiles 2, 
3, and 4 vs. quartile 1; p=0.004). A higher aortic PWV quartile was also significantly 
associated with coronary heart disease (p=0.007) and stroke (p=0.001). These 
associations remained after adjustment for age, gender, race, systolic blood pressure 
and known CVD.(Sutton-Tyrrell et al., 2005) A further study in the very elderly 
specifically analysed whether PWV remained an important prognostic indicator for 
hospital in-patients aged 70 to 100 years. During the 30-month follow-up, 56 patients 
died, including 27 from cardiovascular causes. While age and loss of autonomy were 
the strongest predictors of all-cause mortality, aortic PWV was the strongest predictor 




Table 1.4: Studies Linking Arterial Stiffness to Cardiovascular Outcomes 
Study/Year Number Mean Age 
(years) 




Mitchell et al.(Mitchell 
et al., 2010) 2010 
2232 63  7.8  48% increased CVD risk, 95% CI 1.16-1.91 per SD, p=0.002 
Wang et al.(Wang et 
al., 2010) 2010 
1272 52  15  Each 1 SD (2.3 m/s in men and 2.5 m/s in women) increase in PWV is associated  with 
increased CV mortality (HR 1.56, 95% CI 1.25-1.94 in men and HR 1.94, 95% CI 1.56-2.42 in 
women)  
Anderson et 
al.(Anderson et al., 
2009) 2009 
174 60  19.6 Increased all-cause mortality per 1 m/s increase in PWV, HR 1.15, 95% CI 1.01-1.30 
Willum-Hansen et 
al.(Willum-Hansen et 
al., 2006) 2006 
1678 40-70  9.4  Each 1 SD increment in aortic PWV (3.4 m/s), the risk of an event increased by 16-20%, p<0.05 
Community Older Population 
Mattace-Raso et 
al.(Mattace-Raso et 
al., 2006) 2006 
2835 71  4.1  Increased CHD with increased aortic PWV Second tertile HR 1.72; 95% CI 0.91-3.24; Third 
tertile HR 2.45;95% CI 1.29-4.66 
Sutton-Tyrrell et 
al.(Sutton-Tyrrell et 
al., 2005) 2005 
2488 74  4.6  Higher aortic PWV was associated with all-cause mortality RR, 1.5, 1.6, and 1.7 for aortic PWV 
quartiles 2, 3, and 4 vs. quartile 1; p=0.019 and CV mortality RR 2.1, 3.0, and 2.3 for quartiles 2, 
3, and 4 vs. quartile 1; p=0.004. 
Hospitalised Older Patients 
Meaume et 
al.(Meaume et al., 
2001) 2001 
141 87  2.5  Increased PWV predicts CV mortality, OR 1.19, 95% CI 1.03-1.37, p=0.018 
PCI 
Kaneko et al.(Kaneko 
et al., 2013) 2013  
236 67  0.5-1 Higher brachial ankle PWV (18.3± 3.7 vs. 15.8± 3.1m/s, p<0.001) was an independent predictor 
of PCI to previously non-significant lesions 
CVD-Cardio Vascular Disease, CHD-Coronary Heart Disease, PWV-Pulse Wave Velocity, ESRD-End Stage Renal Disease, T2DM-Type 2 Diabetes Mellitus, STEMI-
ST Elevation Myocardial Infarction, PCI-Percutaneous Coronary Intervention, SD- Standard Deviation, CI-Confidence Interval, HR-Hazard Ratio, RR- Relative Risk, 




1.7.7 Interpretation of evidence on arterial stiffness and CVD 
Arterial stiffness is a measure of atherosclerotic burden in large calibre arteries. Arterial 
stiffness can be measured by both invasive and non-invasive techniques. Arterial 
stiffness has been shown to predict adverse CV outcomes. It has been studied in 
community population but not in patients with established CVD. It has not been studied 
in older patients with ACS. It can be a risk stratification marker like hypertension. 
Similar to arterial stiffness in large calibre arteries, endothelial dysfunction in smaller 
calibre arteries leads on to adverse CV events. Endothelial dysfunction will be 





1.8 Endothelial Dysfunction and Coronary Artery Disease 
The endothelium represents the interface between circulating blood and the vascular 
wall.  Through its role in signal transduction and as a source of multiple vasoactive 
substances, it is a key regulator of vascular homeostasis(Vita and Keaney, 2002). 
Altered endothelial function precedes the development of morphological 
atherosclerotic changes. Indeed, endothelial dysfunction is considered the earliest 
marker of atherosclerosis(Luscher and Barton, 1997) and contributes to lesion 
development and its later clinical manifestations(Ross, 1993). Cardiovascular risk 
reduction therapies such as statins and smoking cessation improve endothelial 
function, whilst the failure of the endothelium to respond to such therapies is associated 
with higher CV risk (Modena et al., 2002). Endothelial dysfunction is also associated 
with increased risk of cardiovascular events and its presence has thus been proposed 
as a marker of heightened CV risk (Schachinger et al., 2000; Suwaidi et al., 2000; 
Halcox et al., 2002).  
 
1.8.1 Role of Endothelium in Regulation of Vascular Tone 
Rather than simply an inert barrier between blood and the vessel wall, the endothelium 
is a monolayer of cells which respond to physical and chemical signals by the 
production of multiple autocrine and paracrine vasoactive factors. These factors 
regulate basal vascular tone, cellular adhesion, thrombogenicity, smooth muscle cell 
proliferation, and vessel wall inflammation (Luscher and Barton, 1997; Kinlay et al., 
2001). Through modulation of vascular tone, the endothelium plays a direct role in 
maintaining the balance between oxygen supply and demand, and maintaining organ 
perfusion (Schechter and Gladwin, 2003). Vascular tone is dependent upon the 
balance between endothelium-derived vasodilators, consisting of Nitric Oxide (NO), 
prostacyclin, endothelium-derived hyperpolarising factors (EDHF) and C-type 






1.8.2 Endothelial Dysfunction 
The mitochondrion is an important source of reactive oxygen species (ROS) and 
production of ROS and mitochondrial superoxide dismutase (SOD) are carefully 
balanced during oxidative phosphorylation (Li et al., 1995). This balance may be 
disturbed during hypoxia, or by obesity-related metabolic disorders and type II 
diabetes, which are conditions characterized by hyperglycaemia and increased 
circulating free fatty acids (Li et al., 1995; Evans et al., 2002). Cardiovascular risk 
factors also modulate expression of chemokines, cytokines, and adhesion molecules 
by the endothelium. This change in endothelial phenotype likely results from a switch 
in signalling from NO-mediated inhibition of cellular processes to one of activation by 
redox signalling, as discussed below. This switch may further lead to interaction with 
circulating leukocytes and platelets and the initiation of inflammation (Hansson, 2005).  
 
1.8.3 Mechanisms of Endothelial Dysfunction 
Sub-endothelial entry and retention of apolipoprotein B–containing lipoproteins plays 
a central role in the initiation of atherosclerosis by activating the inflammatory process 
(Tabas et al., 2007). A variety of cardiovascular risk factors including type II diabetes, 
hypercholesterolaemia, smoking, chronic inflammation and aging are associated with 
an increase in the expression of nicotinamide adenine dinucleotide phosphate 
(NADPH)-oxidases in the vessel wall and consequent overproduction of ROS 
(Griendling et al., 2000; Babior, 2004). Formation of peroxynitrite from the combination 
of ROS and NO has been proposed as an initial step in the chronic dysregulation of 
normal NO production by eNOS that characterises endothelial dysfunction (Koppenol 
et al., 1992; Griendling and FitzGerald, 2003). Central to this change is an increase in 
monomerisation (‘uncoupling’) of eNOS from its tetrahydrobiopterin (BH4) cofactor. In 
monomeric form, eNOS produces superoxide, rather than NO. A vicious cycle is 
initiated, with ROS and superoxide reacting with NO to form peroxynitrite, which in turn 
oxidises BH4 to a biologically inactive BH3 radical, leading to a further uncoupling of 
eNOS and further superoxide production (Milstien and Katusic, 1999; Landmesser et 
al., 2003). Peroxynitrite may have additional direct effects on zinc binding that further 
promote eNOS uncoupling and is itself a mediator of LDL oxidation, with consequent 
pro-atherogenic effects (Griendling and FitzGerald, 2003). When uncoupled, eNOS 
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thus switches from its oxygenase function producing NO to a reductase function 
producing ROS. The consequent oxidant excess then exerts a deleterious effect on 
endothelial and vascular function. 
Oxidative stress is linked to a pro-inflammatory state of the vessel wall. ROS up 
regulate expression of adhesion molecules [intercellular adhesion molecule-1 (ICAM-
1), vascular adhesion molecule-1 (VCAM-1)] and chemotactic molecules [macrophage 
chemo attractant peptide-1 (MCP-1)].(Griendling and FitzGerald, 2003) Increased 
level of C-reactive protein (CRP) has been associated with decreased eNOS 
activity.(Venugopal et al., 2002; Verma et al., 2002) Other important sources of 
oxidative stress in the endothelium are NADPH oxidases and xanthine oxidase, which 
have been shown to have increased activity in the arteries of patients with coronary 








1.8.4 Measures of Endothelial Function 
Endothelium dependent vasomotion can be assessed by invasive and non-invasive 
methods, both in the coronary and peripheral circulation.  
 
1.8.4.1 Assessment of Peripheral Arterial Endothelial Function 
1.8.4.1.1 Invasive  
Coronary endothelial function has been shown to correlate closely with endothelial 
function in the brachial artery.(Anderson et al., 1995) Hence, intra-brachial infusion of 
vasoactive drugs has been used as a surrogate measure of coronary endothelial 
function.(Anderson et al., 1995; Virdis et al., 2001; Wilkinson and Webb, 2001) 
Insertion of a cannula into the brachial artery for local drug infusion allows use of doses 
far lower than would be required to have a biological effect if given systemically. 
Results are expressed as the ratio of the change in flow between the control and 
infused forearm and are highly reproducible.(Petrie et al., 1998) The disadvantage of 
this method is the risk of injury to the brachial artery and median nerve. 
 
1.8.4.1.2 Non-invasive  
1.8.4.1.2.1 Flow-mediated Dilatation (FMD) 
The vascular endothelium is capable of transducing changes in shear stress to 
modulate vascular tone. Although the precise mechanism is still debated, an increase 
in blood flow and shear stress leads to vasodilation. Measurement of flow-mediated 
vasodilatation (FMD) of the forearm arteries is a widely used technique to assess 
endothelial function. Forearm blood flow can be measured by venous occlusion 
plethysmography. Changes in forearm size in response to changes in arterial blood 
inflow during brief venous occlusion are measured using an external strain gauge, with 
the contralateral forearm acting as an internal control.(Whitney, 1953; Wilkinson and 
Webb, 2001) This technique involves baseline ultrasound measurement of brachial 
artery dimensions and Doppler estimation of flow. After 5 minutes of arterial inflow 
occlusion, the BP cuff is released and the effect on brachial arterial size of the resultant 
hyperaemic flow is measured.(Joannides et al., 1995a; Joannides et al., 1995b; 
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Lieberman et al., 1996) Typically a change of 5% in dilatation can be detected but 
measurement of such a small change requires reliable and accurate methods. 
This technique of measuring FMD is technically difficult and requires extensive training. 
A number of parameters including study subject preparation, image acquisition and 
site selection, sphygmomanometer probe position, cuff occlusion time, accurate use of 
edge-detection software and correct characterization of the FMD response, can have 
a major impact on results.(Charakida et al., 2010; Harris et al., 2010; Thijssen et al., 
2011) Because of this, FMD assessment is limited by inter observer variability and 
reproducibility. Nevertheless, peripheral endothelial function as assessed by FMD 
correlates well with coronary artery endothelial function. In a study of 50 patients 
undergoing cardiac catheterisation, coronary endothelial dysfunction was significantly 
associated with impaired-flow mediated dilatation in the brachial artery compared to 
patients with normal coronary endothelial function (4.8 ± 5.5% vs. 10.8 ± 7.6%, p < 
0.01).(Anderson et al., 1995) 
Vasoconstriction of the brachial artery in response to a decrease in blood flow and 
shear stress induced by a distally placed cuff has been termed low-flow-mediated 
constriction (LFMC).(Gori et al., 2008; Gori et al., 2010; Gori et al., 2011) The predictive 
power of a risk factor model based on traditional risk factors for CAD was improved by 
the addition of LFMC and FMD.(Gori et al., 2012) 
 
1.8.4.1.2.2 Peripheral Arterial Tonometry 
Peripheral arterial tonometry (PAT) by finger plethysmography (EndoPAT©; Itamar 
Medical) is a novel way to measure the peripheral vasodilator response.(Lavie et al., 
2000; Kuvin et al., 2003) PAT signal amplitude increases in response to hyperaemia 
and gives a measure of NO mediated endothelial function.(Noon et al., 1996; Nohria 
et al., 2006) PAT signals are recorded from the index fingers with pneumatic probes at 
baseline, during cuff occlusion and during hyperaemia. A measure of endothelial 
function is calculated from the ratio of PAT signal amplitude at baseline and post-
occlusion. The advantages of this technique are that the contralateral arm acts as an 
internal physiological reference and that the device is easy to use. In a study by Bonetti 
et al., (Bonetti et al., 2004) of 94 patients without obstructive CAD, digital reactive 
hyperaemic index was lower in patients with coronary endothelial dysfunction 
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compared with normal endothelial function (1.27 ± 0.05 vs. 1.78 ± 0.08, p < 0.001). In 




1.8.5 Association of Endothelial Dysfunction and CV outcomes 
Traditional risk factors for the development of atherosclerosis such as hypertension, 
diabetes, hypercholesterolemia, smoking and a family history of premature 
cardiovascular disease are associated with endothelial dysfunction.(Vita et al., 1990; 
John et al., 1998; Schachinger et al., 1999) This has raised the question of whether 
endothelial dysfunction is an independent predictor of CV events. 
 
1.8.5.1 Studies Using FMD 
Several studies have now shown an association between endothelial dysfunction and 
poor CV outcomes. The Fire fighters and Their Endothelium (FATE)(Anderson et al., 
2011b) study recruited 1574 male fire fighters who were clinically free of cardiovascular 
disease and had a lower incidence of CV risk factors than a general community 
population. Brachial artery FMD and hyperaemic velocity was measured in each 
participant. Over a mean follow up of 7 years, FMD corrected for shear stress (HR 1.18 
per SD; 95% CI 1.09-1.28; p<0.001) and hyperaemic velocity time integral (VTI) (HR 
0.52 per SD; 95% CI 0.41-0.66; p<0.001) were a significant predictor of CV events 
(n=111, 7% - non-fatal myocardial infarctions [MI], coronary revascularisations, 
cerebrovascular disease and peripheral vascular disease). However, FMD alone did 
not predict CV events (HR 0.92; p=0.54). 
In the Cardiovascular Health Study, (Yeboah et al., 2007) FMD was measured in 2792 
elderly adults (age range 72 - 98 years). After 5 years, 24% of patients had a CV event 
and FMD remained a significant predictor of CV events even after adjustment for 
traditional CV risk factors (HR 0.91; 95% CI 0.83-0.99, p=0.02 per unit SD of FMD).  
In the Multi-Ethnic Study of Atherosclerosis (MESA), brachial artery FMD was 
measured in 3026 adults not known to have history of CVD at recruitment and followed 
up for 5 years (Yeboah et al., 2009). At follow up 6% of patients had CV events. In 
univariate analysis adjusted for age and sex, FMD per unit SD was significantly 
associated with incident CV events including MI, angina, coronary revascularization, 
stroke, resuscitated cardiac arrest, and CVD death (HR 0.79; 95% CI 0.65-0.97; 
p=0.01). Similarly in multivariate analysis adjusted for traditional CV risk factors, FMD 





1.8.5.2 Studies Using Invasive Techniques 
Similar results have been demonstrated when endothelial dysfunction has been 
measured using invasive techniques. In 308 patients undergoing cardiac 
catheterisation for investigation of chest pain or abnormal non-invasive cardiac 
investigations, Halcox et al. (Halcox et al., 2002) measured coronary vascular 
resistance and epicardial coronary artery diameter to assess endothelium-dependent 
and independent coronary vasodilation following intracoronary infusions of ACh and 
sodium nitroprusside, respectively. 11.3% of patients experienced an acute CV event 
during a follow up period of four years. The study population was divided into tertiles 
according to the change in coronary vascular resistance (CVR) with ACh and an 
association between decreased microvascular dilatation and acute CV events (sudden 
cardiac death, MI, unstable angina and stroke) as measured by CBF (CBF increase of 
67 ± 12% versus 114 ± 6%; p=0.007) and CVR (CVR fall of 28 ± 6% versus 46 ± 2%; 
p=0.007) was demonstrated. Acute CV events were more frequent in patients who had 
epicardial constriction following IC ACh (13% versus 9.4%, p=0.003 by Kaplan Meir 
analysis). However, there was no difference in event-free survival when analysed by 
epicardial artery diameter change in response to sodium nitroprusside (p=0.33). From 
this it can be inferred that endothelium-dependent vasodilatation abnormalities have 
prognostic implications but abnormalities of endothelium-independent vasodilatation 
do not. 
Suwaidi et al. (Suwaidi et al., 2000) evaluated coronary flow reserve (CFR) in 157 
patients referred for coronary angiography who had minor CAD. Based on CFR, 
endothelial dysfunction was classified as normal, mild or severe. Over an average 
follow up period of 2.3 years, 14% of patients with severe endothelial dysfunction 
experienced cardiac events (MI, revascularisation and or death) whilst there were no 
events in patients with normal or mild endothelial dysfunction (p<0.05). This study 
suggests that severe endothelial dysfunction may play an important role in the 
progression of CAD. 
In a study by Schachinger et al. (Schachinger et al., 2000) endothelium dependent and 
independent coronary vasodilatation was assessed in 147 patients undergoing 
coronary angiography or single vessel percutaneous coronary intervention (PCI). By 
multivariate Cox regression analysis over a median follow up period of 8 years impaired 
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coronary endothelial vasoreactivity in response to ACh  (p=0.053), cold pressor 
(p=0.012), increased blood flow (p=0.01) and nitroglycerin (p=0.01) was an 
independent predictor of CV events. 
  
1.8.5.3 Studies Using PAT 
Rubinshtein et al., (Rubinshtein et al., 2010) measured reactive hyperaemia index 
(RHI) in 270 patients who presented with unexplained chest pain and low-risk findings 
during stress testing and/or the absence of new obstructive lesions on angiography. 
During a mean follow up period of 5.8 years adverse cardiac events (CV 
death/MI/revascularisation or CV hospitalisation) occurred in 86 patients (31%). 
Adverse events were higher in patients with a natural logarithmic scaled RHI of <0.4 
compared with ≥0.4 (48% versus 28%, p=0.03, HR 1.83, 95% CI 1.18-2.81). This 
finding was mainly driven by increased CV death (3.9% versus 0%, p=0.032) and CV 
hospitalisations (30.5% versus 18.7%, p=0.018, HR 2.06; 95% CI 1.26-3.38). 
 
1.8.6 Endothelial Dysfunction after PCI 
Balloon angioplasty causes coronary endothelial dysfunction, as evidenced by 
impaired vasodilatation in response to intracoronary ACh, 3-6 months after coronary 
angioplasty.(Vassanelli et al., 1994) The severity of endothelial dysfunction 6 months 
after PCI in the left anterior descending artery was worse after PCI with stent compared 
to PCI with balloon angioplasty or directional atherectomy alone.(Caramori et al., 1999) 
A differential effect on endothelial dysfunction has also been noted related to the type 
of drug eluting stents deployed. Coronary vasoconstriction in response to different 
stimuli (ACh, exercise and pacing) has been noted in multiple studies in the chronic 
phase following sirolimus-eluting (SES) and paclitaxel-eluting stents (PES), but not 
with zotarolimus-eluting (ZES) and biolimus-eluting stents (BES), compared with bare-
metal stent (BMS).(Minami et al., 2013) The inflammatory response of the vascular 
wall, stent strut size, the drug eluted and the type of polymer remaining on the stent 




1.8.7 Interpretation of evidence on endothelial dysfunction 
Endothelial dysfunction predisposes to atherosclerotic changes and plaque 
development. It can be measured by both invasive and non-invasive techniques. There 
is a significant association between endothelial dysfunction and adverse CV events. 
Limited studies have assessed endothelial dysfunction in patients with CAD. It has not 
been studied in older patients. 
Carotid intima media thickness has been extensively studied as a marker of 






1.9 Carotid Intima Media Thickness 
Progression of atherosclerosis results in cardiovascular disease leading to 
considerable morbidity and mortality, hence direct visualization of the carotid artery 
quantifying the atherosclerotic burden on the carotid wall can be a useful tool in the 
cardiovascular and cerebrovascular risk assessment. 
 
1.9.1 Marker of Subclinical Atherosclerosis 
Carotid Intima Media Thickness (CIMT) measurements by non-invasive ultrasound 
imaging correlated well with measurements from histology specimens.(Pignoli et al., 
1986) In this study the authors described a characteristic B-mode image of the arterial 
wall composed of two parallel echogenic lines separated by a hypo echoic space which 
was similar to the IMT measured on pathologic examination. The investigators 
concluded that B-mode imaging could be a useful approach to the measurement of 
IMT in vivo. The ‘double echo’ pattern shown to represent the combined width of the 
carotid artery intima and media can be easily accessed for non-invasive imaging by 
ultrasound. Subsequently CIMT is the most widely used non-invasive measurement of 
atherosclerosis to quantify the severity of sub-clinical disease.(O'Leary and Bots, 2010) 
 
1.9.2 Carotid Artery Segments and Layers on Ultrasonography 
Carotid artery is divided into three segments each approximately 1 cm in length. The 
proximal segment, immediately prior to the carotid artery bifurcation is the common 
carotid artery (CCA) which is extra cranial. The mid segment is the carotid bulb formed 
by the diverging near and far walls with the artery beginning to divide into internal and 
external branches. The distal margin of the carotid bulb is defined by the tip of the flow 
divider separating the diverging internal carotid artery (ICA) and external carotid artery 
(ECA). The final distal segment is the proximal 1 cm of the ICA. The proximal CCA can 
be readily and reproducibly visualized in nearly all subjects as the carotid artery is 
superficial, relatively stationary and runs parallel to the neck until bifurcation.(O'Leary 
and Bots, 2010) The tissue layer lying between the luminal border of the artery and the 
boundary between the media and adventitia layers forms the intima media portion. In 
the absence of plaques these layers are distinguished by B-mode ultrasonography as 




Figure 1.8: Carotid artery segments by B-mode ultrasound 
 















1.9.3 Important Considerations with CIMT Measurements 
Intima media thickness need to be differentiated from carotid atherosclerotic plaque. 
Carotid plaque is defined as a focal structure that encroaches into the lumen of at least 
0.5mm or 50% of surrounding IMT value or a thickness >1.5mm from the media 
adventitia interface to the intima lumen interface.(Touboul et al., 2012) Carotid IMT can 
vary according to the cardiac cycle by 0.03mm, being thickest at end of diastole and 
thinnest at peak systole. The CIMT value also varies according to the segment 
measured, near or far wall measurement and method used for measuring (automated 
or manual tracing).(Bots et al., 2003) 
 
1.9.4 Automated Edge Detection for CIMT Measurements 
Automated edge detection programmes reduces the variability in CIMT measures and 
are designed for measuring far wall CIMT in the CCA. The advantage of this method 
is that it reduces differences between readers and abolishes reader drift (change in 
reading behaviour with time).(O'Leary and Bots, 2010) Automated edge detection 
CIMT measurements are more accurate compared to manual measurements.(Touboul 
et al., 1992) The manual and semi manual measures are time consuming and require 
rigorous quality control. It has to be noted that the variation in CIMT values is not only 
influenced by readers but can also be imaging by differing sonographers. Automated 
edge detection works well with clear interfaces and would need manual correction if 
interfaces are not clear.(Tang et al., 2000) 
 
1.9.5 Factors Influencing CIMT 
IMT increases with age from 18 years and is associated with CV risk factors. Increased 
IMT values are associated with multiple CV risk factors like diabetes, hypertension, 
hyperlipidaemia and smoking.(Heiss et al., 1991; Kuller et al., 1994; Lassila et al., 
1997)  Reference values varies according to the age, gender, gender, ethnicity and 
associated risk factors as depicted in Figure 1.9. In addition the differing 
methodologies used in various epidemiological studies makes it difficult to standardise 
reference values.(Bots et al., 2003) Mannheim consensus on CIMT defines the 
methods to be used for CIMT assessment in clinical trials and epidemiological 




Figure 1.9: CIMT values according to age group and CV risk profile 
 











1.9.6 Association of CIMT with CV outcomes 
In the prospective ARIC study (Atherosclerosis in Communities) of 15792 healthy 
subjects (45-65 years), increased mean CIMT at baseline was associated with 
increased risk of CHD over a follow up period of 4-7 years (HR for men 1.85; 95% CI 
1.28-2.69 and HR for women 5.07, 95% CI 3.08-8.36).(Chambless et al., 1997) This is 
the first major epidemiological study linking CIMT to CV events. Similarly in the 
Rotterdam study of 7983 patients (>55 years) over a period of 2.7 years, the risk of 
stroke increased with increasing common CIMT (OR per SD increase in CIMT 1.41, 
95% CI 1.25-1.82). In the same way the risk of MI increased 43% per SD increase in 
common CIMT (OR 1.43; 95% CI 1.16-1.78).(Bots et al., 1997) Excluding the patients 
with previous stroke or MI increased the OR and adjustment for CV risk factors slightly 
decreased the OR. In the Cardiovascular Health Study, 4476 older patients (>65 years) 
without prior CV events were grouped into CIMT quintiles. The risk of MI or stroke 
(adjusted for age and sex) increased for the quintile with the highest thickness as 
compared with the lowest quintile (RR 3.87, 95% CI, 2.72-5.51).(O'Leary et al., 1999) 
There was a stepwise increase in the risk from the lowest to highest quintile groups. 
In a meta-analysis of 8 studies by Lorenz et al,(Lorenz et al., 2007) each SD increase 
in CIMT adjusted for age and sex, increased the risk of MI (RR 1.26, 95% CI 1.21-
1.30). Similarly each 0.10 mm increase in CIMT increased the risk of MI (RR 1.15, 95% 
CI 1.12-1.17). Increased risk of stroke was associated with each SD increase in CIMT 
(RR 1.32, 95% CI 1.27-1.38) and each 0.10 mm increase in CMT (RR 1.18, 95% CI 
1.16-1.21). Variations between the studies were noted for age distribution, carotid 
segment definition and CIMT measurement protocol. This meta-analysis concluded 
that CIMT is a strong and independent predictor of vascular events (stroke more than 
MI). 
In a meta-analysis by Costanzo et al, (Costanzo et al., 2010) of 41 trials involving 
18307 participants from the general population; CIMT regression at follow up 
compared to baseline was not related to CV events (CHD: Tau 0.91, p=0.37), 
Stroke/TIA: Tau -0.32, p=0.75 and all-cause death: Tau -0.41, p=0.69). It was 
concluded that though there was reduction in CV outcomes due to active treatment, 
CIMT regression was not related to the CV outcomes. 
In another meta-analysis of 16 studies by Lorenz et al,(Lorenz et al., 2012) of 16 
studies involving 36984 patients CIMT progression during follow up assessment was 
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not associated with risk of the combined endpoints of stroke, MI or CV death (HR 0.97, 
95% CI 0.94-1.00). But the mean CIMT of the combined baseline and follow up 
measurements was associated with increased CV events (HR 1.16, 95% CI 1.10-1.22). 
In the general population there was no association between CIMT progression and CV 
events. 
 
1.9.7 CIMT in Risk Stratification 
A meta-analysis was performed by Den Ruijter et al, (Den Ruijter et al., 2012) adding 
CIMT to Framingham Risk Assessment for the 10-year CV risk prediction (MI or 
stroke). There was no difference in the C-statistic of both risk models (0.757, 95% CI 
0.749-0.764; and 0.759, 95% CI 0.752-0.766). Addition of CIMT slightly improved the 
net reclassification (0.8%, 95% CI 0.1%-1.6%). Addition of CIMT to Framingham Risk 
Score did not alter the clinical importance of the risk prediction. In another meta-
analysis by van den Oord et al,(van den Oord et al., 2013) CIMT was added to a risk 
model based on traditional risk factors for CV risk assessment. There was no 
statistically significant improvement with the addition of CIMT (AUC of traditional risk 





1.9.8 Interpretation of available evidence on CIMT 
Increased CIMT was associated with increased risk of future CV events. But CIMT 
progression or regression was not associated with increased or decreased CV events 
respectively. Addition of CIMT did not improve the traditional risk models for prediction 
of CV events. CIMT in patients with established CAD patients, especially older patients 
is not known. 
Arterial stiffness, endothelial dysfunction and CIMT, risk stratification markers of 
adverse CV events were discussed in previous sections. In patients with established 
CAD left ventricular function assessment plays a key role in ongoing management to 
prevent further adverse events. In the following section LV function both systolic and 





1.10 Left ventricular Function 
Assessment of LV Systolic and diastolic left ventricular (LV) function by transthoracic 
echocardiography (TTE) can aid in the risk stratification of patients following ACS by 
providing prognostic information. Also it can be used to tailor the treatment. The 
commonly obtained information on TTE assessment are ejection fraction (EF), wall 
motion score index, ratio of early mitral inflow to myocardial velocity (E/e’), left atrial 
size, valvular stenosis or regurgitation, right ventricular systolic pressure. Of these 
ejection fraction and wall score motion index provide a measure of LV systolic function 
while E/e’ and left atrial (LA) size provide information on elevated LV filling pressure (a 
measure of LV diastolic function).  
1.10.1 Physiology of LV function 
The two main functions of the left ventricle are being a compliant chamber during 
diastole allowing the left ventricle to fill even at low LA pressure and alternating into (a 
stiff chamber with rapidly rising LV pressure in systole to eject the stroke volume at 
arterial pressures. The key to normal LV function being is dependent on the LV to 
change between these two states in systole and diastole. Hence routine TTE 
assessment should include both systolic and diastolic function assessments.(Nagueh 




1.10.2 Left ventricular Systolic Function 
1.10.2.1 Simpson’s Biplane Method 
The most commonly measured marker of LV systolic function is the EF which is the 
percentage of chamber volume ejected in systole (ratio Stroke volume [SV] to Left 
Ventricular End Diastolic Volume [LVEDV]). As 2D TTE provides superior spatial 
resolution for determining left ventricular size and function EF can be evaluated by 
Simpson’s rule which employs a method of disks. This involves correct visualisation of 
endocardial borders in apical 2 chamber (A2C) and apical 4 chamber views (A4C). The 
ventricle is divided into disks along the long axis of LV. The ventricular volume is the 
cumulative total of the volume of each of the disks. EF is calculated from the EDV and 
End Systolic Volumes (ESV) obtained from this stack of discs method. These 
calculations are reliant on the accurate tracing of the endocardial borders. Limitations 
of this method are drop out of myocardium (can be overcome by contrast TTE) and 
small volumes can be estimated by foreshortening (transducer not at the true apex). 
1.10.2.2 Wall Motion Score Index 
Left ventricular wall motion is assessed by complete visualisation of all the left 
ventricular walls in all 2D TTE views. It is important to ensure clear endocardial border 
definition as this is very crucial in the wall motion assessment. As changes in wall 
motion are not uniform it is important to obtain different views of the same region. With 
normal LV contraction, the endocardium moves inwards (endocardial excursion) 
resulting in diminished LV cavity size. Simultaneously the distance between the 
endocardium and epicardium increases (wall thickness). Reduction in endocardial 
excursion together with decrease in the amplitude of wall thickening is noticed in wall 
motion abnormality. This can be compared to adjacent, normally contracting regions 
of myocardium. The degree of endocardial thickening is the most reproducible and 
reliable method of wall motion assessment. Translational and rotational motion of the 




1.10.3 Left Ventricular Diastolic Function 
Diastole starts at the closure of aortic valve and comprises of fall in LV pressure, rapid 
LV filling, diastasis and atrial contraction.(Brutsaert et al., 1993) Diastolic function is 
related to the ability of the myocardium to relax and is a passive process modulated by 
myocardial tone. The process by which the myocardium returns to its unstressed length 
and force is called myocardial relaxation. Myocardial relaxation is also under the 
influence of load, inactivation and asynchrony. Dyssynchronous myocardial relaxation 
leads to delayed LV relaxation and elevated LV filling pressures. Diastolic dysfunction 
results in elevated filling pressures.(Brutsaert et al., 1993)  Increased afterload 
especially combined with increased preload delays myocardial relaxation resulting in 
elevating LV filling pressures.(Leite-Moreira et al., 1999) Filling pressures are 
considered elevated when the mean pulmonary capillary wedge pressure (PCWP) is 
>12mmHg or when the LV end diastolic pressure (LVEDP) is >16mmHg on invasive 
pressure measurement.(Paulus et al., 2007) LV filling is determined by LV filling 
pressures and properties. LV stiffness (∆P/∆V) or the inverse, compliance (∆V/∆P) 
describe the filing (end diastolic) properties. The extrinsic factors that influence the end 
diastolic properties are pericardial restraint and ventricular relaxation while the intrinsic 
factors are myocardial stiffness, tone, LV chamber geometry and LV thickness.(Leite-
Moreira, 2006) Practical approach to assess diastolic function is displayed in Figure 
1.10 
 
1.10.3.1 Assessment of Diastolic Dysfunction 
The following are measures of diastolic dysfunction. 
1.10.3.1.1 Left Ventricular Hypertrophy 
Concentric hypertrophy (increased mass and increased wall thickness) can be 
observed in patients with diastolic heart failure while patients with depressed EF have 
eccentric hypertrophy. Hypertension leads to concentric hypertrophy. Hypertensive 
heart disease is the most common cause of diastolic heart failure and is very common 
in older patients because of the high prevalence of hypertension in older 
population.(Nagueh et al., 2009) LV relaxation is delayed in hypertrophied myocardium 
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resulting in elevated filling pressures. LV mass can be measured but is time 
consuming. 
1.10.3.1.2 Left Atrial Volume 
LA volume reflects the cumulative effects of elevated filling pressures over a period of 
time while Doppler velocities indicate filling pressure at the time of assessment. Dilated 
left atria can be associated with bradycardia, anaemia, atrial arrhythmias, mitral valve 
disease in the absence of diastolic dysfunction. In the assessment of diastolic 
dysfunction LA volume needs to be considered in combination with Doppler 
parameters of LV relaxation.(Nagueh et al., 2009) 
1.10.3.1.3 Mitral Inflow 
Mitral inflow velocities (Figure 1.11) by pulsed-wave (PW) Doppler are obtained in 
apical 4 chamber (A4C) view for the assessment of LV filling pressures. Peak E (early 
diastolic) and A (late diastolic) velocities of flow across the mitral valve should be 
recorded by continuous wave (CW) doppler ensuring maximal velocities are obtained 
before applying the PW technique. Then 1-3mm sample volume is placed between 
mitral leaflet tips to record a crisp velocity profile with PW Doppler.(Nagueh et al., 2009) 
With advancing age, the E velocity and E/A ratio decreases, whereas the A velocity 
increases. Mitral inflow velocities are affected by heart rate and rhythm, PR interval, 
cardiac output, mitral annular size and LA function. Older individuals are at higher risk 
of developing diastolic dysfunction due to age related delayed myocardial 
relaxation.(Nagueh et al., 2009) Older patients with uncontrolled and longstanding 
hypertension are associated with abnormal diastolic physiology and filling patterns. 
Transmitral flow velocities can be used to predict LV filling pressures reliably in patients 
with systolic dysfunction (EF≤ 50%), but not so in patients with preserved systolic 




Figure 1.11: Mitral Inflow Doppler Velocities 
 















1.10.3.1.4 Mitral Annulus Tissue Doppler Velocity 
The mitral annular velocity corresponds to LV long axis lengthening rate, as the LV 
apex remains fixed during cardiac cycle. Peak early diastolic velocity (e’) occurs 
simultaneously with the mitral inflow E-wave.(Masutani et al., 2008) Under normal 
conditions both E and e’ increase in response to exercise and volume load.(Opdahl et 
al., 2009) The LV filling pressure is determined by the mean LA pressure and elevated 
LA pressure correlates on TTE are enlarged LA volume, restricted filling pattern with 
short deceleration time (DT) of E-wave, abnormal pulmonary venous flow pattern and 
ratio of E to e’. The most commonly used and easy to interpret parameter is E/e’. Mitral 
inflow E wave is augmented with increased LA to LV pressure gradient and e’ is 
reduced due to slow LV relaxation. Increased E/e’ ratio as result of high E and low e’ 
indicates elevated LA pressure.(Little and Oh, 2009) E/e’ correlates well with 
pulmonary capillary wedge pressure.(Nagueh et al., 2009) An E/e’ value >15 indicates 
elevated pulmonary capillary wedge pressure, whereas an E/e’ <8 is associated with 
normal LA pressure.(Ommen et al., 2000) In the intermediate range (E/e’ 8-15) other 
parameters like LA size, LV filling pattern, DT, iso-volumetric relaxation time, and 
presence of pulmonary hypertension need to be assessed.(Nagueh et al., 2009) E/e’ 
van be obtained either from the medial annular velocity or the lateral annular velocity 
and the cut off values for elevated LA pressure are 15 and 12 respectively and this 
difference is due to the increased annular velocity on the lateral annulus compared to 
the medial annulus. Though an average of the two has been recommended, consistent 
use of one is adequate in clinical practice.(Nagueh et al., 2009) E/e’ may not accurately 
predict elevated LA pressure in case wall motion abnormalities in the base of the LV, 
pericardial constriction and significant mitral valvular pathology.(Little and Oh, 2009) 
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Figure 1.12: Tissue Doppler Velocity of the Mitral Annulus 
 




Figure 1.10: Approach to assess Diastolic Dysfunction 
 
Av. Average; LA left atrium; Val. Valsalva 














1.10.3.2 Prevalence of Diastolic Dysfunction and CV Outcomes 
In 2042 community population (≥ 45 years, mean age 62.8 years [SD 10.6]) of Olmsted 
county, the prevalence of mild diastolic dysfunction was 20.8% (95% CI 19.0%-22.7%), 
moderate diastolic dysfunction was 6.6% (95% CI 5.5%-7.8%) and severe diastolic 
dysfunction was 0.7% (95% CI 0.3%-1.1%). The prevalence of these three grades of 
diastolic dysfunction in the older subgroup (≥ 75 years) was 52.8%, 14.6% and 3.4% 
respectively. The overall prevalence of moderate to severe diastolic dysfunction with 
normal EF was 5.6% (95% CI, 4.5%-6.7%). Both groups of patients with mild diastolic 
dysfunction (HR 8.31, 95% CI 3.00-23.1, p<0.001) and moderate to severe diastolic 
dysfunction (HR 10.17 95% CI 3.28-31.0, p<0.001) were higher risk of all-cause 
mortality after controlling for age, sex and EF. 
In a retrospective study of 36261 patients (mean age 58.3, [SD 15.4] years) with normal 
EF the prevalence of diastolic dysfunction was 65.2% (60.0% mild, 4.8% moderate and 
0.4% severe). Patients with diastolic dysfunction were significantly more likely to be 
males, older (>65 years), obese (BMI >30) and more likely to have CV risk factors and 
established CV disease. Over a mean follow up period of 6.2 (SD 2.3) years, both 
moderate (HR 1.58, 95% CI 1.20-2.08, P<0.001) and severe diastolic (HR 1.84; 1.29-
2.62, p<0.001 for each function was associated with increased mortality risk.(Halley et 
al., 2011) 
1.10.4 Interpretation of available evidence on LV function 
Assessment of LV systolic and diastolic function can add incremental information to 
the management and risk stratification of patients with ACS. Especially diastolic 
dysfunction is common among older patients even with normal LV function and no 
underlying significant CAD. LV function assessment in the context of ACS in older 
patients managed by contemporary treatment has not been studied in detail. 
In addition to preventing adverse CV events in older patients the key management 
strategy is to improve symptoms and quality of life. In the following section cardiac 




1.11 Quality of Life and Symptom Burden 
1.11.1 Quality of Life 
There is no consensus definition of ‘quality of life’ (QoL), but it is deemed to include 
holistic emphasis on the social, emotional, and physical well-being of patients after 
treatment.(Greer, 1984) More pertinently it could be the impact of a person's health on 
his or her ability to lead a fulfilling life.(Bullinger et al., 1993) Health related quality of 
life (HRQoL) refers to the impact of diseases and their symptoms on individual’s QoL 
and in the context of health care, HRQoL is preferred over QoL as the focus is on 
health.(Thompson and Yu, 2003) It can also be an individual's subjective experience 
related both directly and indirectly to health, disease, disability, and impairment.(Carr 
et al., 2001) Reducing the impact of disease is expected to increase the quality of life, 
but severe disease is not always related to poor quality of life.(Evans, 1991) Quality of 
life in an individual patent is influenced by the expectations and experiences of that 
patient.(Calman, 1984) Medical management of diseases focus mainly on mortality 
and morbidity benefits, but equally important is improvement in QoL. QoL needs to be 
considered as an important outcome of patient management in determining therapeutic 
benefits.(Mayou and Bryant, 1993; Treasure, 1999) HRQoL can be used as a 
benchmark to measure the impact of different management strategies on the same 
disease or impact of different treatment on different diseases.(Thompson and 
Roebuck, 2001) 
Current ACS management strategies are aimed at reduction of mortality, morbidity and 
the risk of subsequent adverse CV events. QoL outcomes are not routinely taken into 
consideration in evaluating outcomes of management strategies of ACS. QoL 
outcomes are increasingly becoming relevant in ACS management due to ageing 
population and increased life expectancy with advancing medical resources. Especially 
in older patients QoL outcome is equally if not more important than mortality benefit. It 
has to be noted that QoL can be influenced by symptoms and anxiety associated with 
ACS. Though QoL measures are used in clinical research they are rarely used in the 
clinical setting. QoL measures in the clinical setting helps to focus evaluations and 





1.11.2 Measures of QoL 
HRQoL instruments describe or characterize patient experiences (functioning, general 
health perceptions and overall wellbeing or quality of life) as a result of healthcare and 
are supplementary to traditional health status assessment of biological measures 
(mortality and morbidity benefits).(Wilson and Cleary, 1995) QoL measures do not 
substitute for measures of disease outcomes and may not routinely be the most 
appropriate patient centred outcome to assess.(Higginson and Carr, 2001) It has to be 
used in the holistic assessment to address individual patients’ expectations. As QoL is 
influenced by multiple factors an ideal QoL measure needs to include assessment of 
physical, functional, psychological and social components. There are various QoL 









1.11.2.1 Generic Measures 
1.11.2.1.1 Short Form 36 
Short form 36 (SF 36) comprises 36 response items encompassing 8 health domains 
(physical functioning; role-physical; bodily pain; general health; vitality; social 
functioning; role-emotional; and mental health).(Ware and Sherbourne, 1992) The first 
four constitutes the physical health summary measure and the last four the mental 
health summary measure. The score for each scale ranges from 0 to 100, with a higher 
score representing a higher HRQoL.(Ware JE, 2000) It is a self-administered 
instrument to complete responses for the 36 items and takes about 15 minutes to 
complete all responses. Shortened versions of the SF-36 are the SF-12 and SF-8 
which obviously takes less time to complete responses. SF-36 has been proven to be 
a sensitive instrument for detecting changes in HRQoL among patients with recent 
MI.(Yu et al., 2003)  
 
1.11.2.1.2 EuroQoL 
The EuroQoL comprises EQ-5D and EQ-VAS (Visual Analogue Scale)(Group, 1990) 
and is a descriptive response system of 5 dimensions of physical and emotional 
aspects of everyday life including mobility, self-care, usual activity, pain/discomfort, 
and anxiety/depression. Each dimension has three different levels of responses as no 
problem, some problem, or extreme problem. Subjects are asked to choose the level 







1.11.2.2 Disease Specific Measures 
1.11.2.2.1 Seattle Angina Questionnaire 
Seattle angina questionnaire (SAQ) is a disease specific measure designed to assess 
the functional status of patients with angina.(Spertus et al., 1995) It includes 19 
questions that quantify five clinical domains of physical limitation, stability of angina, 
frequency of angina, treatment satisfaction and disease perception/quality of life. It can 
be used as a generic HRQoL measure as 7 of its 19 items assess emotional health. 
 
1.11.2.2.2 Myocardial Infarction Dimensional Assessment Scale 
Myocardial Infarction Dimensional Assessment Scale (MIDAS) is a patient reported 
outcome measure of the health status after a MI.(Thompson et al., 2002) It comprises 
measures of 35 items on seven dimensions (physical activity; insecurity; emotional 
reaction; dependency; diet; concerns over medication; side effects). It addresses 
concerns specifically related to patients with recent MI. Each dimension is scored 
separately using a simple scoring system to indicate the extent of ill health in each of 





1.11.3 Symptom Burden 
Cardiac symptoms of angina and dyspnoea can have an impact on health status and 
HRQoL. This can be assessed by New York Heart Association (NYHA) dyspnoea 
severity scale (1-4) as in Table 1.5 and Canadian Cardiovascular Society (CCS) 
angina severity scale (0-5) as in Table 1.6.  
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Table 1.5: New York Heart Association Dyspnoea Classification 
I No symptoms and no limitation in ordinary physical activity  
 
II Mild symptoms (mild shortness of breath) and slight limitation during 
ordinary activity. 
 
III Marked limitation in activity due to symptoms, even during less-than-
ordinary activity, e.g. walking short distances (20–100 m). 
Comfortable only at rest. 
 




Table 1.6: Canadian Cardiovascular Society Angina Scale 
0 No Angina 
 
I Angina only during strenuous or prolonged physical activity 
 
II Slight limitation, with angina only during vigorous physical activity 
 
III Symptoms with everyday living activities, i.e., moderate limitation 
 









1.11.4 Quality of Life and Symptom Burden in Relation to Clinical Outcomes 
In a prospective cohort study of CAD patients in outpatient department, prognostic 
utility of SAQ was evaluated. 5558 patients completed the SAQ and were followed up 
for 1 year. SAQ physical limitation was the strongest predictor of health status and 
patients with severe limitations had a relative odds of mortality of 6.2 during follow up 
(95% CI 3.8-10.5). Patients with a significant deterioration in angina over the preceding 
month had a 1-year mortality rate of 11.4% compared with 4.9% for the rest of the 
population. Also patients with severe angina were three (95% CI 1.7-5.3) times more 
likely suffer from ACS than those reporting minimal angina. Inclusion of SAQ domains 
in risk models significantly increased the model c-statistics for both the mortality (0.69 
to 0.72, p=0.004) and ACS (0.69 to 0.73, p=0.003) models. 
The third Randomized Intervention Trial of unstable Angina (RITA-3) evaluated early 
intervention strategy (IS, n=895) versus conservative strategy (CS, n=915) in patients 
with NSTEACS.(Fox et al., 2002) Health status of the patients was assessed using 
EuroQoL, SF36 and SAQ at four months and one year of follow up in addition to EQ5D 
being done at baseline. Baseline EQ-VAS scores were comparable between IS and 
CS patients. Though there was significant improvement in EQ-VAS scores in both 
groups improvement at four months (mean difference of 3.0, 95% CI 1.3-4.7; p<0.001) 
and 1 year (mean difference of 2.3, 95% CI 0.6-4.1; p<0.01) was significantly greater 
in the IS group compared with the CS group. As regards to EQ-5D during both follow-
up times, more proportion of patients in the CS group had a worsening of HRQoL 
related to performing usual daily activities. The change in the EQ-5D global utility score 
was significantly better among patients in the IS group at four months (treatment mean 
difference of 0.036, p=0.005), but this difference was reduced at one year (treatment 
mean difference of 0.016, p=0.20). Patients in the IS group had a higher mean SF-36 
component scores compared to patients in the IS group. The biggest gain in HRQoL 
were made with regard to physical role function and general health and was found 
significant at 4 months and 1 year. Patients in the IS group had significantly better 
mean SAQ component scores compared to patients in the CS group. Though there 
was attenuation of treatment differences at one-year follow-up compared with the four-
month results both remained highly significant. Stability of angina, frequency of angina, 
and disease perception domains had the largest gains in HRQoL.(Kim et al., 2005) 
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The authors conclude that in patients with NSTEACS, an early IS provided 
improvement in HRQOL mainly due to improvements in angina symptoms. 
In 200 Chinese patients with CAD administration of SF-36 HRQoL measure reported 
a poorer HRQoL compared to patients in western countries.(Wang et al., 2014) Older 
age, co-morbidity with heart failure or hypertension, and smoking status were 
significant predictors of poor physical health status by multiple regression analysis. Co-
morbidity with heart failure and perceived social support were predictors of poor mental 
health status. Health status and social support needs to be addressed to HRQoL in 
patients with CAD. 
HRQoL was evaluated in 3220 patients after acute coronary syndrome treated with 
clopidogrel at baseline, two months and four months of follow up.(Chudek et al., 2014) 
38% had STEMI and 62% had experienced NSTEACS. The management strategy was 
medical management (7.2%), thrombolysis (2.4%) and PCI (90.4%). Women reported 
lower levels of HRQoL compared to men across all domains of health status (p<0.001 
for each health status domain) during the first follow up visit. Patients older than 60 
years and patients managed by non-invasive strategy had reported the lowest quality 
of life. During subsequent follow up visits, all aspects of health status improved 
irrespective of the treatment strategy. Also health status differences between the 
treatment groups decreased as time progressed. In the immediate period after ACS, 
invasive treatment strategy especially in older patients had better HRQoL outcomes. 
In 257 patients with ACS, HRQoL was assessed using SF-36 at baseline, 1 year and 
at 3 years to evaluate the effect of ACS trigger on HRQoL.(Bhattacharyya et al., 2010) 
At follow up 76% patients were reassessed at 12 months, and 62% at 36 months. 
Management strategy was medical (36%), PCI (54%) and CABG (10%). Of the patients 
followed up at one year, acute emotional distress was experienced prior to ACS onset 
in 37% and physical exertion in 6% while 3% of patients reported combined physical 
exertion and emotional stress. There was a significant association between emotional 
trigger at ACS onset and poor mental health at one year independent of age, gender, 
social deprivation, GRACE risk score, and ACS type (β=−0.175, S.E. 0.072, p=0.016) 
at 12 months. Mean adjusted scores were 68±22 in the emotional trigger and 75±20 in 
the no trigger patients. Physical health status at 12 months reflected physical activity 
levels before ACS (mean scores of 58.7, 68.7 and 72.3 for inactive, low activity and 
high activity groups respectively, adjusted for age and gender, p=0.011). Patients with 
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physical exertion at the time of ACS onset had significantly lower physical health status 
scores at 3 years (adjusted means 32±12) than those who had not been physically 
active (mean 50±21, p=0.019). ACS triggers had an impact on both physical and 
mental components of HRQoL in the short and medium term after ACS irrespective of 
management strategy. 
1.11.5 HRQoL in Older Patients with CAD 
Health status was evaluated by use of SAQ in 21573 patients undergoing cardiac 
catheterisation and followed up at one year and at three years.(Graham et al., 2006) 
Of these, 15392 patients were <70 years of age, 5198 patients were 70-79 years, and 
983 patients were ≥ 80 years of age. Responses at one year were available in 7883, 
2940 and 439 patients respectively in the three age groups. Patients >70 years 
managed by revascularisation strategy had better SAQ scores compared to medical 
therapy after risk adjustment. In all the three age groups patients managed by CABG 
scored better compared to PCI with the exception of exercise capacity in the two older 
age groups (p<0.001 for all PCI vs. CABG comparisons). At three years responses 
were available for 6612 patients of >70 years, 2185 patients of 70–79 years, and 261 
patients of ≥80 years of age. The risk-adjusted SAQ scores were better for patients 
managed by revascularisation compared to medical therapy especially in patients aged 
>70 years, and those 70–79 years of age. Patient who underwent CABG in ≥80 years 
scored higher than PCI patients in all dimensions except exercise capacity. 
In 624 patients admitted with ACS, SF-36 was administered to evaluate HRQoL 
outcomes at baseline and 6-months of follow up.(Li et al., 2012) Of these 46% 
underwent PCI, 6% underwent CABG and 48% were treated conservatively. At 6 
months’ follow up 82% of enrolled patients responded. Patients treated with PCI had 
higher scores at 6 months in all 8 domains than those treated conservatively especially 
with significant differences in physical functioning, general health, social functioning 
and vitality (p<0.05 for each domain). After risk adjustment, physical health status 
including physical functioning, bodily pain and the physical component summary were 
significantly better for patients aged 60–79 years and >80 years with PCI than medical 
therapy. The biggest increase in score was noted in patients aged >80 years. By 
multivariable analyses PCI (OR 1.79, 95% CI 1.10–2.92) and age (per ten years 
increase, OR=1.27, 95% CI 1.02–1.57) were independent predictors of better PCS 
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scores. Elderly patients received the greatest benefit from PCI in terms of improvement 
in HRQoL by its impact on physical functioning. 
In a prospective cohort of 651 patients who underwent PCI HRQoL was reported using 
SF-36 at 6 months, 1 year and 3 years.(Panasewicz et al., 2013) Patients were 
categorised into two groups of <70 years (74%) and ≥70 years (26%). Older patients 
experienced poor scores which were significant on all four physical domains (p<0.05 
for each domain) whereas of the four mental health domains only vitality and role 
emotional functioning had significantly poor scores in older patients (p<0.05 for each). 
Over increasing follow up periods HRQoL improved in younger patients and worsened 
in older patients. At 36 months follow up, there was a decrease in SF-36 scores in all 
domains and was significant for five domains of physical functioning (–6.42; p=0.003), 
general health (–4.93; P=0.01), social functioning (–7.55; p=0.01), mental health (–
4.13; P=0.02) and vitality (–5.73; p=0.01).  In a further subgroup analysis by four 
different age groups (<60 years, 60-70 years, 70-80 years, and ≥80 years) older 
patients (70-80 years or ≥80 years) reported to experience poor HRQoL than the 
younger patients (<60 years or 60-70 years).  Thus over a period of three years, older 
patients reported poor HRQoL after PCI compared to younger patients. 
In a systematic review of 700 octogenarians (mean age 82.9 years) identified from 11 
studies (published between 1993 and 2012) who underwent PCI HRQoL improved as 
much as in younger patients.(Johnman et al., 2013) Octogenarians gained 
improvement in the areas of physical functioning and improved angina status. The 
benefits are greatest in the early post PCI period (6 months) and continued long term 




1.11.6 Interpretation of available evidence on quality of life 
Quality of life encompasses physical, emotional and social well-being. In patients 
managed by revascularisation for CAD significant improvement in physical and 
functional domains were noted. In older patients the improvement was more in the 
short term, but deteriorated in the long term. In older patients with CAD, quality of life 
improves with PCI, mainly due to improvement in physical functioning and 
improvement in angina status. Quality of life has not been studied with contemporary 
management of CAD in older patients, especially in the context of frailty status. Older 
age is a predictor of poor CV outcomes after ACS and or PCI. Frailty and co-morbidity 
independently have been proven to be predictors of adverse CV outcomes after ACS 
and or PCI. Impact of older age, frailty and co-morbidity on HRQoL after PCI for ACS 
has not been studied. Better understanding of this will help in improving the 




1.12 Cognitive Impairment 
Mild cognitive impairment is the intermediate stage between normal cognitive aging 
and dementia. Mild cognitive impairment is detectable by clinical criteria, but not 
producing impairment in daily functioning whereas dementia, a chronic progressive 
disease is characterized by disturbance of cognitive function in association with 
impairment in functional, emotional and social behaviours. The most common causes 
of dementia are neuro-degenerative dementia (Alzheimer’s dementia) and vascular 
dementia and the uncommon causes are frontotemporal dementia and Lewy body 
dementia.(Knopman et al., 2003). 
In a population based prospective cohort study carotid atherosclerosis was associated 
with an increased risk of dementia during a mean follow up period of 9 years, 
supporting the hypothesis of the role of atherosclerosis in the pathogenesis of 
dementia and Alzheimer’s disease.(van Oijen et al., 2007) A systematic review showed 
coronary artery disease was associated with general cognitive deficits and reduced 
ejection fraction and cardiac output was associated with impairment in executive 
function.(Eggermont et al., 2012) 
In another population based prospective cohort study (614 patients), cognitive 
outcomes assessed by mini mental state examination (MMSE, maximum score 30) 
were worse at 1 year in patients with ACS compared to patients with TIA (mean MMSE 
26.6 SD 2.7 vs. 27.6 SD 2.5, p<0.0001) and ACS was associated with 
moderate/severe cognitive impairment (OR 2.14, 95% CI 1.11-4.13).(Volonghi et al., 
2013) 
A systematic review concluded that frailty increased the risk of cognitive impairment 
and similarly cognitive impairment increased the risk of frailty, implying a common 
causal pathway for cognitive impairment and frailty, associated with ageing.(Robertson 
et al., 2013) 
It is important to understand the prevalence of sub clinical cognitive impairment in older 
patients with acute coronary syndrome, especially managed by contemporary 




1.13 Summary of Introduction Chapters 
With eradication of communicable diseases in the last century and better primary 
prevention measures with cardiovascular disease, the proportion of people in the later 
decades of life are increasing as never before all over the world, more so in the 
developed countries. IHD is a leading cause of morbidity and mortality along with 
dementia and cancer in older patients. Limited evidence available currently in the 
management of these older cohort of patients. Current management of older patients 
with ACS is mostly based on extrapolation from evidence available from research 
studies with couple of decade younger patients. Older patients were under represented 
in clinical trials. 
Older age is associated with frailty and comorbidities. There are different frailty 
assessment tools available. Frailty has been identified as an independent risk factor 
for adverse CV outcomes in patients with acute coronary syndrome. But not the same 
frailty assessment tool was used and patient cohort had differing presentations with 
CAD. Not all these patients were treated with contemporary treatment strategies. 
Frailty in a specific subset of patients like NSTEACS with both Fried and Rockwood 
frailty assessment tools has not been studied in patients managed with contemporary 
treatment strategies. 
Comorbidities play a vital role in older age due to their impact on clinical presentation, 
diagnosis and treatment strategies. As stated earlier older patients are 
underrepresented in clinical trials and even the very small proportion of older patients 
were highly selected with no or few comorbidities. Comorbidities also play a role in the 
development of frailty syndrome. Comorbidities have an impact on adverse CV 
outcomes but has not been studied along with frailty in patients managed with 
contemporary treatment strategy. In every day clinical practice lot of older patients with 
frailty and comorbidities are seen with challenging decisions on management to be 
made. 
Arterial stiffness, endothelial dysfunction, carotid intima media thickness and LV 
function are markers of underlying CV disease burden. They have been shown to 
impact CV outcomes in community population and have been note as risk factors in 
predicting CV outcomes. They have not been studied in older patients with established 
89 
 
CV disease. Understanding CV disease burden with these measures in older patients 
in relation to frailty can be useful. 
Treatment strategies for younger patients were aimed at improving mortality and 
morbidity. In older patients in addition to these outcomes quality of life needs to be an 
important consideration. Frailty and comorbidity could influence quality of life even prior 
to a CV event and hence it is important to consider quality of life prior to invasive 
treatment strategies. Quality of life measures should include physical, mental and 
social wellbeing. Impact of contemporary treatment needs to be studied in relation to 
quality of life in addition to adverse CV outcomes. 
Cognitive impairment is a major cause of morbidity and institutionalisation in older 
patients. Subclinical cognitive impairment in older patients with NSTEACS in the 
context of frailty has not been studied. 





1. Frailty status varies according to the assessment tool used 
2. Frailty is associated with adverse CV outcomes even in patients managed by 
contemporary invasive treatment for NSTEACS 
3. Frailty is associated with the cardiovascular disease burden of older NSTEACS 
patients 
4. Increased comorbidity burden is associated with frailty and adverse CV 
outcomes 
5. Frailty is associated with increased cardiac symptom burden and poor quality of 
life 
6. Older NSTEACS patients have subclinical cognitive impairment 
 
1.15 Aims 
1. To determine the prevalence of frailty and compare frailty status by Fried and 
Rockwood Frailty scales 
2. To assess adverse CV outcomes at one month according to frailty status in 
older NSTEACS patients managed by invasive strategy 
3. To assess cardiovascular disease burden in relation to frailty status  
4. To assess comorbidity burden according to frailty status and asses its relation 
to adverse CV outcomes at one month 
5. To evaluate cardiac symptom burden and the quality of life in older NSTEACS 
patients managed by invasive strategy 

























2.1 Study Design and Protocol 
2.1.1 Study Design 
The study was designed as a prospective observational study of older patients aged 
≥75 years undergoing invasive management (coronary angiography with a view to 
revascularisation) for NSTEACS in a tertiary interventional cardiology centre. The data 
collected for my thesis was part of a larger study - A Study to Improve Cardiovascular 
Outcomes in High Risk PatieNts with Acute Coronary Syndrome (ICON1 study). All the 
data presented in this thesis were collected by me. My role in the study as the primary 
researcher is detailed in the following section. The data collected for the thesis included 
frailty status, comorbidity, CV disease burden, quality of life measures and cognitive 
status. The tools and measures used for the data collection are detailed in the following 
section. The larger ICON1 study involved collection of intracoronary imaging data (not 
part of my thesis) in addition to all the data presented in this thesis. The lead sponsors 
for the study were Newcastle University and Newcastle upon Tyne NHS Hospitals 
Foundation Trust. Approval was obtained from the local research and development 
Newcastle Joint research Office and the National Research Ethics Service committee 
for North East of England based at Sunderland with Regional Ethical Committee 





2.1.2 Study Setting 
This observational study was conducted in Freeman Hospital, Newcastle upon Tyne, 
in the North-East of England. The Freeman Hospital, is a tertiary cardiac centre 
providing advanced cardiac services to a population of 2 million. Approximately 3000 
PCIs are performed per year. The study participants were recruited from patients 
referred to this hospital from the neighbouring district general hospitals for invasive 
treatment of NSTEACS. Patients were transferred the day before or on the day of 
procedure to the tertiary hospital. Suitable patients were identified from the electronic 
referral system and on arrival to the tertiary hospital were approached for recruitment 
into the study. I explained the study to the patient and a patient information sheet was 
provided. If the patient agrees to take part in the study, written informed consent was 
obtained. All patients screened for the study were entered in a screening log with 
details regarding the patients consented, declined, consented but not recruited (due to 




2.1.3 My Role in the Study 
I was working on the project as a clinical research associate. I identified potential 
patients on the electronic referral system and approached them to take part in the study 
on arrival to Freeman Hospital. I explained the study and gave patient information 
sheet to patients as per the inclusion and exclusion criteria. If suitable patients agree 
to take part in the study I obtained written consent. Frailty assessment was performed 
by me prior to the invasive procedure in the ward and the operator for angiogram and 
PCI was blinded to the finding. Similarly all non-invasive investigations were performed 
prior to the patient undergoing invasive procedure. This was strictly adhered to by me, 
to make sure the invasive procedure did not have any impact on the non-invasive test 
findings. When I was on leave, my colleague recruited 10 patients. My colleague was 
appropriately trained. Standard treatment protocol was followed in the clinical care as 
per the instructions from the consultant Interventionist in the lab and the on-call team 
under the supervision of the consultant in the ward.  
I collected the baseline demographics, angiogram and PCI details on the case report 
form. I was independent in performing and reporting transthoracic echocardiogram and 
have been signed off for the same during my 3 years of general cardiology training. I 
had appropriate training in doing the non-invasive investigations which were done as 
per the Standard Operating Procedure (SOP) in the appendix. Quality of life data was 
collected on the questionnaire completed by the patient prior to discharge. If the patient 
had difficulty reading, I read the questions and marked the patient chosen answer. All 
relevant data were collected in the paper case report form. The data was transferred 
to a password protected excel spreadsheet. I collected the follow up data at one month 
from the hospital patient record, summary care record and information faxed from GP 
surgery. 
Overall I was solely responsible for the recruitment of patients, performing non-invasive 
investigations as described in subsequent sections, cognitive assessment, quality of 





2.1.4 Power Calculation  
My thesis is based on an observational study for a holistic assessment of older patients 
undergoing invasive treatment strategy for NSTEACS. Though clinical outcomes at 
one month were collected this was to understand how older patients did based on 
frailty status after invasive procedure, rather than to show clinically relevant difference. 
It has to be noted outcome data in a similar cohort of patients as in my thesis, for 
sample size calculation was not available. With outcomes from Global Registry of 
Acute Coronary Events (GRACE) study mainly based on age (30%), rough estimate 
level of significance of 5% and a power of 80%, a sample size of about 300 patients 
was chosen. My thesis is based on the 240 patients I was involved with recruitment 
and data collection during the two years of my dedicated clinical research period. With 
relatively small number of patients like in my thesis, I do understand the results are 
more likely to be hypothesis generating, than to be definitive of clinical significance in 
the findings and results. Also with contemporary management lower rate of adverse 
CV outcomes, will result in the study being under powered to show significant 
difference between the patient groups for adverse clinical outcomes. I have written this 
thesis from the data collected from my work on 240 patients, to explore and describe 





2.1.5 Inclusion and Exclusion Criteria 
Inclusion and exclusion criteria are displayed in Table 2.2. 
Table 2.2: Inclusion and exclusion criteria for ICON1 study 
Inclusion Criteria 
    ≥ 65 years old 
    Non ST Elevation Acute Coronary Syndrome 
    Planned for CA or PCI 
Exclusion Criteria 
    Cardiogenic shock 
    Primary Arrhythmias 
    Significant valvular heart disease 
    Malignancy with life expectancy <1 year 
    Active Infection 
 Urinary Tract Infection 
 Pneumonia 
 Sepsis 
    Alternative diagnosis after CA (excluded after consent) 
 Pulmonary embolism 
 Takotsubo cardiomyopathy 
 Myocarditis 
 Coronary vasospasm 
    Unable to consent 
 Known Dementia 
 Language barrier 
 Visual impairment 
 Lack of capacity 





2.1.6 Treatment Protocol 
Contemporary treatment of NSTEACS as felt appropriate by the treating interventional 
cardiologist was offered to the patient.(Hamm et al., 2011) According to standard 
practice, patients were revascularised by PCI or coronary artery bypass graft (CABG) 
surgery. Patients may also be managed medically if deemed not appropriate for either 
of the revascularisation strategies at the discretion of the operating cardiologist. 
 
2.1.7 Data Collection  
Data were collected on standardised case report forms by members of the research 
team. The data collected include demographics, baseline characteristics, and details 
of coronary angiography and or PCI. Peri-procedural complications and in-hospital 
complications were recorded. Further data were collected on the cardiovascular status, 
Canadian Cardiovascular Society (CCS) angina grade, New York Heart Association 
(NYHA) dyspnoea grade, frailty category, functional health status, quality of life and 




Table 2.3: Assessments Tools 
Cardiovascular Status 
      Arterial Stiffness 
      Peripheral Arterial Tonometry 
      Carotid Intima Media Thickness 
      Trans-thoracic Echocardiogram 
Cardiac Symptoms 
      New York Heart Association Dyspnoea 
      Canadian Cardiovascular Society Angina 
Frailty Assessment 
      Fried Frailty Index 
      Rockwood Frailty Index 
Quality of Life 
     SF-36, Euro QoL - 5D (EQ-5D™) 
Cognitive Status 
      Montreal Cognitive Assessment (MoCA©)  
Co-morbidity 





2.2 Frailty and Comorbidity Assessments 
Frailty was assessed by Fried Frailty Index derived from Cardiovascular Health 
Study(Fried et al., 2001b) and Rockwood Frailty Index derived from Canadian Study 
of Health and Aging.(Rockwood et al., 2005) Fried frailty index is based on assessing 
5 criteria by both subjective answers from the patient (weight loss, physical energy, 
physical activity) and objective assessment (hand grip strength, walking speed). A 
score of 0 was categorised robust, 1 or 2 as intermediate frail or pre-frail and 3 or more 
as frail. Rockwood criteria was based on assessment by the researcher into categories 
1 to 7 from very fit to severely frail depending on functional status and 
independence/dependence on others for activities of daily living. See appendix for 
Fried and Rockwood tools. 
In addition, the Charlson co-morbidity index,(E, 1987) a method of predicting mortality 
based on weighted index of the number and seriousness of co-morbid conditions is 
evaluated for each patient. Charlson co-morbidity index has been demonstrated to be 
an appropriate indicator of in-hospital and one-year outcomes in the setting of 
ACS.(Radovanovic et al., 2014) 
 
2.3 Functional Status and Quality of Life Measures 
Short form - 36 standard (SF-36® Standard) health survey was completed by each 
patient prior to discharge from the hospital and at one-year follow-up to assess 
functional health and quality of life. The responses will be used to obtain physical 
component summary and mental component summary scores.(Ware and Sherbourne, 
1992)  SF-36 survey was used with permission (License number QM033917) from the 
RAND Corporation. Copyright © the RAND Corporation. RAND's permission to 
reproduce the survey is not an endorsement of the products, services, or other uses in 
which the survey appeared or was applied in this study .In addition EQ-5D™-3L 
questionnaire was used to assess health outcome of each patient at discharge.(Group, 




2.4 Cognitive Status Assessment 
Atherosclerosis is associated with increased risk of cognitive impairment in older 
patients.(van Oijen et al., 2007) To assess the cognitive status of patients during 
admission, the Montreal Cognitive Assessment (MoCA©) (Nasreddine et al., 2005) test 
was utilised (Permission obtained from MoCA Clinic and Institute on behalf of Dr Ziad 
Nasreddine, copyright owner of MoCA) as given in appendix. The MoCA test has been 
shown to have high sensitivity in screening patients with known CV disease for mild 




2.5 Non-Invasive Assessments of Cardiovascular Status 
2.5.1 Arterial Stiffness 
Carotid-femoral PWV was assessed by the Vicorder device (Skidmore Medical 
Limited, Bristol, UK). In addition brachio-femoral PWV, pulse wave analysis (includes 
pulse pressure, augmentation pressure and augmentation index) was also assessed. 
This device has been validated for these measurements.  
 
2.5.2 Endothelial Function 
Endothelial function was measured by EndoPATTM (Itamar Medical, Caesarea, Israel). 
PAT signals are recorded from the index fingers with pneumatic probes at baseline, 
during cuff occlusion and during hyperaemia. A measure of endothelial function is 
calculated from the ratio of PAT signal amplitude at baseline and post-occlusion.  
 
2.5.3 Carotid Intima Medial Thickness 
CIMT was assessed using vivid I GE machine with a vascular probe. CIMT 
measurement is obtained by the semi-automated measurement software which uses 
edge detection technique. CIMT values will be analysed for prediction of adverse 
outcomes and will be incorporated in the risk model. 
 
2.5.4 Trans-thoracic Echocardiogram 
Trans-thoracic echocardiogram was performed using Vivid i GE echo machine, 
according to the British Society of Echocardiography guidelines to assess systolic 
function, diastolic function and valvular heart disease.(Gill Wharton, 2012) Systolic and 
diastolic function will be analysed for prediction of adverse CV outcomes. 
Standard Operating Procedure (SOP) followed in performing the above non-invasive 




2.6 Outcome Measures 
Procedural complications and in-hospital adverse outcomes were followed up until 
discharge. One-month outcomes were recorded from the hospital electronic patient 
record, summary care record and general practitioner summary obtained from the 
patients’ general practice surgeries. Outcome measures were death, myocardial 
infarction,(Thygesen et al., 2007) stroke, unplanned revascularisation and BARC 
(Bleeding Academic Research Consortium)(Mehran et al., 2011) defined bleeding in-




2.7 Statistical Methods 
All the statistical analysis presented in this thesis are done by me using IBM® SPSS® 
(version 22, 2013). I had attended appropriate courses for basic and advanced use of 
SPSS run by Newcastle University. I received statistical guidance on one-one basis 
from the University appointed guide for statistics for post-graduate students (see 
acknowledgment).  
Frequency of categorical data are presented as number and percentage. Normally 
distributed continuous data is presented as mean and standard deviation. Non-
normally distributed data is presented as median and range or interquartile range. 
Differences between groups were assessed by t-tests (normally distributed continuous 
data), Wilcoxon-Mann-Whitney U tests (non-normally distributed continuous data) and 
chi-squared tests (categorical data). The p values are two sided with bonferroni 
correction applied for multiple testing as appropriate. Missing values are excluded from 
analysis (number of missing data are reported). Regression analysis (binary logistic 













A screening log was maintained to keep record of patients with NSTEACS who were 
screened and recruited into ICON1 study from November 2012 to December 2014. A 
total of 496 patients were screened. Figure 3.1 depicts the patient recruitment. Of 
these 129 were excluded as they did not meet the eligibility criteria. Of the remaining 
patients, 49 patients could not be recruited due to consent issues and 60 patients 
declined to take part in the study. So 258 patients were consented of which 18 had to 
be excluded after coronary angiography as they had an alternative diagnosis. Of the 
240 patients recruited into the study further 3 patients could not continue in the study 


















Figure 3.1: Flow chart detailing patient recruitment 
 
CABG Coronary Artery Bypass Surgery, CTPA Computed Tomography Pulmonary Angiogram,  




3.2 Baseline Characteristics of Patient Cohort at Recruitment 
The number of patients recruited into the study from November 2012 to December 
2014 was 237 patients. Of these 89 (37.6%) were females. The mean age of the patient 
cohort was 80.3 years (SD 4.9). The oldest was 93.6 years and the youngest was 66.2 
years old. Patients belonged to the age group 65-80 years (108, 45.6 %) and >80 years 
(129, 54.4%). Most of the patients were ≥ 75 years old (218, 92.5%) and only 18 (7.5%) 
were between the age group 65-74 years. The final diagnosis prior to invasive 
treatment was NSTEMI (196, 82.7%) and UA (41, 17.3%). Baseline characteristics are 
displayed in Table 3.1. 
The cardiovascular risk factor profile of the patient cohort was hypertension (182, 
76.8%), diabetes (61, 25.7%), current smoker (19, 8.0%), ex-smoker (116, 48.9%), 
hypercholesterolemia (146, 61.6%), peripheral vascular disease (22, 9.3%) and 
previous cerebrovascular disease with either stroke or transient ischemic attack (41, 
17.3%).  
Cardiac history included previous MI (81, 34.2%), previous angina (94, 39.7%), 
previous PCI (45, 19.0%), previous CABG (12, 5.1%), previous AF/PAF (30, 12.7%) 
and CCF (18, 7.6%). 
Other medical history of significance were renal impairment (40, 16.9%), peptic ulcer 
disease (10, 4.2%), bleeding problems (6, 2.5%), anaemia (20, 8.4%), COPD (47, 
19.8%), previous malignancy (23, 9.7%) and osteoarthritis (77, 32.5%). There were no 




Table 3.1: Baseline characteristics of patient cohort 
Variable Number of patients 
N=237 
% of total patients 
Male 148 62.4 
Female 89 37.6 
Age in years mean (SD) 80.3 (4.9)  
> 80 years 129 54.4 
65-80 years 108 45.6 
< 75 years 18 7.5 
NSTEMI 196 82.7 
UA 41 17.3 
Hypertension 182 76.8 
Diabetes mellitus 61 25.7 
Current smoker 19 8.0 
Ex-smoker 116 48.9 
Never smoked 102 43.1 
Hypercholesterolemia 146 61.6 
Peripheral vascular disease 22 9.3 
Cerebrovascular disease 41 17.3 
Myocardial infarction 81 34.2 
Angina 94 39.7 
CABG 12 5.1 
AF/PAF 30 12.7 
CCF 18 7.6 
Renal impairment 40 16.9 
Anaemia 20 8.4 
Major bleeding problems 6 2.5 
COPD 47 19.8 
Previous malignancy 23 9.7 
Osteoarthritis 77 32.5 
 
AF/PAF Atrial Fibrillation/Paroxysmal AF, CABG Coronary  Artery Bypass Surgery, CCF Congestive 
Cardiac Failure, COPD Chronic Obstructive Pulmonary disease, NSTEMI Non ST Elevation 




3.3 Frailty Classification 
As per FFC, there are three groups – Frail, Pre-frail and Frail. RFC categorises the 
patients in 7 grades of which 1-4 are non-frail and 5-7 describe the frail patients (Table 
3.2). The analysis in the following sections are done as Frail, Pre-Frail and Robust 
groups and also as Frail and Non-Frail groups for easier comparison between the two 
criteria. Fried criteria was made in to frail and non-frail (combining robust and pre-frail 
groups together). Similarly Rockwood was divided into three groups by describing the 
non-frail as robust 1-2 and pre-frail 3-4; with frail group comprising categories 5-7.  
 
Table 3.2: Frailty Groups Classification 
Three Groups by  
Fried and 
Rockwood Criteria 
Fried Frailty Score Rockwood Frailty 
Category 



















3.3.1 Frailty status 
3.3.1.1 Fried Criteria 
As per FFC, patients are grouped into frail, pre-frail and robust groups. The prevalence 
of these three groups of patients in the study were 30.8% (n=73), 49.8% (n=118) and 
19.4% (n=46) respectively. But when classified as frail and non-frail groups, 69.2% 
(n=164) patients were non-frail. 
 
3.3.1.2 Rockwood Criteria 
As per RFC, the frail and non-frail groups of patients are 10.1% (n=24) and 89.9% 
(n=213) respectively. When the non-frail patients were further sub classified to equate 
with Fried frailty status groups, 59.9% (n=142) were pre-frail and 30.0% (n=71) 

















































3.3.2 Frailty status variation between the two frailty tools 
Frailty status by the two assessment tools vary significantly. As has been depicted in 
the previous bar charts (Figure 3.2) 30.8% of patients are classified as frail by the 
Fried criteria while only 10.1% of the patients are frail by the Rockwood classification. 
The frailty status determined by Rockwood group compared to Fried frailty status was 
similar in 26% of frail, 66.1% of pre-frail and 73.9% of robust patients (Table 3.3). When 
classified as two groups of frail and non-frail only 26% of patients were classified 
similarly as frail by the two criteria but this increases to 97% when classifying non-frail 
groups (Table 3.4). 
Since there was variation in the frailty status depending on the frailty assessment tool, 










Table 3.3: Prevalence of Frail, Pre-Frail and Robust Groups by Fried and 
Rockwood Criteria 
 
 Fried Frailty Groups   
























































Table 3.4: Prevalence of Frail and Non-Frail Groups by Fried and Rockwood 
Criteria 
 
 Fried Frailty Groups   















































3.4 Variables Determining Frailty Status by Fried Variables 
Fried frailty status assessment is based on five variables; three of which are subjective 
responses from patients (weight loss, physical endurance and physical activity) and 
two are objective assessments (handgrip strength and walking speed). The order of 
prevalence of these variables in the frail group are weakness by hand grip strength 
(91.8%), low physical activity (83.6%), poor physical endurance (71.2%), weight loss 
in the last year (64.4%) and slow walking speed (34.7%). In the pre-frail group the 
prevalence of these variables are weakness by handgrip strength (70.1%), weight loss 
in the last year (22.9%), low physical activity (24.6%), poor physical endurance (19.5%) 
and slow walking speed (4.3%). These are displayed in Table 3.5 and Figure 3.3. 
In the frail group a score of 3 was most common (61.6%), followed by score of 4 
(30.1%) and score 5 (8.2%). In the pre-frail group the prevalence of score 2 was 42.2% 
and score 1 was 57.8%. 
When these variables were assessed for Rockwood frailty groups the prevalence of 
these Fried variables in the frail group, weakness by handgrip strength 87.5%, low 
physical activity 75.0%, poor physical endurance 66.7%, weight loss 45.8% and slow 
walking speed 45.5%, the pre-frail group 71.1%, 50.0%, 38.0%, 38.7% and 13.4% 
respectively and robust group 38.6%, 1.4%, 7.0%, 11.3% and 1.4% respectively were 
significantly different between the groups. These are displayed in Table 3.6 and 








Frail Pre-Frail Robust p value 
Weight Loss in 
the last year 
64.4% 22.9% 0% <0.0001 
Poor Physical 
Endurance 
71.2% 19.5% 0% <0.0001 
Low Physical 
Activity 




91.8% 70.1% 0% <0.0001 
Slow walking 
speed 
34.7% 4.3% 0% <0.0001 
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Frail Pre-Frail Robust p value 
Weight Loss in 
the last year 
45.8% 38.7% 11.3% <0.0001 
Physical 
Endurance 
66.7% 38.0% 7.0% <0.0001 
Low Physical 
Activity 




87.5% 71.1% 38.6% <0.0001 
Slow walking 
speed 
45.5% 13.4% 1.4% <0.0001 
 
























3.5 Baseline Characteristics of Patients by Frailty Status 
3.5.1 Demographics, CV Risk Factors, CV Disease Profile and Comorbidities 
3.5.1.1.1 Fried Frailty Status 
The mean age of robust patients was 78.3 (SD 4.9) years compared to 80.8 (4.9) years 
of frail and 80.8 (4.7) years of pre-frail group of patients (p=0.007). The mean age was 
not significantly different when compared as frail and non-frail groups (80.8 vs. 80.1, 
p=0.301). Though the proportion of females were not significantly different between 
the three groups, females comprised more of the frail status compared to non-frail 
status (47.9% vs. 32.9%, p=0.030). Table 3.7 displays the baseline characteristics by 
Fried frailty status. 
Cardiac risk factor profile was similar between the groups but history of cardiovascular 
disease with previous MI (46.6% vs. 28.7%, p=0.011), previous angina (49.3% vs. 
35.4%, p=0.046), previous PCI (27.4% vs. 15.2%, p=0.032), previous cerebrovascular 
disease (26.0% vs. 13.4%, p=0.025) and congestive cardiac failure (15.1% vs. 4.3%, 
p=0.007) was significantly more prevalent in the frail patients compared to non-frail 
patients. There was no significant difference in the prevalence of AF/PAF and PVD. 
From non-cardiac perspective, history of arthritis (43.8% vs. 27.4%, p=0.010) and 
COPD (28.85 vs. 15.9%, p=0.007) was more common among frail patients than non-
frail patients. There was no significant difference in the prevalence of previous 







Table 3.7: Baseline Characteristics by Fried Frailty Status 


















F v NF 












































































7 (15.2) 0.190 40 
(24.4) 
0.521 
Current smoker n (%) 19 (8.0) 7 (9.6) 9 (7.6) 3 (6.5) 0.815 12 (7.3) 0.607 






























3 (6.5) 0.086 24 
(14.6) 
0.190 




























5 (10.9) 0.059 25 
(15.2) 
0.032* 
Previous CABG n (%) 12 (5.1) 5 (6.8) 4 (3.4) 3 (6.5) 0.503 7 (4.3) 0.521 




11 (9.3) 5 (10.9) 0.127 16 (9.8) 0.056 
PVD n (%) 22 (9.3) 8 (11.0) 11 (9.3) 3 (6.5) 0.719 14 (8.5) 0.629 








3 (6.5) 0.021* 22 
(13.4) 
0.025* 






6 (13.0) 0.002* 45 
(27.4) 
0.010* 






6 (13.0) 0.060 26 
(15.9) 
0.033* 
Previous Malignancy n 
(%) 
23 (9.7) 6 (8.2) 12 
(10.2) 




failure n (%) 
18 (7.6) 11 
(15.1) 
6 (5.1) 1 (2.2) 0.012* 7 (4.3) 0.007* 
Previous major 
bleeding problems n 
(%) 
6 (2.5) 3 (4.1) 3 (2.5) 0 (0) 0.381 3 (1.8) 0.375 
Anaemia n (%) 20 (8.4) 9 (12.3) 11 (9.3) 0 (0) 0.055 11 (6.7) 0.204 
AF/PAF Atrial Fibrillation/ Paroxysmal AF, BMI Body Mass Index, CABG Coronary Artery Bypass 
Surgery, COPD Chronic Obstructive Pulmonary Disease, MI Myocardial Infarction, PCI Percutaneous 
Coronary Intervention, PVD Peripheral vascular Disease, SD Standard Deviation   
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3.5.1.1.2 Rockwood Frailty Status 
The mean age of frail patients was 83.1 (4.7) years compared to 79.1 (SD 5.2) years 
of robust and 80.5 (4.5) years of pre-frail group of patients (p=0.002). Similarly frail 
patients were older by 3 years compared to non-frail patients (p=0.004). Frail patients 
were more likely to be females when compared as three groups (62.5% vs. 42.3% vs. 
19.7%, p=<0.001) or two groups (62.5% vs. 34.7%, p =0.0130). Table 3.8 displays the 
baseline characteristics by Rockwood frailty status. 
When compared as frail, pre-frail and robust groups, regarding the CV risk profile 
significant difference was noted in the prevalence of diabetes (16.7% vs. 35.2% vs. 
9.9%, p = <0.001) and hypertension (87.5% vs. 80.3% vs. 67.1%, p=0.045). But when 
compared as frail and non-frail groups there was no significant difference in the CV 
risk profile.  
IHD was more prevalent in the frail patients with previous MI (70.8%), previous angina 
(66.7%), previous PCI (37.5%) and previous CABG (16.7%) when compared either as 
three or two groups. Similarly previous cerebrovascular disease (33.3%) was more 
common in frail patients when compared either as three or two groups but CCF (7.6%) 
was more prevalent in frail patients only when compared as three groups. There was 
no significant difference in the prevalence of AF/PAF and PVD. 
From non-cardiac comorbidities arthritis (54.2%) and anaemia (25.0%) was more 
prevalent in the frail patients when compared to either as three or two groups. COPD 
(25.0%) was more common in frail patients only when compared as three groups but 
not as two groups. There was no significant difference in the prevalence of previous 




Table 3.8: Baseline Characteristics by Rockwood Frailty Status 
 


















F v NF 






































































Diabetes n (%) 61 
(25.7) 
4 (16.7) 50 
(35.2) 
7 (9.9) <0.001 57 
(26.8) 
0.335 
Current smoker n (%) 19 (8.0) 1 (4.2) 15 
(10.6) 
3 (4.2) 0.211 18 (8.5) 0.702 






















Renal Impairment n (%) 40 
(16.9) 
7 (29.2) 16 
(18.3) 
7 (9.9) 0.071 33 
(15.5) 
0.145 






















Previous PCI n (%) 45 
(19.0) 
9 (37.5) 29 
(20.4) 
7 (9.9) 0.009 36 
(16.9) 
0.025* 
Previous CABG n (%) 12 (5.1) 4 (16.7) 4 (2.8) 4 (5.6) 0.016* 8 (3.8) 0.023* 
AF/PAF n (%) 30 
(12.7) 
5 (20.8) 20 
(14.1) 
5 (7.0) 0.154 25 
(11.7) 
0.201 
PVD n (%) 22 (9.3) 2 (8.3) 17 
(12.0) 
3 (4.2) 0.183 20 (9.4) 1.000 




8 (33.3) 26 
(18.3) 
7 (9.9) 0.028* 33 
(15.5) 
0.043* 











COPD n (%) 47 
(19.8) 
6 (25.0) 37 
(26.1) 
4 (5.6) 0.002* 41 
(19.2) 
0.588 
Previous Malignancy n 
(%) 
23 (9.7) 3 (12.5) 13 (9.2) 7 (9.9) 0.876 20 (9.4) 0.713 
Congestive cardiac 
failure n (%) 
18 (7.6) 4 (16.7) 14 (9.9) 0 (0) 0.008* 14 (6.6) 0.094 
Previous major bleeding 
problems n (%) 
6 (2.5) 2 (8.3) 4 (2.8) 0 (0) 0.076 4 (1.9) 0.115 
Anaemia n (%) 20 (8.4) 6 (25.0) 13 (9.2) 1 (1.4) 0.001* 14 (6.6) 0.008* 
AF/PAF Atrial Fibrillation/ Paroxysmal AF, BMI Body Mass Index, CABG Coronary Artery Bypass 
Surgery, COPD Chronic Obstructive Pulmonary Disease, MI Myocardial Infarction, PCI Percutaneous 
Coronary Intervention, PVD Peripheral vascular Disease, SD Standard Deviation   
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3.5.2 Blood Results Prior to Invasive Management 
Baseline blood results are displayed in Table 3.9 for Fried Frailty status and in Table 
3.10 for Rockwood Frailty status. 
3.5.2.1.1 Fried Frailty Status 
The mean haemoglobin level was 13.1 (SD 1.7) g/dl in the 235 patients the result was 
available. The mean level in the frail, pre-frail and robust patients was 12.6 (SD 1.6), 
13.0 (SD 1.7) and 14.1 (SD 1.6) respectively (p=<0.001). When compared as frail and 
non-frail patients this was 12.6 (SD 1.6) and 13.1 (SD 1.7) respectively (p=0.003). 
There was no significant difference in the mean white cell count (8.4 vs. 8.4 vs. 7.7 and 
8.4 vs. 8.2 x103/microlitre) or median platelet counts (235 vs. 243 vs. 235 and 235 vs. 
229 x103/microlitre) according to the three or two groups of frailty status classification. 
The median creatinine was not significantly different between the 3 groups: 92 µmol/L 
in frail, 93 µmol/L in pre-frail and 103 µmol/L in robust patients. The levels when 
compared as frail and non-frail patients were 92 µmol/L and 94 µmol/L respectively. 
The median GFR (ml/min) was not significantly different between the three groups 
(49.0 vs. 51.4 vs. 56.3) or two groups (49.0 vs. 50.9).  
The mean serum glucose and cholesterol levels were not significantly different 
between the groups. It has to be noted that results were available for 178 and 184 
patients respectively. Clotting profile of PT, APTT and fibrinogen were similar between 
the patient groups. 
The median high sensitivity troponin level was 86 ng/L in frail, 119 ng/L in pre-frail and 
153 ng/L in robust patients and this was not significant between the groups. Similarly 
there was no significant difference in median high sensitivity CRP levels between the 
three groups (4.4 vs. 4.1 vs. 2.7, p=0.368).  
Though the frail patients had lower median serum vitamin D levels of 25 nmol/L 
compared to pre-frail (29.5 nmol/L) and robust (43.0 nmol/L), this was not statistically 
significant. Parathormone levels were measured in 142 patients and there was no 
significant difference of median levels between the three groups (6.4 nmol/L vs. 6.0 




3.5.2.1.2 Rockwood Frailty Status 
Similar to the difference noted in the fried frailty groups mean haemoglobin was lower 
in the frail (12.2 g/dL, SD 1.8) compared to pre-frail (12.8 g/dL, SD 1.6) and robust 
(13.9 g/dL, SD 1.7) patients with statistical significance (p <0.001). This remained 
significant when compared as frail and non-frail groups (12.2 g/dL, SD 1.8 vs. 13.2 
g/dL, SD 1.7, p=0.010). 
Though there was no significant difference between the groups for median creatinine 
values but the median GFR values (ml/min) were significantly lower in the frail patients 
compared to pre-frail and robust patients (46.0 vs. 50.9 vs. 56.6, p=0.004). This 
difference persisted even when compared as frail and non-frail patients (46.0 vs. 52.2, 
p=0.001). 
There was no difference noted in the mean serum glucose level, total cholesterol level, 
clotting profile, troponin and HS CRP levels, similar to the fried frailty groups. 
The median vitamin D level was significantly lower in the frail group when compared 
as three groups (25.5 nmol/L vs. 26.0 vs. 39.0, p=0.014) but not when compared as 
two groups (25.5 vs. 30.5, p=0.721). Conversely median parathormone level was 
higher in frail patents when compared as three groups (96.2 nmol/L vs. 6.1 v vs. 5.5 








Table 3.9: Baseline Blood Results by Fried Frailty Status 
GFR Glomerular Filtration Rate by Cockcroft Gault formula, PT Prothrombin Time, APTT Activated 





































































































































226 25-37 31 
(207) 
31 (61) 31 
(207) 
32 (25) 0.416 31 
(207) 
0.414 


























HS CRP median 
(range) mg/L 










































Table 3.10: Baseline Blood Results by Rockwood Frailty Status 
GFR Glomerular Filtration Rate by Cockcroft Gault formula, PT Prothrombin Time, APTT Activated 




























F v NF 
























































































































Peak Troponin (HS) 
median (range) 
ng/L 












HS CRP median 
(range) mg/L 












Vitamin D median 
(range) nmol/L 































3.6 Type of NSTEACS and Management Strategy 
These are displayed in Tables 3.11 and 3.12 as per frailty classifications. 
3.6.1 Arterial access and management strategy 
3.6.1.1 Fried Frailty Status 
There was no significant difference in the presentation with NSTEMI between frail, pre-
frail and robust groups (80.8% vs. 82.2% vs. 87.0%, p=0.676) and also between frail 
and non-frail groups (80.8% vs. 83.5%, p=0.710). Similarly UA presentation was not 
significantly different between the frailty status groups (19.2% vs. 17.8% vs. 13.0% for 
F vs. PF vs. R and 19.2% vs. 16.5% for F vs. NF). 
Frail patients were less likely to have coronary angiogram by radial access compared 
to the other groups (76.7% vs. 91.5% vs. 91.3%, p=0.008 and 76.7% vs. 91.5%, 
p=0.003). Conversely femoral access was more used in frail patients (23.3% vs. 8.5% 
vs. 8.7%, p=0.008 and 23.3% vs. 8.5%, p=0.003). 
In terms of the final management strategy of revascularisation there was no significant 
difference in the use of PCI (87.7% vs. 83.9% vs. 82.6%, p=0.700 and 87.7% vs. 
83.5%, p=0.2) and CABG (4.1% vs. 4.2% vs. 4.3%, p=0.9 and 4.1% vs 4.3%, p=1.0). 
Similarly medical management after coronary angiogram was not different between 




Table 3.11: Type of NSTEACS and Management Strategy by Fried Frailty Status 


















F v NF 















CABG n (%) 10 (4.2) 3 (4.1) 5 (4.2) 2 (4.3) 0.998 7 (4.3) 1.000 
Conservative n 
(%) 






Radial access n 
(%) 





Femoral access n 
(%) 




days mean (SD) 
5.5 (3.1) 5.7 (3.4) 5.4 (2.9) 5.6 
(3.1) 
0.895 5.5 (2.9) 0.713 
Length of stay in 
days median 
(IQR) 
6 (4) 7 (5) 6 (4) 6 (3) 0.391 6 (3) 0.172 
 
Length of stay in 
days median 
(IQR) PCI 
6.0 (4) 7.0 (6) 6.0 (4) 6.0 (3) 0.551 6.0 (3) 0.284 
 
Length of stay in 
days median 
(IQR) CABG 
28.5 (26) 34 (-) 21 (24) 18 (-) 0.056 21 (22) 0.016* 
 




6 (4) 6 (1) 5 (5) 6 (8) 0.771 5 (8) 0.756 
NSTEMI Non ST Elevation Myocardial Infarction, PCI percutaneous Coronary Intervention, CABG 






3.6.1.2 Rockwood Frailty Status 
There was no significant difference in the presentation with NSTEMI between frail, pre-
frail and robust groups (83.3% vs. 81% vs. 85.9%, p=0.666) and also between frail and 
non-frail groups (83.3% vs. 82.6%, p=1.000). Similarly UA presentation was not 
significantly different between the frailty status groups (16.7% vs. 19.0% vs. 14.1% for 
F vs. PF vs. R and 16.7% vs. 17.4% for F vs. NF). 
There was no significant difference in the arterial access for angiography procedure 
between the patient groups for radial access (79.2% vs. 88% vs. 87.3 for F vs. PF vs. 
R and 79.2% vs. 87.8% for F vs. NF). Though femoral access was more used in frail 
patients (20.8% vs. 12.0% vs. 12.7%, p=0.489 and 20.8% vs. 12.2%, p=0.216) this 
difference was not statistically significant. 
In terms of the final management strategy of revascularisation there was no significant 
difference in the use of PCI (75.0% vs. 86.6% vs. 84.5%, p=0.34 and 75% vs. 85.9%, 
p=0.2) and CABG (4.2% vs. 4.2% vs. 4.2%, p=1.0 and 4.2% vs. 4.2%, p=1.0). Though 
medical management after coronary angiography was used more commonly in frail 
patients (20.8% vs. 8.5% vs. 12.7%, p=0.172 and 20.8% vs. 11.0%, p=0.157), this did 
not meet statistical significance. 
 
3.6.1.3 Predictors of Femoral Access 
A binary logistic regression analysis was conducted to predict use of femoral access 
for PCI using age, sex, previous CABG, previous PCI, PVD, weakness by grip strength, 
fried and rockwood frailty categories (as frail and non-frail groups). The regression 
model was statistically significant with chi-square 31.1 (p <0.001). The model explained 
23% (Nagelkerke R2) of the variance of use of femoral access and classified 88% of 
cases correctly with Hosmer and Lemeshow fit of 0.412. Patient with previous CABG 
were 21 times more likely to have femoral access. Femoral access is commonly used 
for clinical reason to access the left internal mammary artery used as a graft to LAD, 
though left radial access can be used for the same reason. Previous PCI, PVD and 
rock wood frailty predicted femoral access but not sex or weakness by grip strength.   
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Table 3.12: Type of NSTEACS and Management Strategy by Rockwood Frailty 
Status 


















F v NF 



















CABG n (%) 10 (4.2) 1 (4.2) 6 (4.2) 3 (4.2) 1.000 9 (4.2) 1.000 
Conservative n 
(%) 




Radial access n 
(%) 







Femoral access n 
(%) 






days mean (SD) 
5.5 (3.1) 6.2 (2.7) 5.6 (3.2) 5.2 (2.9) 0.358 5.5 (3.1) 0.244 
Length of stay in 
days median 
(IQR) 
6 (4) 7.0 (5) 6.0 (4) 6.0 (4) 0.049* 6.0 (4) 0.092 
 
Length of stay in 
days median 
(IQR) PCI 
6.0 (4) 7.5 (5) 6.0 (4) 6.0 (4) 0.070 6 (3) 0.063 
 
Length of stay in 
days median 
(IQR) CABG 
28.5 (26) 34 (0) 29.5 (18) 7 (-) 0.283 28 (25) 0.222 
 




6 (4) 6 (4) 6 (2) 3 (5) 0.464 6.0 (8) 0.715 
NSTEMI Non ST Elevation Myocardial Infarction, PCI percutaneous Coronary Intervention, CABG 





3.6.2 Revascularisation by Percutaneous Coronary Intervention Strategy 
PCI details by frailty status are displayed in Tables 3.13 and 3.14 
3.6.2.1 Fried Frailty Status 
Of the 201 patients revascularised by PCI, radial access was used less in frail patients 
compared to other groups of patients (75% vs. 91.8% vs. 92.1%, p=0.005 in F vs. PF 
vs. R and 75% vs. 92%, p=0.002 in F vs. NF respectively). This in turn resulted in more 
use of femoral access in frail patients (25% vs. 8.1% vs. 7.9% and 25% vs. 8%). Almost 
a third of patients (72.6%) had single vessel PCI and just more than a quarter of the 
patients (27.4%) had multi vessel PCI but there was no significant difference in single 
vessel or multi vessel PCI in the patient groups by frailty status. The volume of contrast 
used for PCI was not significantly different between the patient groups. PCI was 
performed most in left anterior descending artery. But there was no significant 
difference in the coronary artery in which PCI was performed by frailty status. Though 
left main stem PCI was performed more in frail patients (12.5% vs. 8.1% vs. 2.6%, 




Table 3.13: PCI details by Fried Frailty Status 
 Total  
N=201 











F v NF 





Femoral access PCI n (%) 27 (13.4) 16 (25.0) 8 (8.1) 3 (7.9) 0.005* 11 (8.0) 0.002* 
 











Number of stents median 
(range)  
1(6) 1 (6) 1 (5) 2 (3) 0.530 2 (5) 0.419 
Contrast volume ml median 
(range) 






LMS n (%) 17 (8.5) 8 (12.5) 8 (8.1) 1 (2.6) 0.219 9 (6.6) 0.179 















Graft n (%) 2 (1.0) 1 (1.6) 0 (0) 1 (2.6) 0.327 1 (0.7) 0.537 
 
Length of hospital stay 
median (range) in days 
6 (27) 7 (27) 6 (18) 6 (18) 0.193 6 (18) 0.075 
PCI Percutaneous Coronary Intervention, LMS Left Main Stem, LAD Left Anterior Descending, LCx 





3.6.2.2 Rockwood Frailty Status 
Though radial access was used less in frail patients this difference was not statistically 
significant (72.2% vs. 87.8% vs. 88.3%, p=0.173 and 72.2% vs. 88%, p=0.074). 
Similarly more use of femoral access in frail patients was not statistically significant 
either. The proportion of single vessel and multi vessel PCI was not different between 
the frailty groups. More LMS PCI (22.2% vs. 8.2% vs. 5.0%, p=0.252 and 22.2% vs. 
7.2%, p=0.051) and less RCA PCI in frail patients (22.2% vs. 29.3% vs. 43.3%, 
p=0.099 and 22.2% vs. 33.9%, p=0.433) did not reach statistical significance. When 
compared as three frailty status groups volume of contrast used was no different 
statistically (median 140 ml vs. 160 ml vs. 170 ml, p=0.083) but this was significantly 
different. Less contrast used in frail patients when compared as frail and non-frail 





Table 3.14: PCI details by Rockwood Frailty Status 
 Total  
N=201 











F v NF 





Femoral access PCI n (%) 27 (13.4) 5 (27.8) 15 (12.2) 7 
(11.7) 
0.173 22 (12 0.074 
 











Number of stents median 
(range)  
1(6) 1.5 (3) 1 (6) 2 (5) 0.505 1 (6) 0.721 
Contrast volume ml median 
(range) 






LMS n (%) 17 (8.5) 4 (22.2) 10 (8.1) 3 (5.0) 0.069 13 (7.1) 0.051 















Graft n (%) 2 (1.0) 0 (0) 1 (0.8) 1 (1.7) 0.780 2 (1.1) 1.000 
 
Length of hospital stay 
median (range) in days 
6 (27) 7 (11) 6 (26) 6 (18) 0.350 6 (26) 0.609 
PCI Percutaneous Coronary Intervention, LMS Left Main Stem, LAD Left Anterior Descending, LCx 





3.6.3 Revascularisation by Coronary Artery Bypass Strategy 
Only ten patients (4.2%) were revascularised by CABG. 
 
3.6.3.1 Fried Frailty Status 
There was no difference in the proportion of patients revascularised by CABG (4.1% 
vs. 4.2% vs. 4.3% in F vs. PF vs. R, p=0.9 and 4.1% vs. 4.3% in F vs. NF, p=1.0). 
  
3.6.3.2 Rockwood Frailty Status 
Similar to comparison by fried frailty status, there was no difference in the proportion 
of patients revascularised by CABG in rockwood frailty status as well (4.2% vs. 4.2% 





3.6.4 Medical Management Strategy 
 
Twenty six patients (11.0%) were managed by medical treatment only as 
revascularisation was deemed too high risk or the coronary artery anatomy was not 
suitable for PCI as decided by the interventional cardiologist. 
 
3.6.4.1 Fried Frailty Status 
There was no significant difference in the proportion of patients managed by medical 
treatment between the frailty groups (8.2% vs. 11.9% vs. 13.0%, p=0.649 and 8.2% 
vs. 12.2%, p=0.5). 
 
3.6.4.2 Rockwood Frailty Status 
Although more frail patients were managed medically this did not reach statistical 
significance either by three frailty groups (20.8% vs. 8.5% vs. 12.7%, p=0.17) or two 




3.6.5 Time from presentation to invasive treatment and Length of Hospital stay 
 
3.6.5.1 Time from presentation to invasive treatment 
3.6.5.1.1 Fried Frailty Status 
Days from initial admission to local hospital with NSTEACS to invasive treatment with 
coronary angiography and or PCI at Freeman hospital was not significantly different 
between either the three groups of frailty status (F vs. PF vs. R respectively of 5.7 days 
vs. 5.4 days vs. 5.6 days, p=0.8) or the two groups (F vs. NF respectively of 5.7 days 
vs. 5.5 days, p=0.7). 
 
3.6.5.1.2 Rockwood Frailty Status 
Time from initial admission to local hospital with NSTEACS to the day of invasive 
treatment with coronary angiogram and or PCI at Freeman hospital was not 
significantly different between either the three groups of frailty status (F vs. PF vs. R 
respectively of 6.2 days vs. 5.8 days vs. 5.2 days, p=0.36) or the two groups (F vs. NF 




3.6.5.2 Length of Hospital stay 
3.6.5.2.1 Fried Frailty Status 
The median length of stay for all patients was 6 days (IQR of days). There was no 
difference in the median length of stay between the frailty groups (7 vs. 6 vs. 6 days, 
p=0.55 and 7 vs. 6, p=0.17). When the length of stay was compared depending on 
management strategy there was no significant difference for PCI and medical 
management. The difference was noted for management by CABG when compared 
as frail and non-frail patients (34 vs. 21 days, p=0.016) but not as three frailty groups 
(34 vs. 21 vs. 18, p=0.056 for F vs. PF vs. NF). 
 
3.6.5.2.2 Rockwood Frailty Status 
The difference between the lengths of stay of all patients was significant with frail 
patients staying a day longer compared to pre-frail and non-frail patients (7 vs. 6 vs. 6. 
p=0.049) but this difference was not significant when compared as frail and non-frail 
patients (7 vs. 6, p=0.092). There was no difference in the length of stay in hospital 




3.6.6 Secondary Prevention Medications at Discharge 
Medications were prescribed as per the established guidelines for secondary 
prevention.(Hamm et al., 2011) The routine secondary prevention medications were 
aspirin long term and either clopidogrel, ticagerlor or prasugrel as second antiplatelet 
(usually for 1 year), beta-blocker, angiotensin converting enzyme inhibitor (ACEi) and 
statin. The discharge medications relevant to CV disease are displayed in Tables 3.15 
and 3.16. There was high use of these medications in all patients irrespective of the 
frailty status at the time of discharge. Oral anticoagulants (either warfarin or novel oral 
anticoagulant) were used in 6.8% of patients for stoke prophylaxis though 12.7% had 
AF/PAF. The lesser use of oral anticoagulants than indicated was probably due to the 
need for concurrent use of antiplatelet, which can increase the risk of bleeding. Nearly 
42% of patients were discharged on proton pump inhibitor, as there was increased risk 
of upper gastrointestinal bleeding with dual antiplatelets.  
Though only just over a quarter of patients were prescribed Isosorbide Mono Nitrate, 
an anti-angina medication, this was significantly higher in frail patients both by FFC 
(35.6% in F vs. 26.3% in PF vs. 13.0% in R, p=0.025) and RFC (54.2% in vs 23.5% in 
NF, p=0.003). Similarly use of another anti-angina medication, Nicorandil was higher 




























F v NF 
Aspirin  236 
(99.6) 







70 (59.3) 30 (65.2) 0.750 100 
(61.0) 
0.885 












102 (86.4) 35 (76.1) 0.105 137 
(83.5) 
0.153 
Warfarin 12 (5.1) 4 (5.5) 6 (5.1) 2 (4.3) 0.963 8 (4.9) 1.0 














113 (95.8) 43 (93.5) 0.337 156 
(95.1) 
0.281 




40 (33.9) 15 (32.6) 0.942 55 
(33.5) 
0.881 











18 (15.3) 1 (2.2) 0.019* 19 
(11.6) 
0.074 































F v NF 
Aspirin  236 
(99.6) 







82 (57.7) 46 (64.8) 0.221 128 
(60.1) 
0.187 
Prasugrel 2 (0.8) 0 (0) 2 (1.4) 0 (0) 0.509 2 (0.9) 1.0 
Ticagrelor 83 
(35.0) 







113 (79.6) 61 (85.9) 0.394 174 
(81.7) 
0.417 
Warfarin 12 (5.1) 1 (4.2) 8 (5.6) 3 (4.2) 0.887 11 (5.2) 1.0 












24 (100) 136 (95.8) 68 (95.8) 0.590 204 
(95.8) 
0.604 




47 (33.1) 20 (28.2) 0.281 67 
(31.5) 
0.173 









9 (37.5) 23 (16.2) 2 (2.8) <0.001 25 
(11.7) 
0.003* 










3.7 Frailty Status and Major Adverse Cardiovascular Outcomes 
Adverse CV outcomes were classified under procedural complications, in- hospital 
complications and outcomes at 30 days. Procedural complications and in-hospital 
complications were collected from hospital medical notes, PCI database and discharge 
summary. Outcomes at 30 days were collected from GP surgery records faxed to the 
research team at Freeman Hospital. Adverse outcomes as per frailty status are 
displayed from Tables 3.17 to 3.22. 
3.7.1 Procedural complications 
There were 4 (1.7%) procedural complications. They were LAD perforation, two 
cardiogenic shock and 1 cardiac arrest requiring shock treatment. 
The incidence of procedural complications both by Fried frailty status (F vs. PF vs. R 
of 1.4% vs. 1.7% vs. 2.2%, p=0.95 and F vs. NF of 1.4% vs. 1.8%, p=1.0 respectively) 
and Rockwood frailty status (0% vs. 2.1% vs. 1.4%, p=0.74 and 0% vs. 1.9%, p=1.0) 
was not significantly different between the frailty groups. 
3.7.2 In-hospital complications 
There were 13 (5.5%) in hospital complications. They were 1 (0.4%) death, 2 (0.8%) 
unplanned revascularisation, 5 (2.1%) major bleeding problems, 2 (0.8%) stroke and 
3 (1.3%) contrast induced nephropathy. The procedural complications were not 
included in the in-hospital complications. Contrast induced nephropathy were 
managed medically and did not need renal replacement treatment. There was no 
significant difference in these events either by Fried or Rockwood frailty status 
classification. 
3.7.3 30 day MACE rate 
The total number of major adverse events at 30 days were 23 (9.7%) in 17 (7.2%) 
patients. The events were 1 (0.4%) death, 4 (1.7%) acute coronary syndrome, 3 (1.3%) 
unplanned revascularisation, 9 (3.8%) major bleeding, 3 (1.3%) stroke and 3 (1.3%) 
contrast nephropathy. There was no significant difference in the incidence of these 
events when compared by both Fried and Rockwood frailty statuses in comparison 
based either on three groups or two groups. The composite outcomes based on 
number of patients did not show any difference. 
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Table 3.17: Procedural, In hospital and one month primary outcomes by Fried 
Frailty Status 





















4 (1.7) 1 (1.4) 2 (1.7) 1 (2.2) 0.946 3 (1.8) 1.000 
In hospital n 
(%) 
13 (5.5) 7 (9.6) 5 (4.2) 1 (2.2) 0.157 6 (3.7) 0.117 
Composite 
MACE at 30-
day n (%) 
17 (7.2) 8 (11.0) 7 (5.9) 2 (4.3) 0.302 9 (5.5) 0.172 
 
Table 3.18: In-hospital major adverse cardiovascular events by Fried frailty 
status 


















F v NF 
Death n (%) 1 (0.4) 1 (1.4) 0 (0) 0 (0) 0.324 0 (0) 0.308 
Acute coronary 
syndrome n (%) 




2 (0.8) 1 (1.4) 1 (0.8) 0 (0) 0.729 1 (0.6) 0.522 
Major bleeding n (%) 5 (2.1) 2 (2.7) 3 (2.5) 0 (0) 0.538 3 (1.8) 0.645 
Stroke n (%) 2 (0.8) 1 (1.4) 0 (0) 1 (2.2) 0.330 1 (0.6) 0.522 
Contrast 
nephropathy/Renal 
replacement n (%) 
3 (1.3) 2 (2.7) 1 (0.8) 0 (0) 0.364 1 (0.6) 0.225 
 
Table 3.19: 30-day major adverse cardiovascular events by Fried frailty status 


















F v NF 
Death n (%) 1 (0.4) 1 (1.4) 0 (0) 0 (0) 0.324 0 (0) 0.308 
Acute coronary 
syndrome n (%) 




3 (1.3) 1 (1.4) 1 (0.8) 1 (2.2) 0.789 2 (1.2) 1.000 
Major bleeding n 
(%) 
9 (3.8) 5 (6.8) 4 (3.4) 0 (0) 0.155 4 (2.4) 0.139 
Stroke n (%) 3 (1.3) 1 (1.4) 1 (0.8) 1 (2.2) 0.789 2 (1.2) 1.000 
Contrast 
nephropathy/Renal 
replacement n (%) 




Table 3.20: Procedural, In hospital and one month primary outcomes by 
Rockwood status 





















4 (1.7) 0 (0) 3 (2.1) 1 (1.4) 0.741 4 (1.9) 1.000 
In hospital n 
(%) 
13 (5.5) 1 (4.2) 9 (6.3) 3 (4.2) 0.780 12 (5.6) 1.000 
Composite 
MACE at 30-
day n (%) 
17 (7.2) 2 (8.3) 11 (7.7) 24 (5.6) 0.831 15 (7.0) 0.685 
 
Table 3.21: In-hospital major adverse cardiovascular events by Rockwood status 


















F v NF 
Death n (%) 1 (0.4) 0 (0) 1 (0.7) 0 (0) 0.715 1 (0.5) 1.000 
Acute coronary 
syndrome n (%) 




2 (0.8) 0 (0) 1 (0.7) 1 (1.4) 0.776 2 (0.9) 1.000 
Major bleeding n (%) 5 (2.1) 0 (0) 5 (3.5) 0 (0) 0.181 5 (2.3) 1.000 
Stroke n (%) 2 (0.8) 0 (0) 1 (0.7) 1 (1.4) 0.776 2 (0.9) 1.000 
Contrast 
nephropathy/Renal 
replacement n (%) 
3 (1.3) 1 (4.2) 2 (1.4) 0 (0) 0.280 2 (0.9) 0.275 
 
Table 3.22: 30-day major adverse cardiovascular events by Rockwood status 


















F v NF 
Death n (%) 1 (0.4) 0 (0) 1 (0.7) 0 (0) 0.715 1 (0.5) 1.000 
Acute coronary 
syndrome n (%) 




3 (1.3) 0 (0) 1 (0.7) 2 (2.8) 0.362 3 (1.3) 1.000 
Major bleeding n (%) 9 (3.8) 1 (4.2) 6 (4.2) 2 (2.8) 0.875 8 (3.8) 1.000 
Stroke n (%) 3 (1.3) 0 (0) 2 (1.4) 1 (1.4) 0.843 3 (1.4) 1.000 
Contrast 
nephropathy/Renal 
replacement n (%) 





3.8 Frailty and Cardiovascular Status 
3.8.1 Arterial Stiffness Measures by Vicorder in Fried Frailty Status 
The mean peripheral systolic BP was not significantly different between the three 
groups of patients with SBP of 130 mmHg in frail, 134 mmHg in pre-frail and 131 mmHg 
in robust patients. Similarly there was no difference in peripheral DBP between the 
three groups (63 mmHg, 65 mmHg and 64 mmHg respectively). The peripheral pulse 
pressure was 67 mmHg in frail, 68 mmHg in pre-frail and 67 mmHg in robust patients. 
The peripheral MAP was not significantly different (90 mmHg, 93 mmHg and 92 mmHg 
respectively). Aortic SBP and DBP were similar between the three groups. All the 
above were not significant when compared as frail and non-frail patient groups. 
Carotid femoral PWV, a direct measure of arterial stiffness was 9.1 m/s in frail, 9.4 m/s 
in pre-frail and 9.6 m/s in robust patients (p=0.346). Similarly there was no significant 
difference when compared as frail and non-frail groups (9.1 m/s vs 9.5 m/s, p=0.186). 
Aortic PP and augmentation index are the surrogate markers of arterial stiffness. Aortic 
PP was not significantly different between the three groups (63 mmHg vs 66 mmHg vs 
64 mmHg, p=0.447). Augmentation index was 25.8 in frail, 26.6 in pre-frail and 24.9 in 
robust patients (p=0.440). There was no difference noted when compared as frail and 
non-frail groups. There was no difference noted when compared as frail and non-frail 
groups. There was a significant correlation between carotid femoral PWV which is a 
marker of aortic stiffness and brachial femoral PWV (r=0.552, p<0.0001). The Vicorder 











 Table 3.23: Fried Frailty Status and Vicorder Measures 
 


















F v NF 






























































































































































Sternal notch to umbilicus 




































Sternal notch to mid femoral 

















































3.8.2 Arterial Stiffness measures by Vicorder in Rockwood Frailty Status 
The mean peripheral SBP was 132 mmHg in frail, 134 mmHg in pre-frail and 130 
mmHg in robust patients (p=0.382). The mean peripheral DBP was not significantly 
different between the three groups (63 vs 64 vs 65, p=0.683). The peripheral PP (69 
vs 68 vs 65, p=0.230) and MAP (90 vs 93 vs 90, p=0.383) was similar between the 
three groups. Aortic SBP and DBP were similar between the three groups. All the 
above were not significant even when compared as frail and non-frail patient groups. 
 The mean carotid femoral PWV was 9.5 m/s in frail, 9.4 m/s in pre-frail and 9.3 m/s in 
robust patients (p=0.859). There was no significant difference in the surrogate markers 
of arterial stiffness with aortic PP of 65 mmHg, 66 mmHg and 62 mmHg respectively 
(p=0.178) and augmentation index of 26, 25 and 26 respectively p=0.846) between the 
three groups. Similarly there was no significant difference noted when compared as 





 Table 3.24: Rockwood Frailty Status and Vicorder Measures 













F v NF 
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Sternal notch to mid femoral 





















































3.8.3 Age and Arterial Stiffness 
There was a positive correlation between age and arterial stiffness measures of carotid 
femoral pulse wave velocity (r=0.199, p=0.004) and pulse pressure (r=0.209, p=0.002) 
as displayed in Figures 3.5 and 3.6. There was significant correlation between carotid 
and Brachio femoral PWV as displayed in Figure 3.7. 


















3.9 Frailty and Endothelial Function Assessment by EndoPAT®  
Endothelial function assessment was done in 219 patients (92.4%). Recordings made 
in 13 patients (5.5%) were uninterpretable. Of the interpretable recordings normal 
(LnRHI >0.50) was noted in 126 (53.2%) patients and endothelial dysfunction (LnRHI 
≤0.50) was noted in 80 (33.8%) patients. These measures are displayed according to 
frailty status in Tables 3.25 and 3.26. 
 
3.9.1 Fried Frailty and EndoPAT® Measures 
The mean LnRHI was 0.59 in frail patients, 0.59 in pre-frail patients and 0.60 in robust 
patients (p=0.98). The LnRHI suggested normal endothelial function in 42.5% frail 
patients, 56.8% in pre-frail patients and 60.9% robust patients (p=0.09). LnRHI was 
suggestive of endothelial dysfunction in 34.2%, 34.7% and 30.4% patients 
respectively. But when compared as frail and non-frail patients LnRHI was normal in 
42.5% frail patients and 57.9% in non-frail patients (p=0.014). The median 
augmentation index was 10.5% in frail, 18.0% in pre-frail and 20.0% in robust patients 






Table 3.25: Fried Frailty and EndoPAT® Measures 













F v NF 
Normal  

















































AI% (median) 17.0 10.5 18.0 20.0 0.011* 19.0 0.006* 
AI% @ 75 bpm 
(median) 
11.0 4.5 11.0 16.0 0.027* 12.0 0.021* 




3.9.2 Rockwood Frailty and EndoPAT® Measures 
The mean LnRHI was 0.57 in frail patients, 0.60 in pre-frail patients and 0.59 in robust 
patients (p=0.98). The LnRHI suggested normal endothelial function in 41.7% frail 
patients, 53.5% in pre-frail patients and 56.3% robust patients (p=0.23). LnRHI 
suggested endothelial dysfunction in 29.2%, 33.8% and 35.2% patients respectively. 
But when compared as frail and non-frail patients, LnRHI was normal in 41.7% frail 
patients and 54.5% in non-frail patients (p=0.06). The median augmentation index was 
11.0% in frail, 17.0 % in pre-frail and 20.0% in robust patients (p=0.0329). When 





Table 3.26: Rockwood Frailty and EndoPAT® Measures 













F v NF 
Normal  















































AI% (median) 17.0 11.0 17.0 20.0 0.029* 18.0 0.047* 
AI% @ 75 bpm 
(median) 
11.0 -2.0 10.0 12.0 0.158 11.0 0.062 
AI Augmentation Index, Ln RHI Logarithmic Reactive Hyperaemia Index   
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3.10 Correlation between EndoPAT and Vicorder Measures 
There was a significant positive correlation between augmentation indices measured 
by Vicorder and EndoPAT (r=0.262, p<0.0001) as in Figure 3.8. There was no 
significant correlation between carotid femoral PWV and LnRHI (r=-.003, p=0.966). 





3.11 Frailty and Carotid Intima Media Thickness 
CIMT images suitable for assessment was available in 195 (82.3%) patients on the 
right carotid artery and 183 (77.2%) patients on the left carotid artery. The mean left 
posterior CIMT was 0.742 mm (SD 0.180) and right posterior CIMT was 0.743 mm (SD 
0.153). 
3.11.1 Fried Frailty and CIMT 
There was no difference in CIMT between the three groups by Fried Frailty 
classification as displayed in Table 3.27. The mean left posterior CIMT was 0.720 mm 
(SD 0.188) in frail patients, 0.763 mm (SD 0.182) in pre-frail patients and 0.723 mm 
(SD 0.160) in robust patients (p=0.274). This was 0.752 mm (SD 0.177) in non-frail 
patients (p=0.259). 
The mean right posterior CIMT in frail, pre-frail and robust patients was 0.772 mm (SD 
0.156), 0.737 mm (SD 0.161) and 0.721 mm (SD 0.125) respectively (p=0.253). This 
was 0.732 mm (0.151) in non-frail patients (p=0.118).  
Table 3.27: Fried Frailty and CIMT 











F v NF 



































3.11.2 Rockwood Frailty and CIMT 
The mean left posterior CIMT was 0.729 mm (SD 0.170) in frail patients, 0.746 mm 
(SD 0.187) in pre-frail patients and 0.739 mm (SD 0.174) in robust patients (p=0.920). 
This was 0.744 mm (SD 0.182) in non-frail patients (p=0.740) as displayed in below 
Table 3.28. 
The mean right posterior CIMT in frail, pre-frail and robust patients was 0.785 mm (SD 
0.170), 0.747 mm (SD 0.144) and 0.724 mm (SD 0.165) respectively (p=0.355). This 
was 0.739 mm (0.151) in non-frail patients (p=0.262).  
Table 3.28: Rockwood Frailty and CIMT 
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3.12 Frailty and Left Ventricular function 
LV function was assessed by transthoracic echocardiogram (TTE). Ejection fraction 
was visually estimated and classified as normal (EF >55%), mild LV systolic 
dysfunction (EF 45-55%), moderate LV systolic dysfunction (EF 35-45%) and severe 
LV systolic dysfunction (EF <35%).  LA size and tissue doppler measurement of E/e’ 
was used to assess LV filling pressure a reliable measure of diastolic function. 
Image quality was uninterpretable in 7.6% patients (n=18) and TTE could not be done 
in 8.9% patients (n=21). LV systolic function was normal in 35.9% patients (n=85), 
mildly impaired in 21.9% patients (n=52), moderately impaired in 16.0 % patients 
(n=38) and severely impaired in 9.7% patients (n=23). The mean E/e’ was 10.4 (SD 
4.5). 
3.12.1 Fried Frailty and LV Function 
According to Fried frailty classification, normal LV function was noted in 26 % frail 
patients, 39% of pre-frail patients and 43.5% of robust patients. Mild LV impairment 
was noted in 17.8%, 23.7% and 23.9% respectively. Moderate LV impairment was 
noted in 19.2%, 13.6% and 17.4% respectively. Severe LV dysfunction was noted in 
15.1%, 8.5% and 4.3% respectively. There was no significant difference in the above 
findings (p=0.298). The details of LV function according to Fried frailty status are 
displayed in Table 3.29. 
LA size was normal in 32.7% frail, 50.0% pre-frail and 42.1% robust patients. LA was 
mildly dilated in 10.9%, 8.5% and 13.2% respectively. LA was moderately dilated in 
18.2%, 18.1% and 21.1% respectively. LA was severely dilated in 38.2%, 23.4% and 
23.7% respectively. There was no significant difference in the above findings. 
The mean E/e’ in was 11.5 (SD 4.7) in frail patients, 10.4 (SD 4.5) in pre-frail patients 
and 9.0 (SD 2.9) in robust patients (p=0.031). The mean E/e’ was 8.9 (SD 4.1) in non-
frail patients (p=0.041 compared to frail patients). 
Elevated filling pressure suggestive of diastolic dysfunction was present in 52.9 % frail 
patients, 31.1% pre-frail patients and 44.1% robust patients. Filling pressure was not 
elevated in 15.7% frail, 18.9% pre-frail and 14.7% robust patients. Possible elevated 
filling pressure was noted in 15.7%, 18.9% and 14.7% respectively. The above were 
not significantly different (p=0.133). Increasing age was associated with higher E/e’ 
and elevated filling pressures as in Figure 3.9. 
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Table 3.29: Fried Frailty and Transthoracic Echocardiogram Measures 










F v NF 





































23 (9.7) 11 
(15.1) 
10 (8.5) 2 (4.3) 0.298 12 (7.3) 0.068 











LA size Mildly Dilated 19 
(10.2) 
6 (10.9) 8 (8.5) 5 (13.2) 0.403 13 (9.8) 0.166 






8 (21.1) 0.403 25 
(18.9) 
0.166 






9 (23.7) 0.403 31 
(23.5) 
0.166 






9.0 (2.9) 0.031* 8.9 (4.1) 0.041* 


























8 (15.7) 17 
(18.9) 
5 (14.7) 0.133 22 
(17.7) 
0.070 











3.12.2 Rockwood Frailty and LV function 
According to Rockwood frailty classification, normal LV function was noted in 33.3% 
frail patients, 35.2% of pre-frail patients and 38.0% of robust patients. Mild LV 
impairment was noted in 8.3%, 21.1% and 28.2% respectively. Moderate LV 
impairment was noted in 16.7%, 18.3% and 11.3% respectively. Severe LV dysfunction 
was noted in 4.2%, 12.0% and 7.0% respectively. There was no significant difference 
in the above findings (p=0.159). The details of LV function according to Rockwood 
frailty status are displayed in Table 3.30. 
LA size was normal in 13.3% frail, 43.5% pre-frail and 50.9% robust patients (non-frail 
5.9%). LA was mildly dilated in 6.7%, 9.6% and 12.3% respectively (non-frail 10%). LA 
was moderately dilated in 40.0%, 30.4% and 19.3% respectively (non-frail 16.9%). LA 
was severely dilated in 40.0%, 30.4% and 19.3% respectively (non-frail 26.7%). There 
was no significant difference in the above findings when compared as three groups 
(p=0.092) but was significant when compared as frail and non-frail groups (p=0.038). 
The mean E/e’ was 13.0 (SD 3.7) in frail patients, 11.0 (SD 4.6) in pre-frail patients and 
8.7 (SD 3.1) in robust patients (p<0.001). The mean E/e’ was 10.2 (SD 4.3) in non-frail 
patients (p<0.001 compared to frail patients). 
Elevated filling pressure suggestive of diastolic dysfunction was present in 86.7 % frail 
patients, 40.2% pre-frail patients and 26.4% robust patients. Filling pressure was not 
elevated in 13.3% frail, 39.3% pre-frail and 58.7% robust patients. Possible elevated 
filling pressure was noted in 0%, 20.6% and 15.1% respectively. The above were 
significantly different (p<0.001). Increasing age was associated with higher E/e’ and 




Table 3.30: Rockwood Frailty and Transthoracic Echocardiogram Measures  










F v NF 
Normal EF >55% 85 
(35.9) 






















4 (16.7) 26 
(18.3) 





23 (9.7) 1 (4.2) 17 
(12.0) 
5 (7.0) 0.159 22 
(10.3) 
0.066 
Uninterpretable 18 (7.6) 4 (16.7) 9 (6.3) 5 (7.0) 0.159 14 (6.6) 0.066 
Not done 21 (8.9) 5 (20.8) 10 (7.0) 6 (8.5) 0.159 16 (7.5) 0.066 
LA size Normal 81 
(43.3) 







LA size Mildly Dilated 19 
(10.2) 
1 (6.7) 11 (9.6) 7 (12.3) 0.092 18 
(10.5) 
0.038* 
LA size Moderately Dilated 35 
(18.7) 







LA size Severely Dilated 52 
(27.8) 













8.7 (3.1) <0.001* 10.2 
(4.3) 
0.019* 
























0 (0) 22 
(20.6) 
8 (15.1) <0.001* 30 
(18.8) 
<0.001* 




Figure 3.10: Correlation between Age and E/E’ by Rockwood Frailty status and 
elevated Filling pressure 
 
3.12.3 Predictors of elevated filing pressure 
Ordinal logistic regression model to predict elevated filling pressure was built with 
gender, frailty by Fried and Rockwood criteria and history of hypertension. The 
regression model was statistically significant chi-square 31.1 (p <0.001) and Pearson 
goodness of fit of 0.809. The model explained 16% of variance (Nagelkerke R2). The 
model suggests frailty by rockwood criteria as the strongest predictor and female sex 
to be of moderate predictor of elevated filling pressure but not frailty by fried criteria or 




3.13 Frailty and NYHA Dyspnoea Class 
Severity of dyspnoea was classified by NYHA dyspnoea classification. This data was 
obtained from all patients (n=237). Overall 46.0% of patients had class I dyspnoea, 
38.0% class II dyspnoea, 16.0% class III dyspnoea and none reported with class IV 
dyspnoea. 
 
3.13.1 Fried Frailty and Dyspnoea 
Class I dyspnoea was reported in 28.8% of frail patients, 46.6% of pre-frail patients 
and 71.7% of robust patients (p<0.001). Class II dyspnoea was reported in 45.2% frail 
patients, 39.8% pre-frail patients and 21.7% robust patients (p<0.001). Class III 
dyspnoea was reported in 26.6%, 13.6% and 6.5% respectively (p<0.001). When 
compared as frail and non-frail groups; class I, II and III dyspnoea was reported in 
53.7%, 34,8% and 11.6% respectively of non-frail patients (p<0.001). These findings 
are displayed in Table 3.31. 
 
3.13.2 Rockwood Frailty and Dyspnoea 
Class I dyspnoea was reported in 20.8% of frail patients, 33.1% of pre-frail patients 
and 80.3% of robust patients (p<0.001). Class II dyspnoea was reported in 33.3% frail 
patients, 47.9% pre-frail patients and 19.7% robust patients (p<0.001). Class III 
dyspnoea was reported in 45.8%, 19.0% and 0% respectively (p<0.001). When 
compared as frail and non-frail groups; class I, II and III dyspnoea was reported in 
48.8%, 38.5% and 12.7% respectively of non-frail patients (p<0.001). These findings 
are displayed in Table 3.32. 
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Table 3.31: Fried Frailty and NYHA Dyspnoea Class 











F v NF 




























3 (6.5) <0.001* 19 
(11.6) 
<0.001* 
Class IV 0 (0) 0 (0) 0 (0) 0 (0) - 0 (0) 0 (0) 
 
 
Table 3.32: Rockwood Frailty and NYHA Dyspnoea Class 











F v NF 
Class I 109 
(46.0) 







Class II 90 
(38.0) 













0 (0) <0.001* 27 
(12.7) 
<0.001* 





3.14 Frailty and Severity of Angina 
Severity of angina was classified by Canadian Cardiovascular Society (CCS) 
classification. This data was available for all the patients (n=237). Class 0 angina was 
reported in 27.8% of patients, class I angina was reported I 44.3% of patients, class II 
angina in 17.7% of patients, class III in 8.0% of patients and class IV in 2.1% of 
patients. 
 
3.14.1 Fried Frailty and Severity of Angina 
Class 0 angina was reported in 20.5% of frail patients, 28.0% of pre-frail patients and 
39.1% of robust patients (p=0.448). Class I angina was reported in 45.2%, 44.1% and 
43.5% respectively. Class II angina was reported in 21.9%, 18.6% and 8.7% 
respectively. Class III angina was reported by 11.0%, 6.8% and 6.5% respectively. 
There was no significant difference in the angina severity (p=0.448) between the three 
groups. In non-frail patients the reported incidence of class 0-IV angina was 31.1%, 
43.9%, 15.9%, 6.7% and 2.4% respectively (p=0.343 compared to frail patients). These 
findings are displayed in Table 3.33. 
 
Table 3.33: Fried Frailty Status and CCS Angina Category 





F v PF v 
R 
Non-Frail p value 
F v NF 








Class I 105 
(44.3) 
33 (45.2) 52 (44.1) 20 (43.5) 72 (43.9) 
Class II 42 (17.7) 16 (21.9) 22 (18.6) 4 (8.7) 26 (15.9) 
Class III 19 (8.0) 8 (11.0) 8 (6.8) 3 (6.5) 11 (6.7) 





3.14.2 Rockwood Frailty and Severity of Angina 
Class 0 angina was reported in 8.3% of frail patients, 27.5% of pre-frail patients and 
35.2% of robust patients (p=0.448). Class I angina was reported in 44.3%, 43.7% and 
45.1% respectively. Class II angina was reported in 25.0%, 19.7% and 11.3% 
respectively. Class III angina was reported by 12.5%, 8.5% and 5.6% respectively. 
There was no significant difference in the angina severity between the three groups 
(p=0.071). In non-frail patients the reported incidence of class 0-IV angina was 30.0%, 
44.1%, 16.9%, 7.5% and 1.4% respectively (p=0.040 compared to frail patients). These 
findings are displayed in Table 3.34. 
 
Table 3.34: Rockwood Frailty Status and CCS Angina Category 





F v PF v 
R 
Non-Frail p value 
F v NF 
Class 0 66 (27.8) 2 (8.3) 39 (27.5) 25 (35.2)  
 
0.071 
64 (30.0)  
 
0.040* 
Class I 105 
(44.3) 
11 (45.8) 62 (43.7) 32 (45.1) 94 (44.1) 
Class II 42 (17.7) 6 (25.0) 28 (19.7) 8 (11.3) 36 (16.9) 
Class III 19 (8.0) 3 (12.5) 12 (8.5) 4 (5.6) 16 (7.5) 





3.15 Frailty and Comorbidity 
CCI weighted score of <3 was classified as lower burden and ≥3 classified as higher 
comorbidity burden. 
CCI weigted score was available in all the patients. Lower weighted score (<3) 
suggestive of lesser comorbidity burden was noted in 170 patients (71.7%) and higher 
weighted score of (≥3) suggestive of increased comorbidity burden was documented 
in 67 patients (28.3%). The mean risk of mortality based on the CCI score was 13.3% 
(SD 5.7%) at one year. 
 
3.15.1 Fried Frailty Status and Comorbidity Burden 
As per Fried frailty criteria the prevalence of higher comorbidity burden in frail, pre-frail 
and robust patients was 43.8% vs. 24.6% vs. 13.0% respectively compared to lower 
comorobidity burden in the same group of patients (56.2% vs. 75.4% vs. 87.0%, 
p=0.001). When compared as frail and non-frail patients the prevalnce was 43.8% vs. 
21.3% for higher comorbidity burden and 56.2% vs 78.7% for lower comorbidity burden 
(p<0.001). These findings are displayed in Table 3.35. 
The mean risk of mortality at one year was 14.7% (SD 6.0) in frail patients, 13.1% (SD 
5.9) in pre-frail and 11.6% (4.2) in robust patients (p=0.013). In non frail patients this 




Table 3.35: Fried Frailty Status and Comorbidity Burden by Charlson 
Comorbidity Index Score 






























































3.15.2 Rockwood Frailty Status and Comorbidity Burden 
As per Rockwood frailty criteria the prevalence of higher comorbidity burden in frail, 
pre-frail and robust patients was 54.2% vs. 32.4% vs. 11.3% respectively compared to 
lower comorobidity burden in the same group of patients (46.8% vs. 67.6% vs. 88.7%, 
p<0.001). When compared as frail and non-frail patients the prevalnce was 54.2% vs. 
25.4% for higher comorbidity burden and 45.8% vs. 74.6% for lower comorbidity 
burden (p=0.007). These findings are displayed in Table 3.36. 
The mean risk of mortality at one year was 16.1% (SD 6.7) in frail patients, 13.8% (SD 
6.1) in pre-frail and 11.3% (5.7) in robust patients (p<0.001). In non frail patients this 



















Table 3.36: Rockwood Frailty Status and Comorbidity Burden by Charlson 
Comorbidity Index Score 





























































3.15.3 Comorbidity Burden and Cardiovascular Outcomes 
Higher comorbidity burden was not associated with increased rate of procedural or  in 
hospital complicationns. At 30-days there was no significant diifference in the erate of 
death, ACS, unpalnned revascularisation, major bleeding and stroke. Higher 
comorbidity burden was associated with increased rate of contrast nephropathy in 
hospital (4.5% vs. 05, p=0.022). These findings of CV outcomes inrelation to 




Table 3.37: In hospital, one month and one year primary outcomes by 
Comorbidity burden 













4 (1.7) 0 (0) 4 (2.4) 0.579 
In hospital n 
(%) 
14 (5.9) 3 (4.5) 11 (6.5) 0.762 
Composite 
MACE at 30-
day n (%) 




Table 3.38: In-hospital major adverse cardiovascular events by Comorbidity 
burden 










Death n (%) 1 (0.4) 0 (0) 1 (0.6) 1.000 
Acute coronary 
syndrome n (%) 




2 (0.8) 0 (0) 2 (1.2) 1.000 
Major bleeding n 
(%) 
5 (2.1) 1 (1.5) 4 (2.4) 1.000 
Stroke n (%) 2 (0.8) 0 (0) 2 (1.2) 1.000 
Contrast 
nephropathy/Renal 
replacement n (%) 





Table 3.39: 30-day major adverse cardiovascular events by Comorbidity Burden 










Death n (%) 1 (0.4) 0 (0) 1 (0.6) 1.000 
Acute coronary 
syndrome n (%) 




3 (1.3) 0 (0) 3 (1.8) 0.561 
Major bleeding n 
(%) 
9 (3.8) 3 (4.5) 6 (3.5) 0.715 
Stroke n (%) 3 (1.3) 0 (0) 3 (1.8) 0.561 
Contrast 
nephropathy/Renal 
replacement n (%) 
3 (1.3) 3 (4.5) 0 (0) 0.022* 
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3.16 Frailty and Subclinical Cognitive Impairment 
Cognitive status was assessed by Montreal Cognitive Assessment (MoCA) tool. The 
maximum score was 30. MoCA score <26 suggested subclinical cognitive impairment. 
MoCA score was assessed in 215 patients. The mean MoCA score was 25.2 (SD 2.9). 
 
3.16.1 Fried Frailty and Cognitive Status 
The mean MoCA score was 23.8 (SD 3.6) in frail patients, 25.8 (SD 2.4) in pre-frail 
patients and 25.9 (SD 2.2) in robust patients (p<0.001) as in Figure 3.11. In non-frail 
patients the mean MoCA score was 25.8 (SD 2.9, p<0.001).  
MoCA score was <26 in 67.2% of frail, 39.6% of pre-frail and 42.2% of robust patients 
(p=0.002). This was 40.4% in non-frail patients (p<0.001). These are displayed in 
Table 3.40. 
 
Table 3.40: Fried Frailty and Cognitive Status 






























































3.16.2 Rockwood Frailty and Cognitive Status 
The mean MoCA score was 21.9 (SD 3.8) in frail patients, 25.3 (SD 2.4) in pre-frail 
patients and 26.2 (SD 2.6) in robust patients (p<0.001) as in Figure 3.12. In non-frail 
patients the mean MoCA score was 25.6 (SD 2.5, p<0.001). 
MoCA score was <26 in 86.4% of frail, 50.4% of pre-frail and 31.8% of robust patients 
(p<0.001). This was 44.0% in non-frail patients (p<0.001). These are displayed in 
Table 3.41. 
 
Table 3.41: Rockwood Frailty and Cognitive Status 



























































3.17 Frailty and Health related Quality of Life Measures 
3.18 EQ5D-3L 
EQ5D-3L questionnaire assessment was available for all the patients (n=237). In terms 
of mobility 69.2% had no problems in walking about, while 30.8% patients had some 
problems with walking about. There were no patients confined to bed. In terms of self-
care 92% of patients had no problems with self-care compared to 8% of patients some 
problems with washing or dressing. There was no patient who was unable to self-care. 
For usual activities of life 70.9% had no problems, compared to 28.3% having some 
problems and 0.8% patients unable to perform usual activities.   
When responding to pain or discomfort 62% had no pain or discomfort, compared to 
34.2% with moderate pain or discomfort and 3.8% with extreme pain or discomfort. In 
responding to anxiety or depression 76.8% reported not being anxious or depressed, 
21.9% reported moderately anxious or depressed and 1.3% reported being extremely 
anxious or depressed.  
The mean visual analog scale (VAS) score was 67.5 (SD 17.1). The mean EQ5D index 




3.18.1 Fried Frailty and EQ5D-3L 
In responding to problems with mobility 53.4% of frail patients had reported no 
problems in walking about, compared to 70.3% in pre-frail and 91.3% in robust patients 
(p<0.001) but 46.6% frail patients reported some problems with mobility compared to 
29.7% in pre-frail and 8.7% in robust patients. 
In responding to self-care question, 82.2% frail patients reported no problems with self-
care, compared to 79.7% pre-frail and 87% robust patients (p=0.001). Some problems 
with self-care were reported by 8.0%, 17.8% and 5.1% respectively. 
Usual activities were done without any problems by 46.6% of frail patients, 79.7% of 
pre-frail patients and 87.0% of robust patients (p<0.001). Usual activities were 
performed with some problems in 50.7%, 20.3% and 13.0% respectively while 2% of 
frail patients reported unable to perform usual activities. 
No pain or discomfort was reported by 52.1% frail, 63.6% pre-frail and 73.9% robust 
patients (p=0.191). Moderate pain or discomfort was reported by 42.5%, 33.1% and 
23.9% respectively. Extreme pain or discomfort was reported by 5.5%, 3.4% and 2.2% 
respectively. 
There was no anxiety or depression in 71.2% frail, 78.0% pre-frail and 82.6% robust 
patients (p=0.472). Moderate anxiety or depression was reported by 26.0%, 21.25 and 
17.4% respectively. Extreme anxiety or depression was reported by 2.7% frail and 
0.8% pre-frail patients. 
The mean VAS score was 61.1 in frail, 68.2 pre-frail and 74.8% in robust patients 
(p<0.001). The EQ5D index by time trade off was 0.74 in frail, 0.84 in pre-frail and 0.90 
in robust patients (p<0.001). The EQ5D index by VAS was 0.73 in frail, 0.83 in pre-frail 
and 0.88 in robust patients. All the findings of EQ%D-3L in relation to Fried frailty status 




Table 3.42: Fried Frailty and EQ5D-3L 











F v NF 

















4 (8.7) <0.001* 73 
(30.8) 
0.001* 
Level 3 0 (0) 0 (0) 0 (0) 0 (0) - 0 (0) - 
 











Level 2 19 (8.0) 13 
(17.8) 
6 (5.1) 0 (0) 0.001* 6 (8.0) <0.001* 
Level 3 0 (0) 0 (0) 0 (0) 0 (0) - 0 (0) - 
 

















6 (13.0) <0.001* 30 
(18.3) 
<0.001* 


























Level 3 9 (3.8) 4 (5.5) 4 (3.4) 1 (2.2) 0.191 
 
5 (3.0) 0.100 
Anxiety/ 
Depression 

















8 (17.4) 0.472 33 
(20.1) 
0.219 
Level 3 3 (1.3) 2 (2.7) 1 (0.8) 0 (0) 0.472 
 
1 (0.6) 0.219 





































3.18.2 Rockwood Frailty and EQ5D-3L 
In responding to problems with mobility 29.2% of frail patients had no problems in 
walking about, compared to 73.7% in non-frail patients (p<0.001) but 30.8% frail 
patients reported some problems with mobility compared to 26.3% non-frail patients. 
In responding to self-care question, 58.3% frail patients reported no problems with self-
care, compared to 95.8% non-frail patients (p<0.001). Some problems with self-care 
was reported by 41.7% and 4.2% respectively. 
Usual activities were done without any problems by 16.7% of frail patients compared 
to 77% of non-frail patients (p<0.001). Usual activities were performed with some 
problems in 75.0% and 23.0% respectively, while 8.3% of frail patients reported unable 
to perform usual activities. 
No pain or discomfort was reported by 29.2% frail and 65.7% non-frail patients 
(p<0.001). Moderate pain or discomfort was reported by 54.2% and 31.9% 
respectively. Extreme pain or discomfort was reported by 16.7% and 2.3% 
respectively. 
There was no anxiety or depression in 62.5% frail and 78.4% non-frail patients 
(p=0.131). Moderate anxiety or depression was reported by 33.3% and 20.7% 
respectively. Extreme anxiety or depression was reported by 4.2% frail and 0.9% non-
frail patients. 
The mean VAS score was 60.6% in frail and 68.3% non-frail patients (p=0.037). The 
EQ5D index by TTO was 0.56 in frail and 0.85 in non-frail patients (p<0.001). The 
EQ5D index by VAS was 0.57 in frail and 0.83 in non-frail patients. . All the findings of 
EQ%D-3L in relation to Rockwood frailty status are displayed in Table 3.43. 
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Table 3.43: Rockwood Frailty and EQ5D-3L 











F v NF 
Mobility Level 1 164 
(69.2) 













8 (11.3) <0.001* 56 
(26.3) 
<0.001* 
Level 3 0 (0) 0 (0) 0 (0) 0 (0) - 0 (0) - 
 











Level 2 19 (8.0) 10 
(41.7) 
9 (6.3) 0 (0) <0.001* 9 (4.2) <0.001* 
Level 3 0 (0) 0 (0) 0 (0) 0 (0) - 0 (0) - 
 
Usual activities Level 1 168 
(70.9) 













6 (8.5) <0.001* 49 
(23.0) 
<0.001* 




Level 1 147 
(62.0) 

































Level 2 52 
(21.9) 







Level 3 3 (1.3) 1 (4.2) 2 (1.4) 0 (0) 0.157 2 (0.9) 0.131 
 





































3.19 Short Form -36 Health Survey 
Short from 36 health survey questionnaire was completed by all 237 patients at the 
time of recruitment during the hospital stay. The responses when entered in the 
calculator provides with scale score and norm based score for each of the following 
eight domains: Physical functioning (PF), Role-Physical (RP), Bodily Pain (BP), 
General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE) and 






3.19.1 Fried Frailty and SF-36 
These findings as detailed below are displayed in Table 3.44. 
3.19.2 Scale Score 
The median scale score for PF was 30 in frail, 55 in pre-frail and 80 in robust patients 
(p<0.001). This score was 70 in non-frail patients. The median SS RP was 0 in frail, 25 
in pre-frail and 62.5 in robust patients (p<0.001). The median SS BP was 41, 62 and 
73 respectively (p=0.001). The median GH was 45, 62 and 73 respectively (p<0.001). 
The median SS VT was 45, 62 and 72 respectively (p<0.001). The median SS SF was 
50, 62.5 and 81.2 respectively (p<0.001). The median SS RE was 100, 100 and 100 
respectively (p=0.191). The median SS MH was 76, 84 and 86 respectively (p=0.022). 
 
3.19.3 Norm Based Score 
The calculated median NB PF score was 27.8 in frail, 38.3 in pre-frail and 48.8 in robust 
patients (p<0.001). The NB RP scores were 28, 35 and 45.6 respectively (p<0.001). 
The NB BP scores were 37.5, 46.5 and 51.2 respectively (p=0.001). The NB GH scores 
were 38.2, 46.2 and 50.9 respectively (p<0.001). The NB VT scores were 44.3, 49.1 
and 51.4 respectively (p<0.001). The NB SF scores were 35.4, 40.9 and 49 
respectively (p<0.001). The NB RE scores were 55.3, 55.3 and 55.3 respectively 
(p=0.191). The NB MH scores were 50.4, 55 and 56.1 respectively (p=0.022).  
 
3.19.4 Summary Score 
The median PCS was 27.7 in frail patients, 37.1 in pre-frail patients and 46.5 in robust 
patients (p<0.001). The median MCS score was 52.4 in frail, 54.4 in pre-frail and 54.4 





Table 3.44: Fried Frailty and SF36 





F v PF v 
R 
Non-Frail p value 
F v NF 
SS PF 50.0 30.0 55.0 80.0 <0.001* 70.0 <0.001* 
SS RP 0.0 0.0 25.0 62.5 <0.001* 37.5 <0.001* 
SS BP 62.0 41.0 62.0 73.0 0.001 62.0 0.001* 
SS GH 57.0 45.0 62.0 72.0 <0.001* 62.0 <0.001* 
SS VT 50.0 45.0 62.0 72.0 <0.001* 55.0 <0.001* 
SS SF 62.5 50.0 62.5 81.2 <0.001* 75.0 <0.001* 
SS RE 100.0 100.0 100.0 100.0 0.191 100.0 0.081 
SS MH 84.0 76.0 84.0 86.0 0.022* 84.0 0.011* 
NB PF 36.2 27.8 38.3 48.8 <0.001* 44.6 <0.001* 
NB RP 28.0 28.0 35.0 45.6 <0.001* 38.5 <0.001* 
NB BP 46.5 37.5 46.5 51.2 0.001* 46.5 0.001* 
NB GH 43.9 38.2 46.2 50.9 <0.001* 46.2 <0.001* 
NB VT 46.7 44.3 49.1 51.4 <0.001* 49.1 <0.001* 
NB SF 40.9 35.4 40.9 49.0 <0.001* 46.3 <0.001* 
NB RE 55.3 55.3 55.3 55.3 0.191 55.3 0.081 
NB MH 55.0 50.4 55.0 56.1 0.022* 55.0 0.011* 
PCS 34.7 27.7 37.1 46.5 <0.001* 39.5 <0.001* 
MCS 54.0 52.4 54.4 54.4 0.580 54.4 0.301 
SS Scale Score, NB Norm Based, PF Physical Functioning, RP Role-Physical, BP Bodily Pain , GH 
General Health VT Vitality , SF Social Functioning, RE Role-Emotional, MH Mental Health, PCS Physical 




3.20 Rockwood Frailty and SF-36 
These findings as detailed below are displayed in Table 3.45. 
3.20.1 Scale Score 
The median scale score for PF was 22.5 in frail and 55 in non-frail patients (p<0.001). 
The median SS RP was 0 in frail and 0 in non-frail patients (p=0.004). The median SS 
BP was 41 and 62 respectively (p=0.001). The median GH was 32.5 and 62 
respectively (p<0.001). The median SS VT was 32.5 and 55 respectively (p<0.001). 
The median SS SF was 31.2 and 62.5 respectively (p<0.001). The median SS RE was 
66.7 and 100 respectively (p=0.501). The median SS MH was 74 and 84 respectively 
(p=<0.001). 
 
3.20.2 Norm Based Score 
The calculated median NB PF score was 24.6 in frail and 38.3 in non-frail patients 
(p<0.001). The NB RP scores were 28 and 28 respectively (p=0.004). The NB BP 
scores were 37.5 and 46.5 respectively (p=0.001). The NB GH scores were 30.0 and 
46.2 (p<0.001). The NB VT scores were 38.4 and 49.1 respectively (p<0.001). The NB 
SF scores were 27.3 and 40.9 respectively (p<0.001). The NB RE scores were 44.8 
and 55.3 respectively (p<0.001). The NB MH scores were 49.3 and 55 respectively 
(p=0.016).  
 
3.20.3 Summary Score 
The median PCS was 23.5 in frail patients and 36.6 in non-frail-patients (p<0.001). The 




Table 3.45: Rockwood Frailty and SF36 





F v PF v 
R 
Non-Frail p value 
F v NF 
SS PF 50.0 22.5 40.0 85.0 <0.001* 55.0 <0.001* 
SS RP 0.0 0.0 0.0 100.0 <0.001* 0.0 0.004* 
SS BP 62.0 41.0 61.0 74.0 <0.001* 62.0 0.001* 
SS GH 57.0 32.5 55.0 72.0 <0.001* 62.0 <0.001* 
SS VT 50.0 32.5 50.0 87.5 <0.001* 55.0 <0.001* 
SS SF 62.5 31.2 50.0 87.5 <0.001* 62.5 <0.001* 
SS RE 100.0 66.7 100.0 100.0 0.146 100.0 0.501 
SS MH 84.0 74.0 82.0 88.0 <0.001* 84.0 <0.001* 
NB PF 36.2 24.6 32.0 50.9 <0.001* 38.3 <0.001* 
NB RP 28.0 28.0 28.0 56.2 <0.001* 28.0 0.004* 
NB BP 46.5 37.5 46.0 51.6 <0.001* 46.5 0.001* 
NB GH 43.9 30.0 42.9 50.9 <0.001* 46.2 <0.001* 
NB VT 46.7 38.4 46.7 53.8 <0.001* 49.1 <0.001* 
NB SF 40.9 27.3 35.4 51.7 <0.001* 40.9 <0.001* 
NB RE 55.3 44.8 55.3 55.3 0.146 55.3 0.503 
NB MH 55.0 49.3 53.8 57.3 <0.001* 55.0 <0.001* 
PCS 34.7 23.5 32.6 48.6 <0.001* 36.6 <0.001* 
MCS 54.0 46.0 54.0 55.6 0.033* 54.6 0.016* 
SS Scale Score, NB Norm Based, PF Physical Functioning, RP Role-Physical, BP Bodily Pain , GH 
General Health VT Vitality , SF Social Functioning, RE Role-Emotional, MH Mental Health, PCS Physical 















In the following section the key findings, which are grouped in the table below are 
discussed.  
Table 4.1: Table of Key Findings 
Measures Key Findings 
Frailty Status Frailty was very common among older patients 
managed by invasive strategy 
 
A third of patients were frail by Fried criteria and only 
a tenth of patients were frail by Rockwood criteria 
 
Revascularisation There was lesser rate of radial access in frail patients 
 
Very high proportion of patients (85%) were 
revascularised by coronary intervention 
 
There was no difference between frailty groups in the 
revascularisation  strategy 
Cardiovascular 
Outcomes 
There was no significant difference in the rate of 
procedural complications and, in hospital and one 
month MACE by Fried and Rockwood criteria 
Arterial Stiffness Increasing age was associated with increased PWV 
 
Arterial stiffness measures by Vicorder did not vary 




Normal endothelial function was noted more in non-
frail patients by Fried frailty criteria 
 
Augmentation index by EndoPAT was lower in frail 
patients by both frailty status tools 
Carotid Intima 
Media Thickness 
     No difference in carotid intima media thickness 
LV function LV systolic function did not vary according to frailty 
status 
 
E/e’, a measure of diastolic dysfunction was higher in 
frail patients by both frailty status 
 
Diastolic dysfunction was more prevalent in frail 
patients by Rockwood criteria only 
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Comorbidity Increased comorbidity burden as per CCI score was 
present in almost a third of patients 
 
Increased comorbidity burden was significantly 
associated with frailty 
 
Similar to frailty, there was no significant difference in 
in-hospital or one moth MACE based on increased 
comorbidity  
Quality of life More frail patients reported some problems with 
mobility, self-care and daily activities by EQ5D-3L 
 
EQ5D index was lower in frail patients 
 
Physical component summary score was lower in frail 
patients by SF-36 
Cognitive status Sub clinical  cognitive impairment was more prevalent 




4.1 Frailty Status Variation  
4.1.1 Prevalence of Frailty and Frailty Status Variation 
Frailty status varied significantly between the two assessment tools used. Patients 
were three times more likely to be frail by Fried criteria compared to Rockwood criteria. 
30.8% were frail by Fried Frailty criteria and 10.1% patients were frail by Rockwood 
criteria. 
Fried criteria uses objective assessment with grip strength and walking speed in 
addition to three responses from patient - weight loss in the last year, poor physical 
endurance and low physical activity. The most common variable in the frail patients 
was weakness by handgrip strength which was measured in 91.8%. As the invasive 
treatment strategy involved coronary angiogram, and the default access was right 
radial approach (86.9% radial procedures) I assessed the frailty status before patient 
had been to the catheterisation laboratory so that grip strength measure was not 
affected by the procedure. Only 26% of patients classified as frail were similarly 
classified as frail by the Rockwood criteria, whereas 73.9% of patients classified as 
robust by fried criteria were categorised as robust by Rockwood criteria. When 
classified as frail and non-frail groups 97% of non-frail patients by Fried criteria were 
classified non-frail by Rockwood criteria. (p<0.0001). There was a high degree of 
correlation between the Fried frailty score and Rockwood frailty scale (Kendall’s tau-b 
R =0.591, p<0.0001), but this does not translate into categorising patients into different 
frailty groups.  
Though there are different frailty assessment tools used and validated in community 
population, Fried and Rockwood assessment tools are the ones that had been used in 
patients with coronary artery disease. There is no consensus on the use of a 
standardised frailty assessment tool. Hence two commonly used tools were used in 
the same group of patients to understand more about the frailty status variation. As 
frailty status is a syndrome encompassing physical, functional and cognitive 
components it can vary depending on the assessment tools used. It also depends on 
the subjective or objective nature of the assessment tool. Several frailty assessment 
tools have been tested and validated in community population but the prevalence of 
frailty was different by different criteria in hospitalised older patients.(van Iersel and 
Rikkert, 2006) Only 7 out of 27 frailty instruments (26%) have been tested for reliability 
and validity.(Bouillon et al., 2013) The Fried frailty assessment tool has been the most 
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extensively tested for validity and the most commonly used tool in frailty 
research.(Bouillon et al., 2013) Having been used commonly in studies allows for 
easier comparisons of outcomes from different studies. It has to be acknowledged that 
there is no gold standard frailty assessment tool yet available. A consensus need to 
be reached on the various criteria and components to be included in a frailty 
assessment tool.  
More patients were classified frail by Fried criteria and this is possibly related to 
responses from hospitalised patients being affected by their hospital stay in relation to 
energy levels and physical activity. Also it might have taken longer for patients to do 
the timed up to go test as they were hospitalised with restricted mobility  compared to 
being at home and also possible effects of initiation of multiple cardiac medications.  
Only a tenth of patients were classified as frail by Rockwood criteria and this is possibly 
due to the referral bias from local hospitals, that invasive treatment strategy is harmful 
to frail patients. Another factor to be considered in the variation is both frailty 
assessment tools were implemented by me, the primary researcher. I had assessed 
the frailty status by Rockwood criteria before using the Fried criteria. Both patient and 
the PCI operator in the catheterisation laboratory were blinded to the frailty status. This 
was to ensure that the routine treatment was not influenced by the frailty status. 
Different frailty scores classify different subsets of population as frail with agreement 
highest for accumulation of deficits model, but more accurate classification with 
multidimensional model.(Aguayo et al., 2017) 
In view of the variation in frailty status by different tools, a consensus on the frailty 
assessment tool to be used in hospitalised patients with ischemic heart disease need 
to be agreed upon. This will help in standardised frailty classification which can be 
compared between studies for outcomes. 
 
4.1.2  Frailty in relation to age and gender  
In this study, increased age and female gender were independently associated with 
frailty. The mean age of patients was 80.3 (SD 4.9) years and 62.4% were males. In 
the study by Ekerstad et al, 48.5% of 307 hospitalised NSTEMI patients were classified 
frail by Rockwood criteria.(Ekerstad et al., 2011) The patients in this study were ≥ 75 
years old and the mean age of the study population was 84 years and 49% of patients 
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were females. In the study by Singh et al, (Singh et al., 2011) 629 patients ≥ 65 years 
old were recruited and frailty status was assessed by Fried frailty criteria. Frailty status 
was not available in 13.3% of patients. Mean age of patients was 74.3 (6.4) years and 
31% were females. Of the 545 patients with frailty status available 18.6% were frail, 
47.4% were pre-frail and 20.6% were not frail. In the study by Murali-Krishnan et 
al,(Murali-Krishnan et al., 2015) 745 patients were recruited and frailty was assessed 
by Rockwood frailty criteria. The mean age of patients were 62.2 (SD 12.0) years. In 
this study 11% of patients were frail and 30% of patients were female.  In the study by 
Graham et al, of the 183 patients ≥ 65 years old, 30% of patients had high Edmonton 
Frailty Score (≥7). The mean age was 75.4 years and 33% were females.  
Frailty was common among patients with NSTEMI who were managed by invasive 
strategy. The mean age was 80 years and more than half of the patients (54.4%) were 
≥ 80 years old and only 7.5% patients were 65-74 years old. Increased age was 
associated with frailty by both Fried (80.8 vs. 80.8 vs. 78.3 years of F vs. PF vs. R, 
p=0.007) and Rockwood criteria (83.1 vs. 80.0 years for F vs. NF, p =0.004). Only the 
study by Ekerstad et al had such a high proportion of octogenarians. In my study 37.6% 
were females. Though the proportion of female patients were higher in the frail group 
this was not statistically significant by Fried criteria (F vs. PF vs. R of 47.9% vs. 34.7% 
vs. 28.35, p=0.065). But there was strong association between female gender and 
frailty by Rockwood criteria (F vs. NF of 62.5% vs. 34.7%, p=0.013). In the study by 
Ekerstad et al, frailty was associated with increased mean age (F vs. NF of 85 years 
and 83 years, p=0.0003) and female gender was not significantly associated with frailty 
(54.4% vs. 43.7% respectively, p=0.068). Increased age was associated with frailty in 
the study by Singh et al (F vs. PF vs. R of 77.4 vs. 74.6 vs. 72.6 years, p<0.001) and 
females were more likely to be frail (54% vs. 31% vs. 18% respectively, p<0.001). In 
the study by Murali-Krishnan et al, increased age (71.2 vs. 61.1 years for F vs. NF, 
p<0.001) and female gender (51.9% vs. 71.2% respectively, p<0.001) was associated 
with frailty. In the study by Graham et al, increased age was associated with frailty 
(77.2 vs. 73.9 years (p=0.031) but not female gender (38.2 vs. 22.2, p=0.088). 
Similar to the other studies of frailty in coronary artery disease, older age is associated 
with frailty syndrome. As frailty is a result of declining physiological reserve and 
impaired resistance to stressors, older age predisposes to the development of frailty. 
Also older age is associated with increased comorbidity burden which plays a key role 
198 
 
in the development of frailty. In my study frailty assessment was done in patients with 
NSTEACS admitted to hospital, with NSTEACS being the recent significant stressor 
event  To reduce the impact of invasive procedure on the frailty status, frailty 
assessment was done prior to invasive procedure. Compared to other studies my study 
had an increasing proportion of octogenarians and female patients, reflecting the 





4.1.3  Baseline characteristics of patients 
CV risk factors profile like hypertension, diabetes, smoking history and hyperlipidaemia  
were not different between the frailty groups by Fried criteria. Similarly there was no 
significant difference for the above variables between frail and non-frail groups by 
Rockwood criteria. 
Known cardiovascular disease like previous MI, known angina, previous PCI, and 
previous cerebrovascular disease was more prevalent in frail patients both by Fried 
and Rockwood frailty criteria. Known renal impairment and PVD was not significantly 
different between the frailty groups both by Fried and Rockwood assessment tools. 
Prevalence of osteoarthritis was more common in frail patients by both frailty criteria. 
In the study by Singh et al, the prevalence of hypertension, diabetes, PVD, renal 
impairment, CCF, COPD and arthritis was significantly higher in frail patients compared 
to pre-frail and robust groups respectively.(Singh et al., 2011) In the study by Ekerstad 
et al, there was significantly higher proportion of patients with COPD, severe renal 
impairment, dementia and anaemia in the frail group compared to non-frail group. In 
the study by Murali-Krishnan et al, hypertension, diabetes, hyperlipidaemia, PVD, 
cerebrovascular disease, chronic renal impairment and CCF was more common in frail 
than in non-frail patients.(Murali-Krishnan et al., 2015) 
Frailty was not associated with conventional risk factors for IHD like hypertension, 
diabetes, and hyperlipidaemia but were more associated with renal impairment, 
previous IHD, CCF, cerebrovascular disease, arthritis and COPD. Rather than the risk 
factors for CVD; established CVD, lung disease and joint disease were associated with 
frailty by contributing to the physical and functional limitations resulting from these 
comorbidities. 
 
4.1.4 Underlying Presentation and Diagnosis 
The initial diagnosis was NSTEMI in majority of patients (83%) and less than a fifth of 
patients had been diagnosed with unstable angina (17%). The inclusion criteria was 
narrowed down to NSTEACS alone, so that emergency presentations with STEMI 
would not be a confounding factor in the analysis of clinical outcomes.  There was no 
significant difference in the underlying diagnosis of either NSTEMI or UA, both by Fried 
and Rockwood frailty groups. In the study by Ekerstad et al, though all the patients in 
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the study had NSTEMI, more than a third (34.6%) of the patients had Type 2 MI. 
According to the third universal definition of myocardial infarction, (Thygesen et al., 
2012) type 2 MI is defined as myocardial injury with necrosis due to imbalance between 
myocardial oxygen supply and/or demand other than that caused by CAD (like 
anaemia, arrhythmia, and coronary vasospasm). In the study by Singh et al, though all 
the patients were ≥ 65 years old and underwent PCI. There was no significant 
difference in the diagnosis of NSTEMI (17%), STEMI (14%) and no MI within 24 hours 
(69%) between the frailty groups. In the study by Murali-Krishnan et al, about 40% of 
patients had presented with STEMI and no difference between frail and non-frail 
patients. Haemodynamic instability was noted in 11% of patients with significant 
difference between the two groups (21% vs. 9.8%, p=0.002).  
Frailty assessment tools were developed and validated in community populations. The 
same tools were being applied in hospitalised patients with coronary artery disease. 
As per the patient cohort in the studies above, even with acute coronary syndrome, the 
clinical state can vary from type 2 MI secondary to underlying cause like pneumonia or 
anaemia secondary to gastro intestinal bleeding or emergency STEMI presentation 
with cardiogenic shock. The nature of clinical presentation would have impacted the 
frailty assessment irrespective of the tool used. Also the initial presentation would have 
resulted in more adverse clinical outcomes. Hence to get a clearer picture, in my study 




4.1.5 Invasive Management of NSTEACS 
All patients were managed by invasive strategy. Majority of patients were 
revascularised by PCI (85%) and there was no difference in either SVPCI or MVPCI. 
Similarly there was no difference in the vessel intervened between the groups of 
patients either by Fried or Rockwood frailty assessments. There was no significant 
difference in my study between the groups of patients managed by CABG (4%) or 
medical management (11%) by either Fried or Rockwood frailty assessments. The 
lesser proportion of patients referred for CABG reflects the older age group in whom 
CABG has more adverse outcomes peri-operatively. This also explains more 
revascularisation by PCI in which the risks are lesser compared to CABG. Medical 
management was decided in small proportion of the patients in whom even PCI was 
considered to be higher risk.  
Patients were referred from secondary care hospitals to the tertiary care hospital for 
invasive management. There was no difference in length of time from local hospital 
admission to invasive management (mean days) by coronary angiogram at the tertiary 
hospital between the groups by Fried criteria (5.7 vs. 5.4 vs. 5.6 days, p=0.895). 
Similarly there was no difference when compared as frail and non-frail by Rockwood 
criteria (6.2 vs. 5.5 days, p=0.244). All the patients in my study had invasive coronary 
angiogram as part of the management plan. The frailty status assessment was done 
on the day prior to the invasive procedure, so hospital stay for five days could have 
had an impact on the frailty assessments. Further management including 
revascularisation by PCI or CABG and medications only was at the discretion of the 
interventional cardiologist and or the heart team.  
In the study by Ekerstad et al, less than a third (31.2%) of the patients underwent 
coronary angiography. Frail patients were less likely to have coronary angiography 
(15.4% vs. 46.2%, p<0.0001) compared to non-frail patients. This difference was 
significant for revascularisation too (6.7% vs. 30.4%, P<0.0001). In this study more 
than third of patients had type 2 MI. So both the initial presentation and subsequent 
management was not comparable to contemporary clinical practice. In the study by 
Singh et al, 545 patients had percutaneous coronary intervention for either stable 
angina or ACS. Of these 35% were elective, 47% were urgent and 18% were 
emergency PCI procedures. There was no significant difference between frail, pre-frail 
and non-frail patients for elective urgent and emergency PCI procedures. In the study 
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by Murali-Krishnan et al, all the patients had PCI for stable angina or ACS without any 
difference in emergency PCI between frail and non-frail patients. But in both these 
studies, the nature of underlying presentations could have had an impact on clinical 
outcomes.  
Coronary angiography and or PCI was done by radial access in 87% of patients and 
by femoral access in 13% of patients in the study presented in this thesis. As per Fried 
frailty status, frail patients were less likely to have the procedure by radial access and 
hence more likely to have procedure done by femoral access. But when compared by 
Rockwood frailty status there was no significant difference in the use of either radial or 
femoral access. The reason for lesser use of radial access could be due to increased 
proportion of frail patients having had previous PCI (28% vs 15%) resulting in radial 
artery occlusion leading onto femoral access. Previous CABG was the major predictor 
of femoral access followed by previous PCI and PVD by regression analysis. In 
patients with previous CABG femoral access makes it easier to engage and view the 
grafts better. The data on which access route was used for previous PCI was not 
available. Frailty assessment was done prior to the invasive procedure so arterial 
access did not have an impact on the frailty status. 
There was a high proportion (86.0%) of patients revascularised by PCI. There was no 
significant difference in either SVPCI (73%) or MVPCI (27%) between the frailty groups 
of both Fried and Rockwood criteria. This compares to the intervention strategy in the 
study by Singh et al., there was no significant difference in SVPCI (83%) and MVPCI 
(17%).  
Compared to other studies a very high proportion of patients underwent PCI and all 
patients had coronary angiogram. Contemporary invasive treatment strategy was used 
in all patients which helped to assess the impact of invasive strategy on adverse CV 
outcomes in a single cohort of patients with NSTEACS, unlike other studies which had 





4.2 Frailty Status and Major Adverse Cardiovascular Outcomes 
There was no significant difference in the rate of procedural complications, in-hospital 
and 30-day major adverse cardiovascular outcomes based on Fried and Rockwood 
frailty statuses in my study.  
Overall the rate of procedural complications was low at 1.7%, and more importantly 
there was no difference either by Fried frailty status (1.4% vs. 1.7% vs. 2.2%, p=0.946) 
or by Rockwood status (0% vs. 1.9%, p=1.000). This is similar to the findings in the 
study by Singh et al. This is the only comparable study in which data for procedural 
complications was available. There was no difference in procedural complications 
between F vs. PF vs. R groups for the incidence of pseudo-aneurysm, femoral 
bleeding, blood loss requiring transfusion and retroperitoneal bleed.  
Of the 237 patients recruited only single patient died to peri-procedural stroke. This 
compares with outcomes in younger patients for procedure related mortality. Even the 
death of one patient was not significantly different based on frailty status. But it is 
important to note that this patient was classified as frail by Fried criteria and non-frail 
by Rockwood criteria, emphasising the importance of frailty status variation noted and 
discussed earlier.  
Composite major adverse- CV outcomes (including death, acute coronary syndrome, 
unplanned revascularisation, major bleeding, stroke and contrast nephropathy or renal 
replacement therapy) was no different either by Fried groups (11.0% vs. 5.9% vs. 
4.3%, p=0.30) and Rockwood groups (8.3% vs. 7.0%, p=0.685). But in the study by 
Ekerstad et al, in-hospital mortality was significantly higher in the frail patients 
compared to non-frail patients (10.1% vs. 1.9%, p=0.003). The rate of in-hospital major 
bleeding, stroke or need for dialysis was not significantly different between the groups 
(9.4% vs. 3.8%, p=0.06). The increased rate of mortality with no significant difference 
in other major adverse outcomes could be explained by the patient cohort included in 
the study. The inclusion of type 2 MI secondary to conditions like pneumonia, major GI 
bleeding potentially contributed to increased death. 
In my study, at 30 days, there was no additional death of patients other than the one 
discussed above. Composite MACE outcomes at 30 days were not different either by 
Fried (11.0% vs. 5.9% vs. 4.3%, p=0.30) or Rockwood classification (8.3% vs. 7.7% 
vs. 5.6%, p=0.831). In the study by Ekerstad et al, frailty was associated with increased 
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30-day mortality (15.4% vs. 3.2%, p<0.0001). Re-infarction at 30 days (7.5% vs. 5.2%, 
p=0.470) and composite of major bleeding, stroke/TIA or need for dialysis (3.2% vs. 
1.5%, p=0.456) were not significantly different F vs. NF groups. In the study by Singh 
et al, the composite of death, MI, PCI or CABG was 9% vs. 10% vs. 8% (p=0.83) 
between F vs. PF vs. R groups of patients. In the study by Murali-Krishnan et al, the 
30-day mortality rate was 4.9% vs. 1.1% with frail patients five times more likely to die 
compared to non-frail patients (HR 4.8, 95% CI 1.4 to 16.3, p=0.013). 
In my study there was no difference in procedural complications, in-hospital and 30 
day MACE rate. This possibly is explained by the contemporary management strategy 
adopted in all the patients in my study. Also it has to be noted that patients in my study 
are a highly selected cohort of patients due to possible referral bias from the district 
hospitals. I do not have the data of all patients who were admitted with NSTEACS and 
proportion of patients referred for invasive management. The results in my study are 
similar to the study by Singh et al, in which there was no difference in the composite 
outcomes of death, MI, PCI or CABG. In the study by Ekerstad et al, mortality was 
higher in frail patients at 30 days. The patient groups comprised almost a third of 
patients with type 2 MI due to other acute medical presentations and known patients 
with dementia, which are likely to contribute to adverse CV outcomes. Contemporary 
management strategy was not employed as less than a third of patients underwent 
invasive treatment and frail patients were less likely to undergo coronary angiography 
or revascularisation. In the study by Murali-Krishnan et al, mortality was increased in 
frail patients at 30 days and the patient group consisted of nearly 40% with STEMI 
presentation and haemodynamic instability was more common in frail patients. This is 
the likely explanation for the increased mortality in that study. Overall the increased 
incidence of adverse outcomes noted in other comparable studies were likely related 
to the inclusion of different patient cohorts like type 2 MI, STEMI and cardiogenic 
shock. In my study the narrowed inclusion criteria for diagnosis with NSTEACS did not 
show any major differences in adverse outcomes amongst the frailty groups by both 
assessment tools. On the basis that patients at increased risk stand to benefit more 
from contemporary treatment possibly frail patients would benefit from invasive 





4.2.1 Time from Presentation to invasive treatment and total Length of Stay 
There was no significant difference in the time from initial presentation to the local 
hospital to invasive treatment at the tertiary hospital either by Fried (5.7 vs. 5.4 vs. 5.6 
days, p=0.895 for F vs. PF vs. R groups) or Rockwood criteria (6.2 vs. 5.5 days, 
p=0.244 for F vs. NF groups). These times are influenced by the decision by the local 
team to refer the patient for invasive strategy and the availability of beds at the tertiary 
centre. There was no significant difference in the length of stay in hospital between the 
patient groups either by Fried (7 vs. 6 vs. 6 days, p=0.55) or Rockwood frailty (7 vs. 6 
days, p=0.09) classification. In the study by Ekerstad et al, frail patients stayed longer 
in hospital compared to non-frail patients (13.4 vs. 7.5 days, p<0.0001) but it has to be 
noted that large proportion of patients had type 2 MI and patients with dementia were 
included in the study.(Ekerstad et al., 2011) In the study by Murali-Krishnan et al, frail 
patients stayed longer in hospital compared to non-frail patients (14.1 vs. 3.5 days, 
p<0.01). In this study almost 40% of patients had PCI for STEMI.(Murali-Krishnan et 
al., 2015) 
The reason frail patients did not have a delay in invasive treatment and did not stay 
longer in hospital was because of the patient cohort being highly selected for 
NSTEACS diagnosis. These patients were haemodynamically stable at the time of 
recruitment. Patients with Type 2 MI and established cognitive impairment were 
excluded from the study, conditions which could have led to prolonged stay. The 





4.3 Frailty and Cardiovascular Status 
4.3.1 Arterial stiffness 
Arterial stiffness measures were not significantly different between the groups of 
patients classified by either Fried or Rockwood classification. In my study frailty was 
not associated with arterial stiffness measures of carotid femoral PWV, aortic pulse 
pressure and augmentation index assessed non-invasively by Vicorder. These findings 
are similar in that conventional risk factors for CVD like hypertension, diabetes and 
hyperlipidaemia were not associated with frailty. Not many studies have explored the 
relation between frailty and arterial stiffness. Sarcopenia, a risk factor for frailty was 
associated with increased brachial ankle PWV in elderly men but not in women in the 
community.(Ochi et al., 2010) In another study of older patients, frailty by Fried 
classification was not associated with increased aortic stiffness measured by non-
invasive assessment of aortic PWV.(L.M. Kannegieter, 2016) Frailty and arterial 
stiffness measures in the community population can be independent predictors of 
cardiovascular outcomes. So I sought to explore any possible relation between frailty 
and arterial stiffness in patients with established coronary artery disease. 
In my study there was a significant positive correlation between age and pulse wave 
velocity and pulse pressure. Aging is an independent risk factor for atherosclerosis and 
aging arteries are predisposed to vascular smooth muscle hypertrophy leading to 
increased arterial stiffness. Increased stiffness results in pressure waveform reaching 
the ascending aorta in systole rather than diastole as happens in elastic arteries, 
augmenting systolic pressure and decreasing diastolic pressure. These 
pathophysiological mechanisms explains the correlation noted between age and 
arterial stiffness markers of PWV and pulse pressure. Though increased age was 
associated with frailty and increased PWV, arterial stiffness was not associated with 
frailty. This suggests possibly increased age with resultant comorbidities rather than 
the risk factor for the comorbidities like arterial stiffness leads to frailty. In older age 
due to increased pulse pressure and PWV, angina may be precipitated even in the 






4.3.2 Endothelial Dysfunction 
There was no significant association between frailty and endothelial dysfunction by 
both Fried and Rockwood classification. A third of the patients had endothelial 
dysfunction as per the mean LnRHI but this was similar between the three groups (F 
vs. PF vs. R) by Fried classification and between the two groups by Rockwood 
classification (F vs. NF). Endothelial dysfunction is a precursor for coronary artery 
disease but my study patients had established coronary artery disease presenting with 
NSTEACS. As patients had presented with NSTEMI most of my patients were on ACE 
inhibitor and atorvastatin, which possibly could have an effect on endothelial function 
measures. In the Toledo Study for Healthy Aging, endothelial dysfunction assessed by 
measurement of biomarker, asymmetric dimethyl arginine (ADMA) levels was 
associated with frailty assessed by Fried frailty assessment tool.(Alonso-Bouzon et al., 
2014)   
Augmentation index, a measure of arterial stiffness measured by EndoPAT was 
significantly different between the groups of patients classified by both Fried and 
Rockwood classification. AI by EndoPAT has not been validated as a marker of arterial 
stiffness unlike AI by Vicorder. Also AI can vary according to the central or peripheral 
artery used for its measurement. AI by Vicorder utilises a major peripheral artery which 
has been correlated with central aortic AI. AI by EndoPAT utilises the microvasculature 
in the in the pulp of the finger, which may not be reliable for measuring AI but very 
helpful in assessing endothelial dysfunction.  There was significant positive correlation 
between AI measured by EndoPAT and Vicorder (r=0.262, p<0.0001). But it has to be 
noted AI measured by Vicorder was similar between the groups of patients. The 
correlation between EndoPAT AI and cfPWV was weak and not significant (r=0.111, 
p=0.129). In a small study of hypertensive patients arterial stiffness measured by flow 
mediated dilatation had poor correlation with AI measured by EndoPAT (r=0.18, p=not 




4.3.3 Carotid Intima Media Thickness 
There was no difference in the CIMT measurements on both the sides between all 
groups of patients by Fried and Rockwood classification. In community population 
higher common carotid artery CIMT was associated with slower gait speed which is a 
marker of underlying frailty.(Elbaz et al., 2005) In another study of community 
population increase in CIMT thickness was associated with increased probability of 
being frail.(Avila-Funes et al., 2014) Though CIMT measurement can improve CV risk 
prediction a metanalysis suggested that this improvement is not of much clinical 
importance.(Den Ruijter et al., 2012)  
There was no significant difference according to frailty on measures of arterial stiffness, 
endothelial dysfunction and CIMT. These measures have been shown to be predictors 
of CVD in addition to conventional risk factors like hypertension, diabetes, 
hyperlipidaemia and smoking. Hence it can be postulated that frailty is associated with 
disability and the diseases causing it rather than the risk factors causing these disease 
presentations. 
From my study there was no association between CV disease burden like arterial 
stiffness, endothelial dysfunction and CIMT to frailty status. But these were predictors 
of CV outcomes in the community population. It can be interpreted that the frailty 
models used in my study were based on phenotype and accumulation of deficits. In 
these models functional limitation that is symptoms related to underlying comorbidities 





4.3.4 Left Ventricular Function 
There was no difference in the prevalence of systolic dysfunction assessed by 
transthoracic echocardiogram in relation to frailty by both Fried and Rockwood 
classification. Just more than a third of the patients had normal systolic function and 
one tenth of the patients had severe systolic dysfunction. 40% of the patients had 
diastolic dysfunction. Diastolic dysfunction as assessed by elevated filling pressure 
was significantly more common in frail patients by Rockwood criteria but not by Fried 
criteria. Frailty by Rockwood criteria and female gender were predictors of elevated 
filling pressure by regression analysis. Elevated filling pressure is dependent on the 
measurement E/e’ and LA size. E/e’ is an important predictor of diastolic dysfunction 
and this value was increased in frail patients by both the frailty classifications. Limited 
studies have examined the association of echocardiographic findings and frailty. In a 
study of octogenarians in the community, frailty by Fried frailty assessment was 
associated with impaired LV systolic dysfunction assessed by ejection fraction but not 
with diastolic dysfunction measured by E/E’.(Leibowitz et al., 2016) In another study of 
older patients (>65 years old) frailty was assessed in patients who underwent 
transthoracic echocardiography for clinical reasons. In this study frailty was associated 
with increased left atrial volume, decreased stroke volume and higher pulmonary artery 
pressure.(Gharacholou et al., 2015) My study findings adds to the limited existing data 
on LV function and frailty, but it has to be noted that patients with known severe LVSD 
and presentation with pulmonary edema were excluded. This might be a reason for no 
relation between frailty and systolic dysfunction. Also even the patients with LV systolic 
function are likely to develop symptoms only after hospital discharge. LV dysfunction 
noted is the effect of NSTEACS presentation which would improve with successful 
revascularisation. Increased age is a predictor of diastolic dysfunction which is in turn 
associated with frailty. This explains the relation between frailty and diastolic 
dysfunction. Diastolic dysfunction cause symptoms of dyspnoea which in turn can lead 
to frailty due to functional limitation. Again the effect of LV dysfunction either systolic 
or diastolic resulting in clinical symptoms are likely to be associated with frailty. This 
can be noted in the increased association of previous history of CCF with frailty as 





Higher comorbidity burden as calculated by Charlson Comorbidity Index (CCI) was 
present in almost a third of patients. As expected higher comorbidity burden was 
associated with frailty by both Fried and Rockwood classification. This is because 
increased age and comorbidity leads to decreased response to stressors which results 
in frailty. There was no significant association between higher comorbidity burden and 
major adverse cardiovascular events at 30 days except for the higher incidence of 
contrast nephropathy. Comorbidity has significant overlap with frailty and 
disability.(Fried et al., 2004) It is important to recognise this, as each of these can have 
an impact on the specific disease management. Comorbidity burden can be a predictor 
of prognosis in patients undergoing PCI.(Singh et al., 2011) But it has to be noted that 
benefits of appropriate early revascularisation of patents with higher comorbidity 
burden was significantly higher in NSTEACS patients compared with lower comorbidity 
burden.(Palau et al., 2012) Evidence for management of patients with comorbidity 
burden is lacking due to exclusion of patients from research trials.(Sachdev et al., 
2004) The process by which higher comorbidity burden affects outcomes is complex 
and multifactorial. Patients who are older with multiple comorbidities are least likely to 
be treated by invasive strategy. Not offering invasive strategy when needed could 
result in adverse outcomes. Higher comorbidity burden may result in patients not 
receiving appropriate treatment due to interaction of a disease specific treatment 
having adverse effect on the other comorbid condition. Higher comorbidity burden may 
be deemed to increase the risk of a proposed invasive procedure. But these need to 
be weighed against the potential benefits of contemporary management like 
percutaneous coronary intervention. In my study higher comorbidity burden was not 
associated with increased CV outcomes in the short term, likely due to the 
contemporary invasive treatment utilised on these patients. Though comorbidity and 
frailty are related they are defined by different mechanisms, but did not have any 
impact on major CV outcomes. This is likely due to contemporary management with 
invasive strategy in a high volume tertiary centre and also possibly due to selection 
bias from the referral hospitals. My study has shown that invasive coronary procedures 
can be done safely with good outcomes in the short term. How these translate into long 





4.5 Health Related Quality of Life 
4.5.1 Symptom burden of Dyspnoea and Angina 
Frail patients were more likely to have worsening dyspnoea symptom as per NYHA 
classification. This difference was present in frail patients classified by both Fried and 
Rockwood criteria.  Dyspnoea possibly contributes to the frailty status due to functional 
limitation and disability.  Though only a small proportion of patients (7.6%) had history 
of CCF at the time of recruitment more patients described NYHA class II and III 
dyspnoea (54%).  Higher prevalence of CCF and worsening dyspnoea were noted in 
frail patients by both frailty criteria. LV systolic dysfunction is not significantly different 
between the patient groups but E/E’ which is a marker of diastolic dysfunction was 
higher in frail patients. Diastolic dysfunction possibly contributes to the worsening 
severity of dyspnoea noted in frail patients in my study. Increasing severity of dyspnoea 
is significantly associated with self-reported low physical activity, lesser physical 
endurance, slow walking speed but not with history of weight loss and grip strength 
which are measures of the Fried frailty classification. No association of frailty with 
NYHA dyspnoea has been reported. But a systematic review of heart failure in older 
patients assessed for frailty by various tools concluded an association between frailty 
and mortality and morbidity.(Jha et al., 2015) The findings from my study sheds light 
on the association between severity of dyspnoea with frailty by Fried and Rockwood 
classification and three of the five criteria of Fried frailty assessment. Symptom burden 
of dyspnoea possibly contributes to the Frailty syndrome which can have many 
pathophysiological etiology.  The association of dyspnoea to frailty in my study renders 
to the accumulation of deficits theory of frailty syndrome due to physical and functional 
limitation. Severity of angina classified by CCS classification was not associated with 
frailty by Fried criteria but was slightly more prevalent in frail patients classified by 
Rockwood criteria. In older patients symptoms of angina are not typical with chest pain 
but could present with angina equivalent like dyspnoea which possibly explains more 
prevalent symptom of dyspnoea. Association between severity of angina and frailty 




In my study more frail patients reported some problems with mobility, self-care and 
usual daily activities by both Fried and Rockwood frailty classification. In addition to 
the above three dimensions, more patients in the frail group reported some pain and 
discomfort by Rockwood criteria but not by Fried criteria. Anxiety and depression was 
not significantly different between the groups by both criteria. It has to be noted that no 
patients reported they were confined to bed or unable to self-care. Only a very small 
proportion of patients reported unable to perform usual activities (0.8%), in extreme 
pain or discomfort (3.8%) and extreme anxiety or depression (1.3%). These findings 
possibly explains the difference in frailty status by the two frailty criteria in my study. 
Majority of the patient cohort did not have any difficulty with activities in daily living and 
thus Rockwood criteria classified only a tenth of patients as frail Rockwood criteria 
classified patients based on activities of daily living and need for help with self-care, 
whereas Fried criteria classified patients on subjective and objective criteria which 
does not reflect on their daily activities and managing self-care. It is very interesting to 
note that anxiety and depression were not significantly related to frailty status. It can 
be inferred that frailty is associated with effects on physical limitation rather than any 
psychological effects. 
As per the visual analogue score marked by patients from worst imaginable health 
state (scale 0) to best imaginable health state (scale 100), frail patients had scored 
lesser both by Fried and Rockwood criteria. Even frail patients felt that their health 
state was moderate and not worse. So frailty not necessarily means worse health state 
from the patient’s perspective.  
EQ5D index by visual analogue scale technique and by time trade off (TTO) technique 
were low in frail patients by both Fried and Rockwood Frailty groups. EQ5D index by 
TTO and VAS were lower respectively by Rockwood frailty group (0.56 and 0.57) 
compared to fried frailty status (0.74 and 0.73). EQ5D indices are lower in Rockwood 




Based on responses to the SF-36 questionnaire, frail patients scored significantly lower 
scale and norm based scores for Physical functioning (PF), Role-Physical (RP), Bodily 
Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF) and Mental 
Health (MH) by both Fried and Rockwood frailty classification. The scores for Role-
Emotional (RE) were not significantly different by both frailty classification.  
For the summary score, physical component was significantly lower in frail patients by 
Fried classification but not the mental component score. But by Rockwood 
classification both physical and mental components were significantly lower in frail 
patients. This is possibly because rock wood classification of frailty with more physical 
limitation had an impact on the mental health. 
In a metanalysis, frailty assessed by Fried criteria was associated with poorer physical 
and mental components of quality of life assessed by SF-36 in community dwelling 
older population.(Kojima et al., 2016) HRQoL measured by EQ5D and SF 36 showed 
improvement at 4 months and one year in NSTAECS patients managed by invasive 
strategy.(Kim et al., 2005) The biggest gain was noted in the physical component. In 
another study, irrespective of management strategy all aspects of health status 
measured by SF-36 improved in ACS patients treated with clopidogrel.(Chudek et al., 
2014) Poor QoL was independent predictor of long term mortality in patients 
undergoing PCI and addition of frailty, comorbidity and QoL by SF-36 increased the 
discriminatory ability of Mayo Clinic risk score.(Singh et al., 2011) In older patients 
undergoing PCI improves HRQoL improved by its impact on physical 
functioning.(Graham et al., 2006; Li et al., 2012; Johnman et al., 2013; Panasewicz et 
al., 2013)   
Health related quality of life (HRQoL) measures were associated with frailty in my study 
patients. They were mainly associated with the physical components of the measures. 
Thus physical functioning and independent activities of daily living have an impact on 
the frailty status due to accumulation of deficits impacting functional status. The patient 
cohort did not have severe limitations in the physical functions which may explain the 
favourable CV outcomes in hospital and at 1 month. It is not known what the outcomes 
will be if all patients with NSTEACS were included in the study. The recruitment to the 
study was limited to the patients referred to tertiary hospital. Patients whose functional 
ability was very poor may not have been referred to the tertiary hospital.  
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It will be interesting to know the difference in QoL measures at one year and to 
compare with the CV outcomes at one year. By studying these at one year 
improvement or deterioration in QoL measures could be attributed to the invasive 
treatment strategy. Overall functional status assessment measured by QoL measures 
need to be routinely done in older patients to measure difference in absolute CV 
outcomes and QoL difference made by various treatment strategies. Even patients 
would prefer an improvement in functional ability from invasive treatment strategy in 






4.6 Subclinical Cognitive Impairment 
Almost half of 215 patients scored <26 on the Montreal cognitive Assessment 
indicative of subclinical cognitive impairment. The study excluded patients with known 
dementia. Frailty by both Fried and Rockwood classification was associated with 
increased proportion of patients with MoCA score <26. The mean MoCA score was 
lower in frail patients by both classifications. It can be inferred that frailty was 
associated with subclinical cognitive impairment. Frailty syndrome in addition to the 
physical components includes cognitive decline too. Subclinical cognitive impairment 
can have an impact on the delay in presentation, informed decision making and 
compliance with medications. All of these can eventually have an impact on outcomes. 
Cardiovascular disease is an independent predictor of dementia. Dementia is an 
independent predictor of 30 day and one year mortality in hospitalised patients with 
acute myocardial infarction.(Sloan et al., 2004) The two most common etiology of 
dementia are Alzheimer’s and vascular dementia. Subclinical cognitive impairment 
predisposes to dementia.(Petersen et al., 1999) Silent cerebral infarctions are 
associated with diagnostic coronary angiography and this increases the risk of 
developing dementia.(Vermeer et al., 2003; Kim et al., 2011) But it has been shown in 
another study that IHD patients managed by PCI compared to medical management 
had lower risk of dementia with a mean follow up period of five years.(Mutch et al., 
2011) The impact of contemporary management of coronary artery disease on 
subclinical cognitive impairment to development of dementia and cardiovascular 
outcomes is not known. Frailty as assessed by Fried criteria was strongly associated 
with cognitive impairment and dementia.(Kulmala et al., 2014) In the study by Ekerstad 
et al, dementia was more prevalent in frail patients than non-frail patients (27.5% vs. 
5.7%, p<0.0001).(Ekerstad et al., 2011) Though frailty was an independent predictor 
of mortality at 30 days and one year, the impact of dementia on mortality was not 
analysed. But most of the frailty assessment tools do not have cognitive impairment as 
a scoring variable. Both the frailty assessment tool used by us did not include cognitive 
assessment and patients with known dementia were excluded from my study. It is also 
not known how many of patients with known dementia were deemed not suitable for 
invasive treatment by referring local acute medical physicians and cardiologists. In my 
study frailty was significantly associated with lower MoCA score and subclinical 
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cognitive impairment. It is important to consider cognitive impairment as part of the 






4.7 Strengths and Limitations 
The main strength of the study was the recruitment of older patients undergoing 
contemporary invasive treatment in a tertiary centre for NSTEACS, excluding STEMI 
as the outcomes vary depending on the presentation. The study used both Fried and 
Rockwood frailty scores, which are tools validated in community population for a 
specific group of IHD patients presenting with NSTECAS, seeking to understand the 
frailty classification with two different tools on the same group of patients. Holistic 
assessment of patients undertaken in exploring frailty in relation to comorbidity, 
cardiovascular status, cognitive status and quality of life in addition to CV outcomes. 
Inclusion of patients was limited to the patients referred to the tertiary cardiac centre 
by the secondary care team and hence the patient group were highly selected. Patients 
deemed not suitable for invasive treatment for varied reasons by the referral team were 
not known as they would have potentially altered the outcomes. Moreover even from 
346 patients managed invasively for NSTEACS, only 237 patients were included in the 
study as 60 patients declined to take part and 49 patients were unable to consent for 
various reasons. Though this is common in clinical research inclusion of those patients 
could have altered the outcome in my study. It would have been ideal to include every 
consecutive patient but this was not feasible. Also patients with known dementia was 
an exclusion criteria, as frailty status and outcomes in these patients were not known. 
The analysis was done on 237 patients who were recruited by me and the power was 
not enough to show definitive difference between the patient groups. So the results 
and conclusions were more of a pilot study analysis and were not powered enough to 
make conclusions but provided insight into the relatively newer concept of frailty in 
patients managed by PCI especially in the ever increasing proportion of older patients 
with NSTEACS. In case of cardiovascular status assessment, because of the acute 
presentation and limited time of stay at the cardiac centre, medications that may have 
an impact on the measurements like endothelial function and arterial stiffness could 
not be stopped. Transthoracic echocardiogram findings were not available for a 
proportion of patients due to poor image quality and unavailability of echocardiogram 





Older patients usually underrepresented in clinical trials can be recruited in a research 
study. Frailty was prevalent in older patients with NSTEACS managed by invasive 
strategy but the frailty status varied depending on the assessment tool used. Three 
times more patients were classified frail by Fried frailty assessed by a combination of 
subjective and objective assessment compared to Rockwood frailty using subjective 
assessment alone. Most of the clinical presentation was with NSTEMI (82.7%) and 
there was no significant difference between the frailty groups for either NSTEMI or UA 
by both frailty assessment tools. All the patients underwent invasive coronary 
angiogram. Almost 85% of patients were managed by PCI with no difference in the 
frailty groups for management by PCI, CABG or medical management. There was no 
significant difference between the patient groups in length of hospital stay according 
to the management strategy. Procedural complications were very small in number and 
there was no difference between the patient groups. There was no significant 
difference in the rate of in-hospital and 30-day major adverse cardiovascular events 
(MACE) of death, ACS, unplanned revascularisation, major bleeding, stroke and 
contrast nephropathy or renal replacement therapy between the patient groups by both 
Fried and Rockwood assessment tools. Measures of vascular status like arterial 
stiffness, endothelial dysfunction and CIMT were not significantly different in frail 
patients by both the frailty assessment tools. Though LV systolic dysfunction was 
similar among patient groups, but E/e’, a measure of diastolic dysfunction was 
significantly higher in frail patients. Severity of angina was worse in frail patients by 
Rockwood classification only, but severity of dyspnoea was significantly worse in frail 
patients by both frailty assessment tools. Comorbidity burden by Charlson comorbidity 
Index was higher in frail patients by both frailty classification, but the higher comorbidity 
burden was not associated with increased rate of in hospital and 30-day MACE. 
Patients with known dementia were excluded from the study but sub clinical cognitive 
impairment assessed by MoCA was more prevalent in frail patients by both frailty 
assessment tools. HRQoL measures by EQ5D and SF-36, were significantly lower in 
frail patients by both frailty assessment tools for physical components, but measures 




4.9 Future Directions 
The development of a dedicated frailty assessment tool for older patients undergoing 
cardiovascular procedures would more accurately risk stratify patients and identify 
optimal management strategies. 
Frailty should not preclude the older patient provision of standard contemporary 
treatments as, in addition to improving CV outcomes, these treatments may 
significantly improve quality of life. 
Frailty assessments in older patients should include cognitive status and quality of life 
measures in addition to the physical component measures.  
Long term CV and quality of life outcomes should be studied in older patients with 
frailty and comorbidity in larger studies to demonstrate the impact of contemporary 
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 Fried Frailty Index derived from Cardiovascular Health Study 
Criterion Frailty Status 
Shrinking Frailty cut point: 
Baseline: Self-reported unintentional weight loss ≥10lb in previous year 
Follow-up: Unintentional weight loss ≥5% of previous year’s body 





Geriatric Depression Scale: 
Do you feel full of energy?  
During the last 4 weeks how often you rested in bed during day? 
 
Response options:  Every day, every week, once, not at all. 
 
Frailty cut point: 
No to 1 and every day or every week to 2. 
Low physical activity Frequency of mildly energetic, moderately energetic and very energetic 
physical activity.  
 
Response options: ≥3 times per week, 1-2 times per week, 1-3 times 
per month, hardly ever/never 
Frailty cut point: 
Hardly ever/never for very energetic physical activity AND for 
moderately energetic physical activity. 
Weakness Hand grip strength in Kg: GRIP-D hand held dynamometer, dominant 
hand, average of 3 measures. 
Frailty cut point: 
Grip strength: lowest 20% (by gender, body mass index) 
Men                                                  Women 
BMI ≤24                     ≤29                     BMI ≤23                    ≤17 
BMI 24.1–26              ≤30                     BMI 23.1–26        ≤17.3 
BMI 26.1–28              ≤30                     BMI 26.1–29         ≤18 
BMI >28                     ≤32                     BMI >29                           ≤21 
Slow walking speed Walking time in seconds (usual pace) over 15 feet 
 
Frailty cut point: 
Slowest 20%, stratified by gender and median standing height. 
Men                                       Women     
Height ≤173 cm   ≥7 seconds     Height ≤159 cm   ≥7 seconds 
Height >173 cm   ≥6 seconds     Height >159 cm   ≥6 seconds 
 
OR  
Time to complete “timed up and go test” (TUG) 
Frailty cut point: 
TUG time ≥19 seconds  
Frail: ≥3 criteria present; Intermediate or Pre-Frail:1 or 2 criteria present; Robust : 0 criteria present 
 
Adapted from Fried et al, Cardiovascular Health Study Collaborative Research G. Frailty in older 
adults: Evidence for a phenotype. The Journals of Gerontology. Series A, Biological sciences and 
medical sciences. 2001;56:M146-156. 
243 
 
 Rockwood Frailty Index derived from Canadian Study of Health and Aging 
1 Very fit – robust, active, energetic, well-motivated and fit; these 
people commonly exercise regularly and are in the most fit group for 
their age 
 
2 Well – without active disease, but less fit than people in category 1. 
 
3 Well, with treated co-morbid disease – disease symptoms are well 
controlled compared with those in category 4 
 
4 Apparently vulnerable – although not frankly dependent, these people 
commonly complain of being “slowed up” or have disease symptoms. 
 
5 Mildly frail – with limited dependence on others for instrumental 
activities of daily living 
 
6 Moderately frail – help is needed with both instrumental and non-
instrumental activities of daily living 
 
7 Severely frail – completely dependent on others for the activities of 
daily living, or terminally ill. 
 
 
Adapted from Rockwood et al, A global clinical measure of fitness and frailty in elderly people. Canadian 




 Montreal Cognitive Assessment 
 





 Short Form-36® Standard Health Survey 
SF-36 is reproduced here with permission from the RAND Corporation. Copyright © 
the RAND Corporation. RAND's permission to reproduce the survey is not an 
endorsement of the products, services, or other uses in which the survey appear or 
was applied. 
1- In general, would you say your health is: 
  1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
 
2- Compared to ONE YEAR AGO, how would you rate your health in general NOW? 
  1. MUCH BETTER than one year ago. 
  2. Somewhat BETTER now than one year ago. 
  3. About the SAME as one year ago. 
  4. Somewhat WORSE now than one year ago. 




3- The following items are about activities you might do during a typical day.  Does your health now 
limit you in these activities? If so, how much? 
Activities 1. Yes, 
Limited A 
Lot 
2.  Yes, 
Limited  
A Little 
3.  No,  
Not Limited 
At All 
a) Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports? 
         
b) Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf? 
         
c) Lifting or carrying groceries?          
d) Climbing several flights of stairs?          
e) Climbing one flight of stairs?          
f) Bending, kneeing or stooping?          
g) Walking more than a mile?          
h) Walking several blocks?          
i) Walking one block?          




4- During the past 4 weeks, have you had any of the following problems with your work or other regular 
activities as a result of your physical health? 
 Yes No 
a) Cut down on the amount of time you spent on work or other 
activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Were limited in the kind of work or other activities?   1. yes   2. No 
d) Had difficulty performing the work or other activities (for 
example it took extra effort)? 
  1. yes   2. No 
 
5. During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of any emotional problems (such as feeling depressed or anxious)? 
 Yes No 
a) Cut down on the amount of time you spent on work or other 
activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Didn’t do work or other activities as carefully as usual?   1. yes   2. No 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbors, or groups? 
  1. Not at all   2. Slightly   3. Moderately       4. Quite a bit       5. Extremely 
 
7. How much bodily pain have you had during the past 4 weeks? 
  1. None        2. Very mild       3. Mild       4. Moderate      5. Severe       6. Very severe 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? 




9. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have been 
feeling.  How much of the time during the past 4 week … 





3. A good 











a) Did you feel full of pep?                   
b) Have you been a very 
nervous person? 
                  
c) Have you felt so down in the 
dumps that nothing could cheer 
you up?  
                  
d) Have you felt calm and 
peaceful? 
                  
e) Did you have a lot of 
energy? 
                  
f) Have you felt downhearted 
and blue? 
                  
g) Do you feel worn out?                   
h) Have you been a happy 
person? 
                  
i) Did you feel tired?                   
 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
 





11. How TRUE or FALSE is each of the following statements for you? 










a) I seem to get sick a little easier 
than other people? 
               
b) I am as healthy as anybody I 
know? 
               
c) I expect my health to get worse?                













 EuroQol-5D-3L Health Questionnaire 
Please tick which statements best describe your own health state today. 
1A. Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
1B. Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
1C. Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
1D. Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
1E. Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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 EQ5D Visual Score 
To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) 
on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 
0. 
We would like you to indicate on this scale how good or bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to whichever point on the scale indicates how good 




























   90 









   Worst imaginable 
0 
     Best imaginable 
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 Definitions of outcome measures 
Outcome Definition 
Death Death from any cause 
Classified as cardiovascular or non-cardiovascular 
Myocardial Infarction* Defined as below 
Type 1 Spontaneous myocardial infarction related to ischaemia due to a primary 
coronary event such as plaque erosion and/or rupture, fissuring, or dissection 
Type 2 Myocardial infarction secondary to ischaemia due to either increased oxygen 
demand or decreased supply, e.g. coronary artery spasm, coronary embolism, 
anaemia, arrhythmias, hypertension, or hypotension 
Type 3 Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischaemia, accompanied by presumably 
new ST elevation, or new LBBB, or evidence of fresh thrombus in a coronary 
artery by angiography and/or at autopsy, but death occurring before blood 
samples could be obtained, or at a time before the appearance of cardiac 
biomarkers in the blood 
Type 4a Myocardial infarction associated with PCI 
Type 4b Myocardial infarction associated with stent thrombosis as documented by 
angiography or at autopsy 
Type 5 Myocardial infarction associated with CABG 
Revascularisation PCI to lesions not identified previously.  
CABG for new symptoms or complications of PCI 




Re-interventions inside the implanted stent or within 5 mm proximally or distally 
Target Vessel 
Revascularisation 
Re-interventions in the same vessel by PCI or by CABG 
Stroke Stroke is defined as the presence of a new focal neurologic deficit thought to 
be vascular in origin, with signs or symptoms lasting more than 24 hours.   
It is strongly recommended (but not required) that an imaging procedure such 
as CT scan or MRI be performed.   
Stroke will be further classified as ischaemic, haemorrhagic or type uncertain. 
Heart Failure Heart failure will be defined as a hospital admission with any of the following 
symptoms and signs: worsening breathlessness, fatigue, fluid overload, 
pulmonary oedema, elevated venous pressure and elevated Brain Natriuretic 
Peptide.   
Confirmation of heart failure according to local expert judgement and evidence 
of impaired left ventricular function will be required for the event to be classified 
as heart failure. 
Rehospitalisation Repeat hospitalisation for any reason during follow up period 
Adverse Event Any untoward medical occurrence 
Serious Adverse Event Any untoward medical occurrence that: Results in death and is life-threatening. 
The term "life-threatening" in the definition of "serious adverse event" refers to 
an event that 1. Requires hospitalisation or prolongation of existing inpatient’s 
hospitalisation; 2. Results in persistent or significant disability or incapacity. 
PCI-Percutaneous Coronary Intervention, CABG-Coronary Artery Bypass Graft, CT-Computerised 
Tomography, MRI-Magnetic Resonance Imaging 
Outcome definition as per British Cardiovascular Intervention Society  
* Adapted from Thygesan et al, Universal definition of myocardial infarction, European Heart Journal 




 Bleeding Academic Research Consortium (BARC) definition for bleeding 
 
*Corrected for transfusion (1 U packed red blood cells or 1 U whole blood1 g/dL haemoglobin). 
†Cell saver products are not counted. 
 
Adapted from Mehran et al, Standardized bleeding definitions for cardiovascular clinical trials: A 
consensus report from the bleeding academic research consortium Circulation. 2011;123:2736-2747 
 
Type 0 No bleeding 
 
Type 1 Bleeding that is not actionable and does not cause the patient to seek 
unscheduled performance of studies, hospitalization, or treatment by a 
healthcare professional. May include episodes leading to self-
discontinuation of medical therapy by the patient without consulting a 
healthcare professional. 
 
Type 2 Any overt, actionable sign of haemorrhage (e.g. more bleeding than 
would be expected for a clinical circumstance, including bleeding found 
by imaging alone) that does not fit the criteria for Type 3, 4 or 5 but does 
meet at least one of the following criteria: (1) requiring non-surgical, 
medical intervention by a healthcare professional, (2) leading to 
hospitalization or increased level of care, or (3) prompting evaluation. 
 
Type 3a Overt bleeding plus haemoglobin drop of 3 to <5g/dl* (provided 
haemoglobin drop is due to bleed) 
Any transfusion with overt bleeding 
 
Type 3b Overt bleeding plus haemoglobin drop ≥5g/dl* (provided haemoglobin 
drop is due to bleed) 
Cardiac tamponade 
Bleeding requiring surgical intervention for control (excluding dental/ 
nasal/ skin/ haemorrhoid) 
Bleeding requiring intravenous vasoactive agents 
 
Type 3c Intracranial haemorrhage (does not include micro-bleeds or 
haemorrhagic transformation, does include intraspinal) 
Subcategories confirmed by autopsy or imaging or lumbar puncture 
Intraocular bleed compromising vision  
 
Type 4: CABG-related bleeding 
Perioperative intracranial bleeding within 48 hours 
Reoperation following closure of sternotomy for the purpose of 
controlling bleeding 
Transfusion of ≥5 units of whole blood or packed red blood cells within a 
48-hour period† 
Chest tube output ≥ 2 litres within a 24-hour period 
If a CABG-related bleed is not adjudicated as at least a Type 3 severity 
event, it will be classified as ‘not a bleeding event’. 
 
Type 5a Probable fatal bleeding; no autopsy or imaging confirmation, but 
clinically suspicious 
 
Type 5b Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation 
253 
 
 Standard Operating Procedures 
 Hand-grip Strength Test for Fried Frailty Assessment 
Title: SOP for assessment of Handgrip Strength 
Author: M Veerasamy 
Responsibilities: 
Research investigators trained in the method of handgrip strength assessment are 
responsible for proper assessment 
Clear explanation of the procedure to the patients 
Ensuring that the equipment used for the assessment is in optimal working condition 
Equipment: 
Electronic Hand Dynamometer and 2 x AAA batteries 
 
Aim 
The purpose of this test is to measure the maximum isometric strength of the hand and 
forearm muscles. 
Procedure 
Press ‘On/Set’ button on the front of the dynamometer 
Then press ‘Start’ and it is ready to be used 
The patient holds the dynamometer in the dominant hand to be tested, with the arm at 
right angles and the elbow by the side of the body.  
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The handle of the dynamometer is adjusted if required - the base should rest on first 
metacarpal (heel of palm), while the handle should rest on middle of four fingers.  
When ready the subject squeezes the dynamometer with maximum isometric effort, 
which is maintained for about 5 seconds. 
The subject should be strongly encouraged to give a maximum effort. 
The strength is displayed on the LCD screen in kilogram 
Record the finding in the study database 
 Pulse Wave Velocity and Pulse Wave Analysis 
Title: SOP for recording of PWA, PWV and ABI 
Author: M Veerasamy 
Responsibilities: 
Research investigators trained in the method are responsible for accurate 
measurement and recording of PWA, PWV and ABI using Vicorder from patients 
Clear explanation of the procedure to the patients 
Ensuring that all equipments used for the procedure are in optimal working condition 
Equipments: 
Vicorder console 
3 pressure cuffs - Brachial, Thigh and Ankle 
1 pressure cuff - Neck 
2 colour coded (Blue and Red) pneumatic hoses 
1 measuring tape 
Toshiba Satellite Pro Laptop with Vicorder software installed 
Carry bag for above 







Make sure all the connections are secure 
When using cuffs the patients should be informed about the mild constriction when 
they are inflated 
Cuffs should automatically deflate from the controls but if for some reason they fail to 
deflate unplug the pneumatic cuff connectors 
Cleaning the Vicorder, its components and leads should only be undertaken by wiping 
with a soft cloth moistened with mild soap or antiseptic solution 
Vicorder will require calibration every six months as per instruction manual of its 
pressure channels to maintain its accuracy 
There are no other special pre-warnings or contra-indications 
Instructions for using the Vicorder 
The investigators must read the accompanying instruction manual and familiarise 
themselves with the equipments. Step-by-step instructions for day-to-day use will be 
kept with each device. 
Connecting the Vicorder:  





2. Connect the 2 colour coded pneumatic hoses to Press1 and Press2 on the Vicorder 
front panel.  
 
 
3. The Vicorder software may be activated by double clicking on the Vicorder icon in 
the Control Panel or by launching it from the Start menu which will open the 
administration page.  
 
 
Navigation and setting  
Navigate and set within the screens:  
Screen buttons - To move left / right use the Laptop left / right arrow keys or the 
Vicorder left / right quadrant keys or the Laptop Function keys or the mouse pointer 
and left click.  
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Settings - To change up / down use the Laptop up / down arrow keys or the Vicorder 
up / down quadrant keys or the left / right mouse keys. 
 
New Patient entry screen  
Click ‘File’ on the Vicorder administration page and click ‘New Patient’. 
 
 
Enter Study ID, DOB, Sex, Height, Weight. No patient identifiable details are entered 
for confidentiality reasons. 
 
Click ‘Save and Exit’ 
 
Patient Position 
Patient to be comfortable and lying in supine position at with head and shoulders at 
about 30 degree angle – this will prevent venous signals affecting arterial signals 
A pillow or a neck wedge can be used for this purpose 
Positioning the pressure cuffs  
Neck cuff is placed around the patient’s neck with pressure pad over right carotid area,  
Arm cuff above the cubital fossa  
Thigh cuff around the upper part of the thigh   
Ankle cuff just above the ankle joints  
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Recording the measurements 
Connect the blue pneumatic hose to the thigh cuff and the red pneumatic hose to the 
brachial cuff. 
From the Quick Launch menu in the administration page click ‘OSC BP’. 
Click ‘Inflate’ and click ‘Save’ to store the systolic and diastolic blood pressure. 
Press ‘Escape’ to go to the administration page. 
Pulse Wave Analysis (PWA) 
From the Quick launch menu click on ‘PWA’.  
 
On the pop up PWV/PWA study screen enter length measured in cm between the top 






Then click ‘Multi-Chan’ which will show two traces on the screen one for the brachial 
and the other for the thigh cuff. 
Click ‘Inflate’ and after acquiring steady pulses of data click ‘freeze’. Scrolling left or 





Calculated readings are stored by clicking ‘Save’.  
Press ‘Escape’ to go to administration page. 
 
Pulse Wave Velocity (PWV) 
1. The neck pad is placed around the patient’s neck with the pressure pad over 
the right Carotid area and secured with the Velcro fixing, do not over-tighten and 




   
 
 
Measure the distance from the suprasternal notch to the top of the thigh cuff. From the 
Quick Launch menu select PWV and on the pop up window enter the measured length 
in cm. Also enter systolic, MAP and Diastolic pressures. Click ‘OK’. 
In PWV mode the display is always Dual channel. After acquiring several steady pulses 
of data pressing the space bar will freeze the display, the Pulse Wave Velocity in 






Ankle Brachial Pressure Index (ABI) 
Connect the red pneumatic hose to brachial cuff and the blue pneumatic hose to ankle 
cuff. 
From the quick launch menu select ‘ABI’. Press ‘Inflate’. After acquiring several steady 
pulses of data pressing the space bar will freeze the display and calculated ABI is 
shown. Click ‘Save’ to store. 
 
At the end of the procedure 
After completing the study press ‘File’ and select ‘Exit Vicorder’ 
Remove the cuffs and pack all equipment. 
Thank the patient 
Exporting data into spreadsheet 
All the saved measurements are uploaded by default into the Vicorder excel 
spreadsheet in addition to being stored in the Vicorder patient list 
  







 Peripheral Arterial Tonometry 
Author: M Veerasamy 
Responsibilities: 
Research investigators trained in the method are responsible for 
accurate measurement and recording of Endothelial Function using EndoPAT 2000 
Clear explanation of the procedure to the patients 
Ensuring that all equipments used for the procedure are in optimal working condition 
Equipments: 
One Endo-PAT2000 device 
Two pneumo-electric tubing 
Power adapter 
Power cable 
Foam finger anchors 
Toshiba Satellite Pro Laptop with EndoPAT software installed 
Carry Bag 
A set of two PAT probes 
Blood pressure cuff (capable of sustaining high pressures for 5 minutes) 
Adhesive tape 
Pair of arm supports 
Equipments needed for EndoPAT were stored in a locked cupboard in a room in ward 
27.  
Connecting the Endo-PAT2000 to the Computer 
Place the Endo-PAT2000 and computer in close proximity to the examination bed or 
chair. The device should be placed at a distance from the bed or chair that is shorter 
than the pneumo-electric tubing (less than 1.8 meters/ 6 feet). 





Connect the MOXA Adapter to the COM TO COM cable and tightly screw the bolts. 
  
Connect the COM TO COM cable to the ENDO device and tightly screw the bolts. 
 
Connect both pneumo-electric tubing to the Endo-PAT2000 front panel pneumoelectric 
connectors and secure by hand tightening the screws 
Make sure the power switch is off. Connect the power supply first to the Endo-PAT2000 
and then to an electrical outlet. Turn the power switch on. 











Prepare the Patient for an Endo-PAT Study 
Prior to the study, ensure the patient has fasted for at least 4 hours, and has refrained 
for at least 8 hours from caffeine, tobacco, vitamins or medications that might affect 
vascular tone. The patient may wish to use the restroom prior to the study. 
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The Endo-PAT study should be conducted in a quiet, dimly lit, temperature-controlled 
exam room to reduce fluctuations in vascular tone. Thermoneutral room temperature 
must be maintained at all times: 21ºC-24ºC 
Cell phones or paging devices should be silenced, and restrictive clothing that could 
interfere with blood flow to the arms should be removed. The patient should also 
remove watches, rings, or other jewellery on the hands or fingers. 
Inspect the patient's fingers for any deformities or injuries that could affect the study. 
Do not place the probes on a finger that is cut or injured. Fingernails should not extend 
more than 5mm or 1/5 of an inch beyond the tip of the finger tissue. Trim or file 
fingernails if necessary to avoid damaging the internal membranes of the PAT probes 
and displacing the finger from the sensing region of the probe.5. The index finger is 
recommended for the study; however, if this finger is unsuitable, a different digit (except 
the thumb) may be used, as long as the same finger is used on both hands. 
The patient should be supine and comfortable for 15 minutes so as to attain a 




Measure the blood pressure using the control arm (the arm that is not occluded during 
the Endo-PAT study. 
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Place a blood pressure cuff on the arm to be occluded during the Endo-PAT study. 
Apply the cuff snugly, but without excess pressure. Do not inflate the cuff at this time. 
Prepare the Endo-PAT System for Study 
Launch the Endo-PAT 2000 software and click the "Patient Information" icon on the 
tool bar to create a new patient file. 
Complete the Patient Information dialog box, including patient ID, name (optional), age, 
gender, height, weight, systolic and diastolic blood pressures. Optional fields allow for 
free text comments. Select your name from the pre-defined list in the Patographer 
name field. 
 
Select two new PAT probes and connect to the pneumo-electrical tubing. To connect 
the probes, insert the connector tab into the probe slit and gently press the connector 








Place the connected probes into the sockets of the arm-supports and press the 
"Deflate" button on the top of the Endo-PAT 2000 device. 
Place the patient’s index fingers completely into the probes, confirm with the patient 
that he or she can feel the very end of the probes, and press the "Inflate" button on the 
top of the Endo-PAT 2000 device. 
Place a foam anchor ring at the base of the adjacent middle finger. Ensure that the 
foam ring and the PAT sensor do not touch. Otherwise the ring may mechanically 
interfere with the sensor. 
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Create an approximately 7-10cm loop with the pneumo-electrical tubing. The loop 
should extend from the PAT sensor and return to the foam ring on the adjacent finger 
while the rest of the tubing that connects to the EndoPAT device is pointing out tubing 
to the tip of the finger. 
Hands setup 
 
Position the patient's arms so the forearms are supported on the arm supports and the 
fingers dangle freely off the edge of the support. Make sure the probes are not in 
contact with any object, including the arm support, foam ring, tubing, the mattress or 
another finger. 
Ask the patient to refrain from moving the fingers, as this will create mechanical 
artefact. It is important for the patient to be relaxed throughout the study. Explain to the 
patient that during the test you will inflate the arm cuff, and during that time they may 
feel some discomfort, numbness, or tingling. 
Performing the Study 
Click the "Standby" icon   on the Endo-PAT's computer interface. Adjust the time 
base to 1 minute and adjust the signal gain on the screen to maximize signal clarity. 
Inspect the tracings of the PAT signals from the two probes to confirm that they are 
free of artifactual signals. If artifactual signals are present, verify that the probes are 





To begin the study, click the "Go" icon  on the computer interface. Start the 
stopwatch, by clicking the "Start/Stop Timer" icon. This will initiate a five minute count 
down for the baseline recording period. After five minutes, stop the stopwatch by 
clicking the "Start/Stop Timer" icon. 
 
 
Tell the patient that you are going to inflate the cuff for the occlusion phase and that 
he or she should stay relaxed and not move the fingers. 
Rapidly inflate the blood pressure cuff to a supra-systolic pressure of 60mmHg above 
the patient's systolic pressure or 200mmHg, whichever is higher and start the 
stopwatch again. Complete cessation of blood flow to the hand is verified by the 
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absence of a PAT signal from the occluded arm. To confirm occlusion increase the 
gain on the screen of the channel of the occluded side to 20,000 while keeping the 
gain of the contra-lateral side constant. Decrease the time base of both channels to 30 
seconds. Verify that you do not observe any signals at a periodicity that matches the 
signal from the control arm as this indicates an incomplete occlusion. If this is the case 
then further inflate the cuff until no signals are seen. The cuff may be inflated to a 




This will initiate a five minute count down for the arterial occlusion recording period. 
Toward the end of the occlusion period tell the patient you are going to release the cuff 
and that they should continue to refrain from moving their fingers. After exactly five 
minutes, deflate the cuff abruptly as quickly as possible and stop the stopwatch by 
clicking the "Start/Stop Timer" icon . 
Click the "Start/Stop Timer" icon again to initiate a five-minute post occlusion 
recording period. Stop the timer after five minutes and click the 
"Test Stop" icon   to complete the study. The probes will automatically deflate. 
Remove the probes, tape, and foam rings from the patient's fingers and disconnect the 
PAT probes from the pneumo-electrical tubing. Discard the used probes. 
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Review and Analysis 
Click the Icon , or select Automatic Analysis from the Test Analysis menu. In the 




The occlusion period will be highlighted in blue 
 
   
The test result will be displayed, including the Reactive Hyperaemia Index (RHI) and 





To review the results of the study, click the icon . The table lists relevant study 
parameters and results, for all analyses performed to date, with the last line in the table 
containing data from the most recent analysis performed. 
To review the study report select the “View report” option in the Test Analysis pull down 
menu or click the icon . The report will be exported to a picture viewer (it will take 
a few seconds). This report can be printed or exported to other formats (i.e. PDF). 
 
Study Data Retrieval 
From the toolbar click the icon   or select Open File from the menu bar. The 




Select the desired file from the list (note that the file name is the same ID number used 

















 Carotid Intima Media Thickness 
Title: SOP for CIMT measurement 
Author: M Veerasamy 
Responsibilities: 
Trained research investigators are responsible for performing CIMT measurement by 
using Vivid-I 
Clear explanation of the procedure to the patients 
Ensuring that all equipments used for the procedure are in optimal working condition 
Equipment: 
Vivid-I (GE)  
12L-RS phased array probe 
Power adapter unit and cord 
3 ECG leads – red, green and black 
Hospital bed or couch with recliner facility for patient positioning 
Skintact Ultrasonic Gel 
Carry bag 
Connections 
Connect the AC power adaptor output plug into the appropriate socket on the rear of 
the Vivid I 
Ensure that the wall outlet is of appropriate type 
Secure the power plug in the wall outlet 
Connect the probe to the appropriate socket and make sure it is locked 
Connect the ECG cable                            
Instructions for Using Vivid-I 
The investigator must read the accompanying manual and familiarise themselves with 
the equipment.  
Beginning an exam consists of three steps: 
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• Creating a new patient record  
• Selecting Probe and Application 
• Start scanning  
Entering a new Patient  
Press ‘On/Off’ key on top right of the control panel to turn the machine on. 
Press ‘Patient’ key which will bring the patient list screen. 
Press ‘Create New Patient’ 
Enter Patient’s details – Study ID and DoB 
Press ‘Create Patient’ to store details 
Selecting the vascular probe 
Press ‘Application’ on the control panel 
A list of the connected probes will pop up 
Make sure 12L-RS probe is selected. 
Patient positioning 
Patient to be lying down in supine position comfortably with pillow below the head 
The head is rotated by 45 degree to the left or right according to the side of examination 
Both neck regions need to be fully exposed 
Inform the patient about slight discomfort when the probe is placed on the neck 
Acquiring Images 
The side of examination to be marked on the image by using ‘Txt’ key on the control 
panel 
Use gel on the probe and start acquiring images 
A longitudinal image of carotid artery to be obtained as per CIMT imaging protocol 
Optimise the image by using depth and focus settings 
Press ‘Freeze’ 






Press ‘Measure’, select ‘Vascular’ and select ‘IMT’ 
If measuring the IMT of posterior wall of the right common carotid select ‘Rt’ and ‘CCA’ 
‘IMT’ ‘Post’ 
Place the cursor in the artery closer to the posterior wall and press ‘Set’ to anchor the 
start of search region 
Move the cursor parallel to the artery to define the endpoint of the search region. Make 
sure the intima and media are within the search region. Press ‘Set’ to anchor the point 
Automated software will automatically detect the IMT and will do the calculations. The 




Images are stored by pressing ‘Store’ 
Complete the exam by clicking ‘End Exam’ 
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Provide tissue for the patient to wipe off the gel 
Disconnect the probe, clean and pack the equipment in the carry bag 
Copy the images into CD-R  













 Left Ventricular Function 
Title: SOP for Transthoracic Echocardiogram 
Author: M Veerasamy 
Responsibilities: 
Trained research investigators are responsible for performing transthoracic 
echocardiogram by using Vivid-I 
Clear explanation of the procedure to the patients 
Ensuring that all equipment used for the procedure are in optimal working condition 
Equipment: 
Vivid-I (GE)  
3S-RS phased array probe 
Power adapter unit and cord 
3 ECG leads – red, green and black 
Hospital bed or couch with recliner facility for patient positioning 
Skintact Ultrasonic Gel 
Connections 
Connect the AC power adaptor output plug into the appropriate socket on the rear of 
the Vivid I 
Ensure that the wall outlet is of appropriate type 
Secure the power plug in the wall outlet 
Connect the probe to the appropriate socket and make sure it is locked 
Connect the ECG cable                             
Instructions for Using Vivid-I 
The investigator must read the accompanying manual and familiarise themselves with 




Patient to be lying down on the bed or couch in left lateral decubitus position with head 
end reclined at around 45 degrees. 
Make sure the patient is comfortable, if not perform the scan in a comfortable position 
for the patient and make a record of the position 
Patient has to undress down to umbilicus level 
Place three ECG stickers and connect them with respective leads (Red to right 





1. Assignable keys (soft-menu elements;                           8. Trackball 
part of the Extended keyboard)                                          9. Trackball buttons 
2. Soft menu rocker                                                           10. Mode selection keys 
3. TGC sliders                                                                   11. Navigation keys  
4. GAIN rotary                   12. Freeze keys  
5. Alphanumeric keyboard                                13. On/Off button 
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6. Alphanumeric function keys: (Help, Config…) 
7. Extended keyboard 
Starting an examination 
Beginning an exam consists of three steps: 
Creating a new patient record  
Selecting Probe and Application 
Start scanning  
Entering a new Patient  
Press ‘On/Off’ key on top right of the control panel to turn on the machine 
Press ‘Patient’ key which will bring the patient list screen 
Press ‘Create New Patient’ 
Enter Patient’s details – Study ID and Date of Birth 
Press ‘Create Patient’ to store details 
Selecting the cardiac probe 
Press ‘Application’ on the control panel. A list of the connected probes will pop up. 
Make sure 3S-RS probe is selected. 
Acquiring Images 
Make sure a good ECG tracing is available in the bottom of the screen. If not press 
‘Physio’ and adjust gain. 
Place ultrasonic gel on the probe and start acquiring images 
Images are to be acquired as per the minimum dataset for a standard Transthoracic 
Echocardiogram from the British Society of Echocardiography education committee.  
Images in this SOP are for illustration purposes only 
To store a cineloop 
While in scanning mode, press the ‘Store’ button to store the last heart-cycle loop 




While in cine-loop preview mode press ‘Store’ to store the selected loop. 
To store a single image 
Press ‘Freeze’ 
Press ‘Store’ to store the image digitally 
The thumbnail of the image is displayed on the clipboard 
Views: 
PLAX parasternal long axis 
 
PSAX parasternal short axis 
 
A4C apical four chamber 
 





A2C apical two chamber 
 
ALAX apical long axis or apical three chamber 
 








M mode Doppler 
 
PW pulse wave Doppler 
 
CW continuous wave Doppler 
 













At the end of the Examination 
Press ‘End Exam’ 
Provide tissues for the patient to wipe off the gel 
Clean the probe and ECG leads 
Disconnect the probe and ECG leads 
Store them in the carry bag 
Images will be analysed offline and report generated as per BSE protocol  
 
Archiving and exporting data in to database 
Insert removable media in the drive (CD-R) 
Press ‘PATIENT’ on the control panel and then select ‘Patient List’ 
Select the source archive in dataflow field: Local Archive-Int.HD 
286 
 
Press ‘Export’, and then select ‘CD/DVD Archive’ as destination 
Press OK, a window will appear: Current media is not formatted. Do you want to format 
it? Select Yes. 
Select the examination from ‘Patient List’ that you want to export 
Press ‘Copy’ and then OK to resume export. And finally press ‘Done’ in the Export 
patient window to complete the process 
Press Alt+E to eject the CD 
The CD will be filed as part of the study documents. 
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